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Introduction and outline of the thesis 
Head and neck cancer
Head and neck cancers encompass a rare group of malignancies, localized in the lip, 
oral cavity, nasal cavity, paranasal sinuses, pharynx (oropharynx, hypopharynx and 
nasopharynx), larynx and salivary glands (Figure 1). Apart from the latter, almost all 
these tumors are squamous cell carcinomas. In 2016 3192 new cases of head and neck 
squamous cell carcinoma were diagnosed in the Netherlands, which account for 3% of the 
total number of newly diagnosed cancer patients in that year. 1 Two-thirds of the patients 
with head and neck cancer are male. 
Figure 1. Anatomy of the head and neck region where squamous cell carcinoma can develop
Risk factors for developing head and neck squamous cell carcinomas are the use/abuse 
of tobacco and alcohol, and, especially in oropharyngeal cancer, infection with the human 
papillomavirus (HPV).2 
The five-years overall survival of patients with head and neck squamous cell carcinoma is 
largely dependent on disease stage. Thirty to forty percent of the patients present with 
early disease (stage I and II), their 5-years overall survival ranges from 60 to 98% and varies 
between tumor sites. These patients are mainly treated with surgery and/or radiotherapy. 
Locally advanced head and neck cancer (LAHNC) (stage III and IV) is present in more than 
50% of the patients. LAHNC patients are treated with combined modalities, comprising (1) 
primary surgery with or without postoperative radiotherapy or chemoradiotherapy or (2) 
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primary concomitant chemoradiotherapy or radiotherapy in combination with cetuximab 
(bioradiotherapy) or radiotherapy as single treatment. Primary surgery is the treatment of 
choice in patients with locally advanced oral cavity cancers and hypopharyngeal and laryngeal 
cancer without a functional larynx. Despite these intensive treatments, the prognosis of 
these patients is in general poor, with 5-years overall survival rates ranging from 30-50%. 
Locally advanced HPV-associated oropharyngeal cancer patients have a distinct behaviour 
and have overall a better prognosis. This HPV positive group can be divided in three risk 
groups based on smoking habits and the T or N stage: a good-risk, an intermediate risk and 
a poor risk group with a 3-year overall survival of 94%, 67% and 42%, respectively. 3 
Treatment of locally advanced squamous cell cancer of the head and neck
Chemoradiotherapy
In locally advanced oropharyngeal, hypopharyngeal and laryngeal cancers 
chemoradiotherapy is the standard treatment in patients with a good performance score. 
Primary chemoradiotherapy can be given for two reasons:  1. organ preservation or 2. 
unresectable disease. In case of locally advanced laryngeal cancer chemoradiotherapy 
is most frequently given for organ preservation. The primary goal is to retain the organ, 
i.e. the voice. In one of the first landmark studies of the Radiation Therapy Oncology 
Group (RTOG) three treatment options were studied: induction chemotherapy followed 
by radiation, concurrent chemoradiotherapy and radiotherapy alone. Concomitant 
chemoradiotherapy was most effective for larynx preservation and locoregional control.4 
In patients with unresectable LAHNC treated with concomitant chemoradiotherapy the 
primary goal is to improve survival. Chemoradiotherapy in this setting is also proven to 
be more effective compared to radiotherapy alone. 5,6 
In a large meta-analysis containing 93 trials with 17,346 patients, the effect of chemotherapy 
in head and neck cancer has been evaluated.7 An absolute survival benefit of 4.5% at 5 years 
has been found when chemotherapy was added to locoregional treatment (radiotherapy or 
surgery). The most effective modality was concomitant chemoradiotherapy with a hazard 
ratio of death of 0.81 (95% confidence interval 0.78 -0.86) and an absolute survival benefit 
of 6.5% at 5 years. Single agent chemotherapy is equally effective as polychemotherapy 
and amongst the different cytostatic treatments, platin-based chemotherapy is the most 
effective, with most trials using cisplatin. In this meta-analysis locoregional treatment followed 
by chemotherapy and induction chemotherapy followed by locoregional treatment did not 
show to be significantly better than loco-regional treatment alone.   
Chemoradiotherapy is not only used as primary treatment, but also in the adjuvant setting, 
after surgery, especially in oral cavity cancers. Postoperative chemoradiotherapy has 
1INTRODUCTION AND OUTLINE OF THE THESIS
11
proven to be more effective than radiotherapy alone in patients with high risk pathological 
features, i.e. irradical resection or extracapsular extension of lymph nodes. 8,9 
Different schedules of primary chemoradiotherapy
The most commonly applied treatment schedule (RTOG schedule) in locally advanced head 
and neck cancer patients consists of cisplatin 100 mg/m2 on days 1, 22 and 43 combined 
with conventional radiotherapy (70 Gy in 35 fractions in 7 weeks).4,5  
In an attempt to improve local-regional control and survival, accelerated radiotherapy 
has been studied. It is hypothesized that acceleration of radiation treatment reduces the 
repopulation of tumor cells and thus could lead to improvement of locoregional control.10,11 
Accelerated radiotherapy has shown a higher local control rate (hazard ratio 0.74 CI 0.67-
0.83) and a slightly better locoregional control rate (hazard ratio 0.79 CI 0.72 – 0.87) 
compared to conventional radiotherapy.10 This results in a benefit of 7.3% in locoregional 
control at 5 years, but only a small benefit of 2% in 5-years survival compared to conventional 
radiotherapy. 
Patients treated with accelerated radiotherapy cannot be treated with cisplatin 100 mg/
m2 on days 1, 22 and 43 because the shortening of the overall treatment time (around 
35 days). Therefore, alternative cisplatin schedules have been studied. One of the most 
frequently used alternative schedules is weekly cisplatin 40 mg/mg2 concomitant with 
accelerated radiotherapy.12-14 A direct comparison in a prospective randomized trial in 
LAHNC between cisplatin 100 mg/m2 with conventional radiotherapy and weekly cisplatin 
40mg/m2 with accelerated radiotherapy as primary chemoradiotherapy has not been 
performed yet. 
Bioradiotherapy
In 90% of the squamous cell carcinomas of the head and neck the expression of the 
epidermal growth factor receptor (EGFR) is high. EGFR mutations are very rare. Cetuximab 
is an IgG1 monoclonal antibody against the ligand-binding domain of EGFR and has 
synergistic activity when given combined with radiotherapy in mice models. Therefore, 
in a phase III study the combination of cetuximab and radiotherapy was compared to 
radiotherapy alone.15 Cetuximab was given in a loading dose of 400 mg/m2 one week 
before start of radiotherapy and then weekly in a dose of 250 mg/m2 during radiotherapy. 
The combination of cetuximab and radiotherapy resulted in a significant prolonged 
locoregional control rate, progression-free survival and overall survival compared with 
radiotherapy alone. Compared to radiotherapy alone, in the combination arm with 
cetuximab more grade 3 toxicity and more acneiform rash and infusion reactions were 
observed. Otherwise toxicities were not different between the two treatment arms.
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Unfortunately, no phase III studies have been performed comparing concomitant 
chemoradiotherapy with concomitant bioradiotherapy. Although a comparison between 
the phase III studies is not allowed, three years overall survival rates are in favor of 
cisplatin-based chemoradiotherapy, making the latter still standard of care. 16 Alternatively, 
cetuximab in combination with radiotherapy can be given in patients who cannot tolerate 
chemoradiotherapy with cisplatin, e.g., patients with hearing problems or decreased 
renal function. A phase III study in which the addition of cetuximab to cisplatin-based 
chemoradiotherapy was  evaluated, did not show any survival benefit for the combination, 
but it led to increased toxicity, and did not change the standard of care.17 
Induction (or neo-adjuvant) chemotherapy 
Adding induction chemotherapy prior to radiotherapy is another attempt to improve 
survival of LAHNC patients. The main objectives of induction chemotherapy are reduction 
of tumor volume and eradication of systemic micrometastases.18 Furthermore, in some 
studies, induction chemotherapy was used as a measure for radiosensitivity, i.e., response 
to chemoradiotherapy, especially in organ-preserving studies in larynx cancer.18-20
In the seventies and eighties the first studies on induction chemotherapy in head and neck 
cancer were published, most often using a combination of cisplatin and bleomycin.21-23 
Later, three pilot studies were performed at the Wayne State University, to test feasibility 
of three different treatment schemes:24 (1) two cycles of bleomycin, cisplatin and vincristine 
were compared to (2) two cycles of cisplatin with 96-hour infusion of 5-fluorouracil or (3) 
to three cycles of cisplatin with 120-hour infusion of 5-fluorouracil. The latter schedule 
showed the highest complete response (54%) and overall-response (93%), making this the 
standard treatment scheme for induction chemotherapy for many years. 
Two phase III trials compared this Wayne State University scheme (cisplatin/5-flourouracil, 
i.e. PF) to the combination of docetaxel, cisplatin, 5-fluorouracil (TPF) to evaluate efficacy. The 
TAX 323 compared 4 cycles TPF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 and 5-fluorouracil 
750 mg/m2) versus PF followed by radiotherapy in patients with locally advanced head 
and neck cancer.25 TPF significantly improved progression-free (11.0 versus 8.2 months) 
and median overall survival (18.8 versus 15.5 months), respectively). The TAX 324 study 
compared 3 cycles of TPF (docetaxel 75 mg/m2, cisplatin 100 mg/m2 and 5-fluorouracil 
1000 mg/m2) with PF, both followed by chemoradiotherapy with weekly carboplatin AUC 
1.5. The median overall survival in this study was also significantly in favor of the TPF arm 
(71 versus 30 months). 26 As described earlier, in a meta-analysis no survival benefit has 
been found for induction chemotherapy, however, TPF based schedules were not included 
in this analysis7. 
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Neo-adjuvant chemotherapy prior to standard cisplatin-based concomitant 
chemoradiotherapy has not been studied, yet. When TPF would be combined with 
cisplatin-based chemoradiotherapy, patients receive up to 600 mg/m2 cisplatin in total, 
which can lead to profound toxicity. This raises the question if TPF followed by cisplatin-
based chemoradiotherapy is feasible. Moreover, TPF has not been administered prior to 
accelerated chemoradiotherapy. 
Treatment induced toxicities and quality of life
Patients with head and neck cancer, who are treated with radiotherapy or concomitant 
chemoradiotherapy experience a lot acute and late toxicities. Most local toxicities, such as 
impaired speech and decreased adequate oral intake due to swallowing problems, have 
a large impact on quality of life. 
Acute toxicity induced by chemoradiotherapy consists of mucositis, dermatitis, 
swallowing problems, dysgeusia, ototoxicity and fatigue. Oral and pharyngeal mucositis, 
grade 3-4, is reported in approximately 25% of the patients treated with conventional 
radiotherapy.27 However, in schedules with accelerated or hyperfractionated 
radiotherapy grade 3-4 mucositis is observed in 60-70% of the patients.27,28 Dermatitis 
can vary from hyperpigmentation until moist desquamation. Dysphagia leads to feeding 
tube dependency in approximately 80% of the patients, and 4 - 30% of patients will 
remain dependent on tube feeding after end of treatment. 14,29.  Since the introduction 
of intensity modulated radiotherapy (IMRT), significantly less xerostomia and dermatitis 
are reported.30 
Table 1. Overview of acute and late toxicities of treatment with chemoradiation in head and neck cancer 31
Acute toxicities Late toxicites
Mucositis Xerostomia
Dermatitis Aspiration
Dysphagia Dysphagia
Xerostomia Osteoradionecrosis
Dysgeusia Caries
Fatigue Trismus
Nausea and vomiting Thyroid dysfunction
Nephrotoxicity Ototoxicity
Ototoxicity Myelitis
Polyneuropathy Fibrosis
Nephrotoxicity
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Common and potentially permanent side effects encountered in patients treated with 
cisplatin-based chemoradiotherapy are ototoxicity and nephrotoxicity. Cisplatin-induced 
nephrotoxicity can be manifested as an impaired glomerular infiltration rate, or as a 
tubulopathy, causing reduced serum magnesium and potassium levels.32,33 Nephrotoxicity 
is cisplatin dose-dependent and can be dose-limiting.12,32   
Ototoxicity can be induced by radiotherapy and by the use of cisplatin. Radiotherapy-
induced ototoxicity is less commonly observed but has become more clinically relevant 
since radiotherapy is combined with cisplatin. Radiotherapy-induced ototoxicity has 
different manifestations. It can present as conductive hearing loss as a result of edema 
and/or fibrosis of the middle ear, or secondly, as sensorineural hearing loss, which is 
most likely caused by lesions in the cochlea, which can be irreversible.34 As a result of the 
radiotherapy fields radiation-induced ototoxicity is especially seen in patients with tumors 
at the skull base or nasopharyngeal tumors, and less frequently in other head and neck 
tumors. Ototoxicity caused by cisplatin is dose- and schedule dependent.35,36 The incidence 
of sensorineural hearing loss after chemoradiotherapy with cisplatin schedules in head 
and neck cancer patients is 17-88%.34 
Late toxicity presents months to years after end of treatment and can be permanent. 
Xerostomia is the most common long-term complication of chemoradiation, as a result of 
damage of the salivary glands. Moreover, patients with head and neck cancer are at risk 
for development of second malignancies in head and neck and elsewhere in the body. 
Most of this risk is due to smoking and alcohol abuses, but they can also be caused by 
radiation treatment itself. 
The toxicity of treatment, in combination with the disease itself, has a major impact on quality 
of life of head and neck cancer patients. During radiotherapy and chemoradiotherapy the 
global health score of the quality of life decreases, but this recovers to baseline levels  one 
year after end of treatment.37 38,39 
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Aim of the thesis 
As described above, prognosis of patients with locally advanced head and neck cancer is 
poor and treatment is associated with a high frequency of severe toxicities and a negative 
impact on quality of life. The main aim of the research described in this thesis is to evaluate 
options to improve the efficacy and decrease toxicity of concomitant chemoradiotherapy 
in patients with LAHNC.
In Chapter 2 a retrospective analysis is performed to evaluate the toxicity, efficacy and 
feasibility of weekly cisplatin 40 mg/m2 combined with accelerated radiotherapy in 104 
LAHNC cancer patients. 
In Chapter 3 we compare the effects on nephrotoxicity of patients treated with 
chemoradiotherapy with high dose cisplatin (100 mg/m2 on days 1, 22 and 43) or 
intermediate dose cisplatin (40 mg/m2 weekly). Furthermore, we describe different grading 
systems for nephrotoxicity.  
As described above, no data are available on cisplatin-based chemoradiotherapy after 
TPF induction chemotherapy. To evaluate feasibility of induction chemotherapy with TPF 
followed by two different schedules of cisplatin-based chemoradiotherapy, a phase II study 
in LAHNC, the CONDOR study, was designed. In this study we particularly focused on the 
feasibility of the total dose of up to a maximum of 600 mg/m2 cisplatin. Patients were 
treated with 2-4 cycles TPF (with a maximum of 300 mg/m2 of cisplatin) and, thereafter, 
were randomized to either conventional radiotherapy with cisplatin 100 mg/m2 on days 
1, 22 and 43 or accelerated radiotherapy with weekly cisplatin 40 mg/m2. The results of 
this study are described in Chapter 4. The effect of both treatment regimens on quality of 
life, a secondary endpoint, is described in Chapter 5. The patients in our study underwent 
audiological testing. The effects on hearing of the high dosages cisplatin in combination 
with radiotherapy in both arms of the study were studied and reported in Chapter 6. The 
use of genetic variants to predict cisplatin-induced ototoxicity and nephrotoxicity in LAHNC 
patients is described in Chapter 7.
This thesis ends with a summary of the studies and future perspectives in Chapter 8. 
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Abstract
Background: The purpose of this report was to present the results of accelerated 
radiotherapy with concomitant weekly cisplatin in head and neck cancer. 
Methods: One hundred six patients received concomitant cisplatin 40 mg/m2  weekly with 
accelerated radiotherapy up to a dose of 68 Gy over 5.5 weeks. 
Results: Ninety-nine percent of the patients received planned radiotherapy and 90% 
received ≥ 5 cycles of cisplatin. Moist desquamation of skin developed in 45% and confluent 
mucositis in 82%. Feeding tubes were required in 79% of the patients, and after 12 months 
in 4%. One patient developed nephrotoxicity. Three-year locoregional control, disease-
free survival and overall survival (OS) were 72%, 54% and 61%, respectively. Human 
papillomavirus (HPV) status was positive on polymerase chain reaction (PCR) and p16 in 
11 of 50 tested oropharyngeal carcinoma patients. Three-years OS was 81% and 66% in 
HPV-positive versus HPV-negative patients with oropharyngeal carcinoma.
Conclusion: Concomitant weekly cisplatin 40 mg/m2 with accelerated radiotherapy was 
well tolerated and treatment compliance was high.
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Introduction
In locally advanced head and neck cancer (LAHNC), concomitant chemoradiotherapy is 
standard treatment in patients with a good performance score because of a better overall 
survival (OS) compared to radiotherapy (RT)  alone or neoadjuvant chemotherapy followed 
by RT1. The most widely used schedule is concomitant cisplatin 100 mg/m2 on days 1, 
22 and 43 with conventional RT (Radiation Therapy Oncology Group [RTOG] schedule)2. 
Acute toxicity, such as mucositis, dermatitis, dysphagia, nausea, vomiting, polyneuropathy, 
ototoxicity, nephrotoxicity, and bone marrow suppression with neutropenic fever, is 
significant and approximately 25% of the patients cannot tolerate all 3 cisplatin courses2,3. 
About 80% to 90% of the patients treated with this schedule will receive ≥ 200 mg/m2 
cisplatin2,4. Late toxicity, pharyngeal dysfunction or laryngeal dysfunction, was observed 
in 39% to 51% of the patients5,6. 
Several attempts have been made to improve outcome of LAHNC patients. One of 
the advantages of accelerated RT is a higher local control rate and a slightly higher OS 
compared to conventional RT7,8. The normally used high-dose cisplatin schedule of once 
per 3 weeks 100 mg/m2 on day 1,22, 43 cannot be combined with accelerated RT because 
of the shortened period of RT (around 35 days). In our institution patients with LAHNC 
are treated with accelerated RT combined with weekly cisplatin 40 mg/m2. This weekly 
intermediate-dose cisplatin schedule in combination with RT has been described for 
nasopharyngeal cancer and cervical cancer with an increase in local control, OS, and a 
good feasibility9,10. However, in LAHNC data on chemoradiotherapy with weekly cisplatin 
are limited4,11-13.  
With this retrospective analysis we aim to add new data on acute toxicity, efficacy and 
feasibility to the current literature, describing our series of LAHNC patients treated with 
concomitant weekly cisplatin 40 mg/m2 and accelerated RT. Data on late toxicity were 
reported earlier14. 
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Patients and methods
Patients 
Between 2003 and 2010, patients with a histologically proven LAHNC  (oral cavity, 
oropharynx, hypopharynx or larynx), aged between 18 and 70, and Karnofsky performance 
status ≥70 received concomitant weekly cisplatin 40 mg/m2 with accelerated RT and were 
analyzed retrospectively. These patients had their diagnostic workup and were all treated 
at the Radboud University Medical Center. All patients were seen by the multidisciplinary 
head and neck oncology team. Routine pretreatment evaluation consisted of a complete 
medical history, physical examination, endoscopic evaluation, CT or MRI, ultrasonography of 
the neck nodes and chest X-ray or CT. All cases were discussed in the multidisciplinary head 
and neck oncology tumor board for tumor classification and treatment recommendations.
Treatment
Cisplatin 40 mg/m2 in 1 L NaCl 0.9% was administered weekly as a 1-hour intravenous 
infusion, with a maximum of 6 cycles at the outpatient clinic. Patients received standard 
antiemetics, such as dexamethasone and ondansetron. Prehydration consisted of 1L NaCl 
0.9% in 1.5 hours and posthydration consisted of 1.5 L NaCl 0.9% in 2 hours respectively 
with addition of potassium chloride and magnesium chloride. The scheduled time between 
the end of chemotherapy and start of radiotherapy was at least 1 hour. On days of twice 
daily RT, the cisplatin administration was in between 2 fractions. Cisplatin was delayed 
or discontinued in case the Karnofsky Score fell below 70, neutrophils < 1.5 x 109/l, or 
thrombocytes < 75 x 109/l. In case the creatinine clearance was below 60 ml/min due to 
dehydration, cisplatin was only administered if the creatinine clearance recovered to ≥ 
60 ml/min after rehydration. 
From 2003 until 2006, a 3D-conformal RT was used. Thereafter, intensity-modulated 
radiation therapy (IMRT) with simultaneous integrated boost was gradually introduced 
for all tumor sites. Radiation dose was 68 Gy in 34 fractions for the primary tumor and 
macroscopic involved lymph nodes, the elective area received 44 Gy in 22 fractions with 
3D-conformal RT or 50.3 Gy in 34 fractions with IMRT with a simultaneous integrated 
boost. An accelerated fractionation schedule  delivering 2 fractions per day during the 
last 1.5 weeks was used with both modalities. The overall treatment time was 5.5 weeks.
Although this schedule could be administered on an outpatient clinical base, a number 
of the patients was admitted to the hospital during the twice daily RT mainly for logistic 
reasons, in particular travel distance. 
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Evaluation of toxicity and efficacy
During treatment, the patients consulted a medical oncologist, radiation oncologist, nurse, 
dietician and oral hygienist at least weekly. According to international guidelines, patients 
who already had more > 10% weight loss before start of therapy were given nasogastric 
tube feeding. All other patients were closely monitored during treatment and were given 
a feeding tube if they had > 10% weight loss during the course of therapy or had clearly 
inadequate oral intake for several consecutive days. 
Blood samples were drawn weekly for hematology and chemistry. The medical oncologist 
used the ‘Common Toxicity Criteria version 3.0 (CTC version 3.0)15, the radiation oncologist 
used a validated list of criteria for the acute radiation toxicity16.   
After completion of treatment, patients were seen on a weekly basis until acute toxicity 
resolved and thereafter every 2, 3, 4 and 6 months for the first, second, third, fourth 
and fifth years, respectively. The response during and after treatment was assessed by 
physical examination complemented with endoscopic evaluation, when indicated. When 
tumor recurrence was suspected, imaging was performed to document the extent of the 
disease and biopsies were taken for pathological confirmation. The toxicity data as well as 
data on loco-regional tumor control, distant metastasis and survival were retrieved from 
the patients’ records and from the general practitioners.
Human papillomavirus analysis
Human papillomavirus (HPV) status was determined in all patients with oropharyngeal 
carcinomas. 
p16 Immunohistochemistry
Paraffine-embedded specimens were used for immunohistochemical (IHC) analysis. 
They were immunostained using an anti-p16 monoclonal antibody (clone G 175-405; BD 
Pharmingen, San Diego, CA) at a dilution of 1:10. As positive control, a cervical carcinoma 
tissue specimen with high p16 expression was used. p16 IHC was scored positive if a 
strong nuclear and cytoplasmic staining was present in > 70% of the malignant cells17,18. 
All other staining patterns were scored as negative. 
Polymerase chain reaction
Polymerase chain reaction (PCR) analysis was performed as described by Melchers et al19. 
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Statistical analysis
The endpoints for efficacy were locoregional control (LRC), distant metastasis-free survival, 
disease-free survival (DFS) and OS. Locoregional failure was defined as recurrent or 
residual disease in the head and neck region, biopsy proven, at least 6-8 weeks after 
ending chemoradiotherapy. DFS was measured from the date of diagnosis to the date of 
recurrent/residual disease or death and OS was measured from the date of diagnosis to 
the date of death. Patients who received a salvage cervical lymph node dissection were 
considered to have a recurrence. All survival data were measured from time of diagnosis of 
the primary tumor. The closeout date for survival was January 1, 2012. Cumulative survival 
data and toxicity data were calculated using the Kaplan-Meier method. For comparison 
of categorical variables, the chi-square test was used. All analyses were performed using 
SPSS for Windows version 20.0.
2EFFECTIVITY OF ACCELERATED RADIOTHERAPY WITH WEEKLY CISPLATIN
25
Results
Patient characteristics and achievement of planned therapy
Patient characteristics of the 106 analyzed patients are summarized in Table 1. For 2 
patients, despite having a Karnofsky Score of 60 this treatment was deemed as their best 
option and they were included in this analysis.
Table 1. Patient and tumour characteristics (n =106) 
Variable No. of patients (%)
Sex
 Male 81 (76.4)
 Female 25 (23.6)
Age, median (range) 56 (32-72)
Karnofsky score  
     100 6   (5.7)
       90 62 (58.5)
       80 26 (24.5)
       70 9  (8.5)
       60 2 (1.9)
Primary tumor site
     Oral cavity 12 (11.3)
     Oropharynx 53 (50.0)
     Hypopharynx 34 (32.1)
     Larynx 7   (6.6)
T classification
     T1 4  (3.8)
     T2 13 (12.3)
     T3 46 (43.4)
     T4 43 (40.6)
N classification
     N0 15 (14.2)
     N1 14 (13.2)
     N2a   3 (2.8)
     N2b 29 (27.4)
     N2c 37 (34.9)
     N3 8  (7.5)
Stage
    III 19 (17.9)
    IV 87 (82.1)
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Sixty-four patients received all 6 planned cisplatin cycles and 31 patients received 5 cycles; 
thus, 89.6% of the patients received at least 200 mg/m2 cisplatin. Reasons to skip a dose 
of cisplatin were: hematological toxicity (50%), clinical deterioration for non-infectious 
reasons (21%), infection (10%) or ototoxicity (2%). In 7 patients the sixth cisplatin dose was 
not administered due to other reasons, such as severe moist desquamation.  
RT was given as planned without any delay in all but 1 patient, who discontinued RT after 
a dose of 54 Gy, due to clinical deterioration. In 28% of the patients, IMRT was used, in 
the other 72%, conventional RT was used.
Acute toxicity
The acute cisplatin-related toxicity is presented in Table 2. Overall, the tolerability of this 
schedule was relatively good, with a low frequency of grade 3 or 4 adverse events. Twelve 
patients (11%) developed neutropenic fever. 
Table 2. The main acute toxicities  according to Common Toxicity Criteria version 3.0 
No. of patients (%)
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 All grade 
Nausea 44 (41.5) 10 (9.4) 4 (3.8) 58 (54.7)
Vomiting 26 (24.5) 9 (8.5) 4 (3.8) 39 (36.7)
Anemia 81 (76.4) 13 (12.3) 94 (88.7)
Neutropenia 14 (13.2) 18 (17.0) 30 (28.3) 6 (5.6) 68 (64.2)
Thrombocytopenia 30 (28.3) 14 (13.2) 5 (4.7) 49 (46.2)
Nephrotoxity  1  (0.9)  1 (0.9)
Local toxicity within the irradiated area was high with confluent mucositis in 77% and 
moist dermatitis in 27% of patients treated with IMRT and in 87% and 54% patients 
treated with 3D conformal RT, respectively. Moist desquamation was significantly less 
in patients treated with IMRT (p <0.05). Incidence over time of mucositis, dermatitis and 
dysphagia during the first 12 weeks after start of chemoradiotherapy is presented in 
Figure 1. 
In total, 78% of the patients needed tube feeding, and 39% of the patients had an elective 
placement of a percutaneous radiologic gastrostomy before start of treatment. The 
median duration of tube feeding was 8.0 weeks (range 1 to 108 weeks). Four patients 
(4%) needed tube feeding for more than 1 year. Fifty-eight patients (55%) were admitted 
to the hospital during or within 2 weeks after the end of the chemoradiotherapy. In 21% 
the admission was for logistic reasons (ie, a long travelling distance to the hospital). 
Other  reasons for admission were fever (24%), pneumonia (12%), dehydration (12%), 
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nausea or vomiting (7%),  or problems with taking care for dermatitis or mucositis 
(7%). Very often a combination of adverse events (often grade 1 or 2)  determined the 
necessity of admission. 
Figure 1. Scores for mucositis (A), dermatitis (B), and dysphagia (C) percentage of patients reaching a 
certain score versus the time after the start of chemoradiotherapy
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Tumor response and survival 
After a median follow-up of 34 months (range 2-92 months), 28% of the patients developed 
a local or loco-regional recurrence and 8% developed distant metastasis, of which 1 had 
concurrent local failure. Eight patients (8%) had a cervical lymph node dissection because 
of a residual lymph node after treatment. The actuarial estimate of loco-regional control 
at 3 and 5 years was 72% and 65%, respectively (Figure 2). The distant control rate at 3 
and 5 years was 92%. A loco-regional failure rate at 3 years of 15% versus 52% (p =0.054) 
was observed with IMRT versus 3D conformal RT, respectively.
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At the end of the evaluation period, 51 (48%) patients had died: disease progression 
(n = 30); myocardial infarction during neutropenia and pneumonia 4 days after end of 
treatment (n =1);  second primary malignancy (n = 6; 2 of whom died with a second head 
and neck tumor); other causes (n =7); unknown cause of death (n =7). Three-year DFS and 
OS were 54% and 61% respectively, the 5-year DFS and OS 39% and 48%, respectively 
(Figure 2). 
Figure 2. Kaplan–Meier estimate of disease-free survival (DFS), overall survival (OS), and locoregional 
and distant control
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Survival and HPV status
In 50 of 53 patients with oropharyngeal carcinoma, the HPV status was determined. In 
11 patients (22%) both PCR on HPV 16, 18 or 33 and p16 IHC were positive, and in 28 
patients (56%) both were negative. Discrepancy between IHC and PCR was seen in 22% 
of the patients (Table 3) . DFS and OS at 3 years were 85% and 85% in p16  positive OPC, 
respectively, versus 51% and 63% in the p16 negative OPC (p =0.09 and p =0.18). DFS 
and OS at 3 years for the patients with HPV PCR positive were 79% and 84%, respectively, 
versus 46% and 58% in the patients with HPV PCR negative oropharyngeal carcinoma (p 
=0.10 and p =0.11).  
2EFFECTIVITY OF ACCELERATED RADIOTHERAPY WITH WEEKLY CISPLATIN
29
Table 3. HPV status of patients with oropharyngeal cancer
HPV status PCR No. of 
patients (%)
negative HPV 16 HPV 18 HPV 33 unknown total
p16 positive 2 11 0 1 1 15 (30)
p16 negative 28 4 1 0 2 35 (70)
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Discussion
We retrospectively evaluated the feasibility, efficacy and toxicity of concomitant weekly 
cisplatin 40 mg/m2 with accelerated RT in a large cohort of LAHNC patients. The feasibility 
of the schedule was excellent, with RT given as planned without delay to all but 1 patient. 
Sixty percent of the patients received all 6 planned cycles of cisplatin,  whereas 90% of 
the patients received a cumulative dose of at least 200 mg/m2 cisplatin. It is assumed that 
a cumulative dose of 200 mg/m2 cisplatin is sufficient for antitumor effects, because this 
dose has probably no diminishing effect on locoregional and distant control rates6,13,20. 
Compared with other studies, we were able to administer this dose in a higher number of 
patients than reported before. Only 41%, 65%, 68% and 71% of the patients in four other 
retrospective studies using concomitant weekly cisplatin 40mg/m2 with radiotherapy 
received a cumulative dose of at least 200 mg/m2 cisplatin4,12,13,21. In a prospective 
study in 37 patients with weekly cisplatin 40 mg/m2  combined with hyperfractionated 
radiotherapy, only 7 patients (19%) received a cumulative dose of at least 200 mg/m2 
cisplatin11. These observations led to question why we could administer a much higher 
cumulative dosage of cisplatin. Taking into consideration the known risk factors, such as 
age and performance score, we had a relatively young population of patients, median 
56 versus 55-65 years of age in the other retrospective studies4,11,13. Unfortunately, 
performance score was not mentioned in the studies mentioned above. Other reasons 
may be the way of administration of cisplatin and other supportive care measures. In 
contrast to the description in other studies, we administer a larger volume of NaCl 0.9% 
during prehydration and posthydration (ie, 3,5L of NaCl 0.9% in 5.5 hours), which may have 
impact on the tolerance and toxicity of cisplatin11,12. With regard to acute cisplatin-induced 
nephrotoxicity, the incidence of 0.9% in our study is much less then described previously, 
which may be due to our larger volume pre- and posthydration4,11-13.
Until now no randomized studies comparing cisplatin weekly 40 mg/m2 and cisplatin 
100 mg/m2 on days 1,22 and 43, have been performed. Acknowledging the limitations 
of retrospective comparisons, treatment-related grade 3-5 toxicity of the 100 mg/m2 
schedule with conventional RT was higher for hematological toxicity 45% versus 39%,and 
renal toxicity 7-8% versus 1% in our population, but less for mucositis, 42% versus 77% in 
our population; the latter is probably caused by the accelerated RT 2,22. 
In a study  using the same accelerated radiotherapy schedule we observed a similar 
incidence of confluent mucositis of 79%, which indicates that concomitant weekly 
cisplatin does not further enhance mucosal toxicity23. Studies using conventional RT 
combined with weekly cisplatin showed 31-75% mucositis ≥ grade 3, but similar rates of 
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hematological and renal toxicity as we found.21,24-26 Hospital admissions were required 
in 55% of our patients, 40% for acute reasons and 15% for logistical reasons. In a study 
using conventional RT with weekly cisplatin the number of admissions was comparable 
to our results (40%) and thus, the accelerated radiotherapy does not seem to contribute 
much to the admissions.27
Seventy-eight percent of our patients were temporarily feeding tube dependent, of 
whom only 4 patients were still feeding tube dependent after one year. In the RTOG 
0129 study feeding tube rates at the end of treatment were 67% and 69% for accelerated 
and standard fractionation and after one year 26 and 29%, respectively. 28 In other 
chemoradiation trials approximately 80% of the patients received tube feeding during 
treatment and 4-39% after one year of treatment, which is in the same range as in our 
series.6,11,12,29
Comparing our efficacy data with previous studies is prone to bias, but nevertheless 
provides a rough indication of the effectiveness of our schedule. In this study we found 
3-years DFS and OS of 54% and 61% and 3-years LRC of 72%. These results are consistent 
with those described in other studies using weekly cisplatin 40 mg/m2 which report 2-years 
DFS and OS in a range of 46-78% and 51-67%, respectively and LRC of 69-79%4,11,12. Phase 
III studies with chemoradiotherapy with cisplatin 100mg/m2 reported 5-years OS in a range 
of 30-54%, which is in concordance with our 5-year OS of 48%2,22. 
We found a significant difference between LRC rates in patients treated with or without 
IMRT. However, patient and tumor characteristics between the 3D-conformal RT (n 
=76) and IMRT (n =30) differed greatly. For example, our IMRT-treated patients were 
significantly younger and had a significantly higher p16 positive rate. This makes that 
these results are hard to interpret. The RTOG 0129 trial compared accelerated versus 
standard fractionation in combination with cisplatin 100mg/m2 in a phase III study.28 
They did not show a difference in overall survival. However, there were no differences in 
grade 3-5 toxicity. Furthermore, the GORTEC 99-02 study showed no gain in efficacy of 
accelerated chemoradiotherapy compared to conventional RT.29 Although these studies 
showed no benefit of accelerated RT with chemotherapy in the general population 
of head and neck cancer patients, there might be subgroups that an profit from this 
strategy. Two studies have shown that patients with tumors with a high EGFR-expression 
benefit from accelerated RT whereas low EGFR-expressing tumors do not.30,31 Selection of 
patients based on their EGFR-expression in the tumor, or possible other key-molecules 
of downstream signaling pathways, will possibly show significant differences between 
conventional and accelerated (chemo)radiotherapy.
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The difference in OS between HPV-positive and HPV-negative oropharyngeal carcinoma 
in our study was not significant, as has been described in other series17. This might be 
caused by the low number of HPV-positive oropharyngeal carcinoma . It is known that 
patients with HPV-negative oropharyngeal carcinoma have a worse prognosis, with a 
3-years OS of 32%-57%17,32. However, in our study, we found a 3- years OS in p16-negative 
and p16-positive oropharyngeal carcinoma of 63% and 85%, respectively. Since smoking 
status of our patients was not known, we were not able to determine if the p16-negative 
oropharyngeal carcinoma cases were at intermediate or high risk, as described by Ang 
et al17.  
In conclusion, our schedule of concomitant cisplatin 40mg/m2 weekly combined with 
accelerated radiotherapy in LAHNC patients is feasible, and compliance is excellent and 
compares well to previously described combined chemoradiation schedules with weekly 
cisplatin. Although there seems to be more local toxicity because of the accelerated 
radiotherapy, we observed less hematological and much less renal toxicity compared to 
the conventional chemotherapy schedule, whereas the OS of our schedule is in the upper 
range of previous studies. Selection based on biological tumor features and not only on 
clinical characteristics will likely improve identification of patients who are most likely to 
benefit from this treatment strategy.  We therefore plea to further investigate the value of 
this weekly cisplatin 40 mg/m2 concomitant schedule head-to-head with the still standard 
3 weekly schedule of 100 mg/m2 in a prospective randomized multicenter trial.
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Degree of nephrotoxicity 
after intermediate or high dose 
cisplatin-based chemoradiotherapy 
in patients with locally advanced 
head and neck cancer 
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Abstract 
Background: The purpose of this study was to compare the occurrence of cisplatin-
induced nephrotoxicity between concomitant chemoradiotherapy with high versus 
intermediate-dose cisplatin. 
Methods: One hundred forty-four patients with locally advanced head and neck (LAHNC) 
or nasopharyngeal cancer (NPC) were included; 40 patients received cisplatin 100 mg/m2 
(high dose)  on days 1, 22 and 43, and 104 patients received cisplatin 40 mg/m2 weekly 
(intermediate dose) during 6 weeks in combination with radiotherapy. 
Results:  During treatment with intermediate- dose cisplatin, 6.7% developed an increase 
of ≥50% serum creatinine versus 60.0% treated with high-dose cisplatin (p<0.05). 
Nephrotoxicity (all grades) scored by Common Toxicity Criteria for Adverse Events (CTCAE) 
version 3.0 or CTCAE version 4.03 was 53% and 100% in the high-dose group and 4.8% 
and 68% in the intermediate- dose group, respectively. 
Conclusion: Significantly less nephrotoxicity occurs during chemoradiotherapy with 
intermediate-dose cisplatin compared with high-dose cisplatin. The CTCAE version 4.03 
seems to be more appropriate in scoring nephrotoxicity than the CTCAE version 3.0.
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Introduction
Concomitant chemoradiotherapy is the standard treatment for patients with locally 
advanced head and neck cancer (LAHNC) based on the results of 2 meta-analyses.1,2 
Concomitant chemoradiotherapy showed a survival benefit of 8% compared to 
radiotherapy alone. Radiotherapy with concurrent cisplatin 100 mg/m2 on days 1, 22 and 
43 is worldwide the most often used schedule for treatment of patients with LAHNC in 
primary and post-operative settings. 3-6 For patients with nasopharyngeal cancer (NPC), 
chemoradiotherapy with cisplatin 100 mg/m2 is proven superior to radiotherapy alone.7 
Although very effective, this treatment is associated with high rates of acute toxicity. An 
alternative treatment schedule is radiotherapy with weekly cisplatin 40 m/m2 with good 
feasibility and efficacy.8,9 
The main adverse events associated with cisplatin-based treatment are nephrotoxicity, 
ototoxicity and neuropathy. The clinical manifestations of nephrotoxicity are an impaired 
glomerular filtration rate (GFR) leading to a higher serum creatinine, and reduced 
serum magnesium and potassium levels as common symptoms of cisplatin-induced 
tubulopathy. 10-12 The onset of renal failure is gradual, occurring approximately 3 to 5 
days after administration and is dose-dependent. 10 Because of this acute nephrotoxicity, 
a number of patients do not receive the optimal cisplatin dose.8 A suboptimal cisplatin 
dose can lead to decreased survival rates.13 In addition, life-threatening and even fatal 
renal damage has been reported in patients with head and neck cancer receiving definitive 
chemoradiotherapy, often due to reduced oral intake because of mucositis.14,15 
In literature nephrotoxicity is reported using several scoring systems, such as: (1) a 
predefined absolute or relative increase in serum creatinine; (2) the Common Terminology 
Criteria for Adverse Events (CTCAE) version 3.0; (3) the updated CTCAE version 4.0; or (4) 
the Risk, Injury, Failure, Loss, End-stage (RIFLE) kidney disease criteria.3,8,16-19 The RIFLE have 
been published by the Acute Dialysis Quality Initiative Group as a consensus definition and 
classification system with the purpose to create a uniform definition of acute kidney injury 
20,21. In other fields than oncology, these criteria are widely accepted. Classification in the 
CTCAE version 3.0 and earlier was based on subcategories defined on serum creatinine 
relative to the local upper limit of normal value, whereas the RIFLE criteria classify renal 
function relative to baseline serum creatinine, or decrease of estimated glomerular 
filtration rate (Table 1). The CTCAE version 4.03 takes into account both upper limit of 
normal and baseline creatinine.  This  broad variation in scoring systems is the reason 
why studies are not always comparable. In addition, this could presumably lead to an 
underestimation of nephrotoxicity.   
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The purpose of this retrospective analysis was to compare nephrotoxicity in patients 
with LAHNC or NPC treated with high-dose cisplatin 100 mg/m2 administered once per 
3 weeks or intermediate-dose cisplatin 40 mg/m2 administered weekly with concurrent 
radiotherapy.  Furthermore, we compared nephrotoxicity, as scored by CTCAE version 3.0, 
with the updated CTCAE version 4.03 and the RIFLE criteria.
Table 1. CTCAE and RIFLE criteria for ‘creatinine increase - nephrotoxicity’ and acute kidney injury
Grade
1 2 3 4
CTCAE v 3.022 >ULN – 1.5 x ULN > 1.5-3.0 x ULN >3.0-6.0 x ULN >6.0 x ULN
CTCAE v 4.0319 >1-1.5 x baseline;
  ULN-1.5x ULN
>1.5-3.0 x baseline;
>1.5-3.0 x ULN 
>3.0 x baseline; 
>3.0-6.0 x ULN
>6.0 x ULN
Stage
Risk Injury Failure Loss ESRD
RIFLE ≥ 1.5-2.0 x 
baseline
Decrease eGFR 
≥ 25%
≥ 2.0-3.0 x 
baseline
Decrease eGFR 
≥ 50%
≥ 3.0 x baseline
Decrease eGFR 
≥ 75%
S-creatinine ≥ 354 
mM with acute 
rise of ≥ 44 mM
Complete loss of 
renal function > 4 
weeks
End stage renal 
disease
Abbreviation: ULN = upper limit of normal 
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Patients and methods
Patients
We reviewed the medical records of LAHNC or NPC patients treated with cisplatin-
containing concomitant chemoradiotherapy at the Radboud university medical center 
from 2003 to 2011. Inclusion criteria for this retrospective study were LAHNC patients 
for whom treatment with concurrent chemoradiotherapy was chosen as primary curative 
treatment or as adjuvant postoperative treatment. In addition, patients with NPC treated 
with concurrent chemoradiotherapy were included. Patients, of whom data on baseline 
serum creatinine and one or more repeated serum creatinine during treatment were not 
available, were excluded from this study. 
Before the patients started with concomitant chemoradiotherapy, the Multidisciplinary 
Head- and-Neck Oncology Team discussed all patients, as part of the diagnostic workup. 
Treatment
Post-operative LAHNC patients and NPC patients received cisplatin 100 mg/m2 every 
3 weeks in combination with conventional radiotherapy. Patients who were primarily 
treated with concomitant chemoradiotherapy received weekly cisplatin 40 mg/m2 in 
combination with accelerated radiotherapy.9 From 2003 until 2006, a 3D-conformal 
radiotherapy technique was used. Since 2006, intensity-modulated radiation therapy with 
simultaneous integrated boost (IMRT-SIB) was gradually introduced for all tumor sites and 
both schedules.
Cisplatin 100 mg/m2 was administered in 1 L of saline as a 3-hours infusion on days 1, 22 
and 43 in a clinical setting. Prehydration consisted of 1 L saline and posthydration of 3 L 
of saline in 18 hours with potassium and magnesium chloride, 30 mmol and 15 mmol in 
total, respectively. Patients received antiemetics, including dexamethasone, ondansetron 
and aprepitant. 
Cisplatin 40 mg/m2 was administered intravenously in 1 L of saline as 1-hour infusion 
weekly, with a maximum of 6 cycles in the outpatient clinic. Prehydration and posthydration 
existed of 1 L and 1.5 L of saline with addition of potassium and magnesium chloride, 25 
mmol, and 25 mmol in total, respectively. Patients received standard antiemetics, such 
as dexamethasone and ondansetron. Dose modifications for cisplatin were done in case 
the neutrophils were below 1.5 x 109/L or the platelets were below 75 x 109/L. In case the 
estimated glomerular filtration rate was below 60 mL/min, cisplatin was only administered 
if the estimated glomerular filtration rate recovered to ≥ 60 mL/min after rehydration. 
Patients treated with high-dose cisplatin dose received a dose reduction in case of the 
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neutrophils or the platelets did not recover after a week’s delay and cisplatin was delayed 
or discontinued in case Karnofsky Score fell below 70. Applying similar toxicity rules to 
patients treated with intermediate-dose cisplatin, courses were skipped or discontinued, 
without dose reductions.
Nephrotoxicity evaluation
Baseline creatinine was obtained within 4 weeks prior to the start of the chemoradiotherapy. 
During treatment, the highest creatinine level measured between the administration of 
the first dose of cisplatin and 4 weeks after the last dose was recorded. During treatment, 
creatinine was measured weekly until 1 week after end of treatment. Thereafter, it was 
measured only when indicated (eg, when renal function was not restored to normal). 
During follow up, the highest creatinine level was retrieved from four weeks after the 
last dose until one year after the end of treatment to determine late nephrotoxicity. 
There were no standardized follow-up measurements in our patients. In some patients, 
no measurements were performed in this period, whereas, in other patients, multiple 
measurements were performed.  
The RIFLE classification uses  an increase of 50% in serum creatinine or a decrease in 
estimated glomerular filtration rate of 25% as the main criteria for acute kidney injury .21 
That is why our main analysis was performed with an increase of creatinine of 50% as 
primary outcome measure.  The estimated glomerular filtration rate was calculated using 
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.23 This formula 
takes age, race and sex into account calculating the glomerular filtration rate, and is better 
suited to estimate glomerular filtration rate in individuals with normal renal function than 
other algorithms.  
The secondary aim was to compare the CTCAE version 3.0, on which most of the current 
literature on the evaluation of cisplatin-induced nephrotoxicity is based, with the newer 
version 4.03.18,19 Because the adverse event “acute renal toxicity” is only defined in the 
CTCAE version 4.03 and not in  CTCAE version 3.0, we used the adverse event  “serum 
creatinine increase” to compare renal function according to the both versions. As is stated 
in Table 1, the main difference between these 2 versions in grading nephrotoxicity is the 
comparison of current serum creatinine with the upper limit of normal in version 3.0, while 
in version 4.03 also the difference between the current serum creatinine with baseline 
serum creatinine is defined. Hospitalization because of nephrotoxicity and outpatient 
rehydration were also taken into account when evaluating nephrotoxicity. 
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Other factors of interest
As baseline laboratory parameters creatinine, albumin and magnesium, were considered 
in our analysis. Furthermore, concurrent medications were evaluated for an association 
with nephrotoxicity, in particular loop diuretics, angiotensin-converting-enzyme (ACE) 
inhibitors, and angiotensin II receptor antagonists.16 In addition, comorbidity, such as 
diabetes mellitus and hypertension, were considered in the analysis.
Statistical analysis
Data on treatment, hospitalizations, and follow-up were assessed through the patient 
information system of the Radboud University Medical Center and individual patient 
charts. All statistical analyses were performed using SPSS version 20, and a p-value <0.05 
was considered significant.  
For all nominal independent data, number and percentage was calculated, as was the 
mean and SD for continuous independent variables.  Differences in mean values between 
the two regimes were analyzed using the independent-samples t test, if shown to have a 
normal distribution.
We performed a logistic regression analysis with serum creatinine increase of 50% over 
baseline level as the dependent variable and as independent variables age, treatment 
group, sex, hypertension, diabetes mellitus, treatment with loop diuretics, ACE inhibitors 
or angiotensin receptor antagonists and baseline albumin and magnesium levels. 
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Results
In total 144 patients were included, of whom 40 patients received cisplatin 100 mg/m2 on 
days 1, 22, and 43, and 104 patients received cisplatin 40 m/m2 weekly, with a maximum 
of 6 weeks. Patient baseline characteristics are listed in Table 2.
Table 2. Patient characteristics
Cisplatin 40 mg/m2
(n =104)
Cisplatin 100 mg/m2
(n = 40)
Sex
     Male 80 (76.9) 28 (70.0)
     Female 24 (23.1) 12 (30.0)
Age, mean (SD) 55.83 (7.607) 49.25 (10.337)
Tobacco use
     Yes 54 (51.9) 6 (15.0)
     Quit 40 (38.5) 19 (47.5)
     No 9 (8.7) 15 (37.5)
     Unkown 1 (1.0) 0 (0.0)
Alcohol use
     Moderate or Heavy drinker 48 (46.2) 7 (17.5)
     Social drinker 25 (24.0) 9 (22.5)
     Quit 22 (21.2) 8 (20.0)
     No 6 (5.8) 16 (40.0)
     Unkown 3 (2.9) 0 (0.0)
Karnofsky score
     100 6   (5.8) 2 (5.0)
       90 61 (58.7) 25 (62.5)
       80 26 (25.0) 11 (27.5)
       70 9  (8.7) 2 (5.0)
       60 2 (1.9) 0 (0.0)
Primary tumour site
     Oral cavity 12 (11.5) 11 (27.5)
     Oropharynx 52 (50.0) 0 (0.0)
     Hypopharynx 33 (31.7) 1 (2.5)
     Larynx 7   (6.7) 2 (5.0)
     Nasopharynx 0 (0.0) 22 (55.0)
     Vestibulum nasi 0 (0.0) 1 (2.5)
     Unknown primary 0 (0.0) 1 (2.5)
     Regional recurrence 0 (0.0) 2 (5.0)
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Table 2. Continued
Cisplatin 40 mg/m2
(n =104)
Cisplatin 100 mg/m2
(n = 40)
T classification
     T1 4  (3.8) 7 (18.9)
     T2 13 (12.5) 9 (24.3)
     T3 44 (42.3) 6 (16.2)
     T4 43 (41.3) 15 (40.5)
N classification
     N0 15 (14.4) 7 (18.9)
     N1 14 (13.5) 12 (32.4)
     N2a 3 (2.9) 0 (0.0)
     N2b 28 (26.9) 5 (13.5)
     N2c 37 (35.6) 2 (5.4)
     N2 (NPC) 0 (0.0) 6 (16.2)
     N3 7  (6.7) 5 (13.5)
Treatment intention
    Primary 104 (100) 22 (55.0)
    Postoperative 0 (0.0) 18 (45.0)
Baseline serum creatinine, mean (range) 69 µmol/l (41 – 105) 68 µmol/l (32 - 102)
Baseline CKD-EPI, mean (range) 97.8 (60.4 – 123.3) 103.4 (76.7 - 125)
Abbreviations: NPV, nasopharyngeal cancer; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration
Treatment compliance 
Sixty-eight percent of the patients treated with high-dose cisplatin received all planned 3 
cycles, 20% received 2 cycles, and 13% received only 1 cycle of cisplatin 100 mg/m2. Of all 
patients treated with high-dose cisplatin, 53% received the planned 300 mg/m2, and 88% 
of the patients received ≥200 mg/m2 cisplatin. Of the patients treated with intermediate-
dose cisplatin, 62% received all planned 6 cycles and, thus, the planned 240 mg/m2, 
whereas 28% received 5 cycles (ie, 200 mg/m2), 9% received 4 cycles (ie, 160 mg/m2) and 
2% received only 3 cycles (ie, 120 mg/m2). Thus, a total of 90% of the intermediate-dose 
cisplatin patients received ≥200 mg/m2 cisplatin. 
Nephrotoxicity was the reason for delayed administration or terminating cisplatin in 18% 
of the patients treated with high-dose versus 0% of the patients with intermediate-dose 
cisplatin (p<0.05). Other reasons for modifying cisplatin were ototoxicity (8% vs 1%, p 
=0.07), hematological toxicity (20% vs 15%, p =0.33), infection (0% vs 4%, p =0.27), clinical 
deterioration (0% vs 9%, p <0.05) and other (0% vs 10%, p <0.05) in the high-dose versus 
intermediate-dose groups, respectively. 
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Nephrotoxicity
At baseline, there was no statically significant difference (p =0.78) in serum creatinine 
levels between the 2 patient groups (Table 2). At baseline, all patients had an estimated 
glomerular filtration rate using the CKD-EPI formula of 60 or more, and there was no 
statistical difference in estimated glomerular filtration rate between the two groups ( 
p <0.001; Figure 1). An increase of ≥50% in serum creatinine relative to baseline (RIFLE 
criteria) was found in 60% of patients in the high-dose versus 6.7% in the intermediate-dose 
group (p <0.001). The median rise in serum creatinine was 57% versus 6%, respectively. 
Figure 1. Delta creatinine in the 2 treatment groups. The black line in each group represents the median 
value in that group. The dotted line on the graph represents 50% increase of creatinine
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In patients treated with the high-dose cisplatin, who developed an increase of ≥50% in 
serum creatinine, the maximum increase in serum creatinine was reached most often 
after 1 or 2 cycles of cisplatin, whereas patients treated with intermediate dose cisplatin, 
reached the maximum increase in serum creatinine mostly after 6 cycles (Table 3). In the 
high-dose schedule 32.5% developed a decrease of ≥25% in CKD-EPI during treatment 
relative to baseline compared to 2.9% in the intermediate-dose regime.
Table 4 provides the distribution of cisplatin-induced nephrotoxicity during treatment 
graded by the CTCAE version 3.0 and version 4.03 and the RIFLE criteria in the 2 treatment 
regimes. Fifty-three percent of the patients in the high-dose group experienced at least 
grade 1 nephrotoxicity according to CTCAE version 3.0, compared to 100% of the patients 
when CTCAE version 4.03 was used. For the intermediate-dose group these numbers were 
5% and 75%, respectively. Scoring with the CTCAE version 4.03 showed that nephrotoxicity 
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grade 2 and 3 occurred in 60% versus 6.7% in the high-dose versus the intermediate-
dose, whereas scoring with the CTCAE version 3.0 showed nephrotoxicity grade 2 and 3 
only in 10% versus 0%, respectively. Using the RIFLE criteria, only 6.7%  of patients in the 
intermediate-dose group were classified in the Risk category,  and no Injury or Failure, 
whereas the high-dose group scored 17% of patients in the Risk catergory, 10% in Injury 
and 7.5% in Failure. 
Table 3. The table shows all patients that developed an increase of ≥50% in serum creatinine and illus-
trates after which dose the highest serum creatinine was reached
  Dose after which the highest creatinine 
was reached
No. of patients (%)
Cisplatin 100 mg/m2
total (n = 24/40)
100 mg/m2
200 mg/m2
280 mg/m2
300 mg/m2
8 (33.3)
8 (33.3)
1 (4.2)
7 (29.2)
Cisplatin 40 mg/m2
total (n = 7/104)
160 mg/m2
200 mg/m2
240 mg/m2
2 (28.6)
2 (28.6)
3 (42.9)
Table 4. Nephroxoticity according to the Common Terminology Criteria for Adverse Events version 3.0 and 
4.03 (using elevation above baseline with version 4.03) and the Risk, Injury, Failure, Loss, Endstage criteria
Cisplatin 100 mg/m2
No. of patients (%)
Cisplatin 40 mg/m2
No. of patients (%)
CTCAE 3.0
0
1
2
3
4
19     (47.5)
17     (42.5)
3       (7.5)
1       (2.5)
0       (0.0)
99     (95.2)
5       (4.8)
0       (0.0)
0       (0.0)
0       (0.0)
CTCAE 4.03
0
1
2
3
4
0       (0.0)
16     (40.0)
21     (52.5)
3       (7.5)
0       (0.0)
26     (25.0)
71     (68.3)
7       (6.7)
0       (0.0)
0       (0.0)
RIFLE criteria
Risk 
Injury
Failure
Loss
End stage renal disease
17     (42.5)
4     (10.0)
3     (7.5)
0     (0.0)
0     (0.0) 
7       (6.7)
0       (0.0)
0       (0.0)
0       (0.0)
0       (0.0)
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; RIFLE, Risk, Injury, Failure, Loss, End-
stage renal disease
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Data of renal function during follow-up were not always available, because serum creatinine 
was not routinely evaluated after treatment. Serum creatinine after treatment could be 
retrieved in 30 of 40 patients from the high-dose regime and in 51 of 104 patients from 
the intermediate- dose regime. Of these patients, 37% and 4% (p <0.05) had an increase of 
≥50% in serum creatinine in comparison to baseline in the high-dose versus intermediate-
cisplatin group, respectively. Ninety percent of these patients acquired the impaired renal 
function during treatment, whereas 10% developed it after the end of treatment. 
In the high-dose regime, 3 of 40 patients (8%) are currently being treated by a nephrologist 
because of renal impairment, whereas none of the patients in the intermediate-dose 
group are attending. Two of these patients received a cumulative dose of only 100 mg/m2 
cisplatin and 1 of 200 mg/m2. Their baseline creatinine levels were 60, 66 and 74 μmol/L 
and, after only 1 cycle their serum creatinine increased to 308 and 291. The patient who 
received 2 cycles of cisplatin had a creatinine of 508 μmol/L after these two cycles. None 
of these patients needed renal replacement therapy.  
Hospitalization and rehydration
Overall, patients treated with high-dose cisplatin needed significantly (p < 0.05) more 
unplanned hospitalizations. Thirty of the 40 patients (75%) in the high-dose group 
were admitted, of whom 15 were admitted twice. Sixty of the 104 patients (58%) in the 
intermediate-group were admitted, of whom 16 needed 2 hospitalizations and 2 needed 3.
Nephrotoxicity in combination with dehydration was the main reason for hospitalization 
in 44% of patients in the high-dose cisplatin versus none in the intermediate-dose 
cisplatin group. Other reasons for hospitalization in both regimes were: dehydration 
without nephrotoxicity, nausea and vomiting, fever, leucopenia and rarely pneumonia, 
pain, delirium, mucositis, hyponatremia or complications of percutanous endoscopic 
gastronomy tube. Additionally, in 9% of patients in the high-dose group who had alternative 
main reasons for hospitalization, nephrotoxicity was diagnosed during the hospitalization, 
which prolonged the hospital stay.
In case of a minor increase of creatinine or urea, extra fluids were given in an outpatient 
setting. Twent- five percent of the patients treated with high-dose cisplatin needed extra 
fluid versus 12% in the intermediate-dose group (p =0.08). Of the patients treated with 
high-dose cisplatin 58% needed a percutanous endoscopic gastronomy tube versus 79% 
of the patients treated with intermediate-dose cisplatin (p =0.01). 
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Other factors of interest
The logistic regression analysis showed that the main determinant of nephrotoxicity is 
the cisplatin dose (Table 5). A low magnesium was the only baseline laboratory parameter 
that was correlated with an increase in serum creatinine > 50% that was proven to be 
statistically significant. At baseline, there was no statically significant difference (p=0.54) 
in serum magnesium levels between the 2 patient groups. The use of ACE inhibitors was 
also significantly correlated with renal function (ie, the use of ACE inhibitors was associated 
with an increase in serum creatinine of > 50%). However, as only 12 of the 144 patients 
had a hypomagnesaemia at baseline and only 11 of the patients used ACE inhibitors, it is 
hard to draw firm conclusions. Clinical parameters, other medication, or co-morbidities 
were not correlated with the development of nephrotoxicity. 
Table 5. Association between nephrotoxicity  and various clinical and treatment parameters
Variable Significance Exp(B) Confidence interval
Sex 0.405 0.54     [0.13-2.28]
Treatment group 0.000 140.58 [21.66-912.20]
Age 0.193 1.05 [0.98-1.12]
Hypertension 0.196 0.15 [0.01-2.64]
Diabetes mellitus 0.695 0.47 [0.01-21.32]
Loop diuretics 1.000 0.00 [0.00]
ACE inhibitors 0.014 57.82 [2.29-1460.96]
Angiotensin receptor antagonists 0.213 18.72 [0.9-1890.18]
Baseline albumin 0.719 1.03 [0.87-1.23]
Baseline magnesium 0.036 0.00 [0.00-0.51]
Abbreviation: ACE, angiotensin-converting enzyme
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Discussion
In this retrospective study we evaluated nephrotoxicity of 2 cisplatin-based 
chemoradiotherapy schedules in patients with LAHNC. Our study showed that 100 mg/
m2 cisplatin on days 1, 22, and 43 led to more acute and chronic kidney injury, compared 
to weekly cisplatin 40 mg/m2 during six weeks. Patients treated with high-dose cisplatin 
needed significantly more hospitalizations, with nephrotoxicity being one of the main 
causes. Moreover, we showed that within the same dataset, using CTCAE version 4.03 
significantly more cases of nephrotoxicity and higher nephrotoxicity scores were reported 
than using the CTCAE version 3.0. The CTCAE version 4.03 correlated better with the 
nephrotoxicity defined as ≥ 50% increase of creatinine than the CTCAE version 3.0. The 
combined grade 2 to 4 nephrotoxicity scored with the CTCAE version 4.03, expectedly, 
correlates well with classification using the RIFLE criteria. 
Although a former retrospective study already showed a trend toward higher incidence 
of acute renal failure in high-dose cisplatin when defining acute renal failure as a ≥25% 
increase in serum creatinine, our study found a significant difference between high-dose 
and intermediate-dose cisplatin treatment using several scoring systems and definitions 
of acute renal failure.8 Both Espeli et al and our group showed that there was a higher 
incidence of chronic kidney injury in the high-dose cisplatin schedule. In a retrospective 
study comparing 4 different chemoradiotherapy regimes in patients with LAHNC, 
renal function was evaluated using the CTCAE version 2.0 (similar to CTCAE version 3.0 
in creatinine increase).24 They found a significant difference in grade 3 nephrotoxicity 
between patients treated with cisplatin 100 mg/m2 on days 1, 22, and 43 and cisplatin 20 
mg/m2 on days 1-5 and 29-33 of 8% versus 1% (p =0.02). 
In the landmark studies of chemoradiotherapy with cisplatin 100 mg/m2, nephrotoxocitiy 
is reported using the CTCAE version 3.0 or older.3-5 They report an incidence of grade 3 
to 4 nephrotoxicity of 4% to 8%. In our study, we found a grade 3 to 4 according to CTCAE 
version 3.0 with an even lower incidence (2.5%). Importantly, we demonstrated a 3 times 
higher incidence of grade 3 to 4 nephrotoxicity (7.5%) according to CTCAE version 4.03 
than using the CTCAE version 3.0. Moreover, grade 2 nephrotoxicity according to the 
CTCAE version 4.03 means an increase in serum creatinine of 50 to 300%, which is clinical 
relevant nephrotoxicity. This suggests that nephrotoxicity as defined by CTCAE version 3.0 
in the landmark studies is substantially underestimated. Of note, the RIFLE criteria are 
internationally adopted criteria for acute kidney injury (Table 1). 
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Acute nephrotoxicity was found in a high number of patients, especially those treated 
with high-dose cisplatin. None of these patients though, became dialysis dependent. 
However, it is important to realize that acute renal failure, with or without the need for 
temporary dialysis, is associated with increased long-term mortality risk, independent 
of the residual kidney function.25 Moreover, an episode of acute kidney injury in 
patients with normal baseline creatinine, despite complete recovery, is associated 
with increased risk of later developing CKD-EPI estimated glomerular filtration rate of 
< 60 mL/min/1.73m2.26 This indicates that cisplatin-induced nephrotoxicity, even with 
normalization of renal function at the end of treatment, can still have impact on long-term 
morbidity and mortality. The long-term results of the Radiation Therapy Oncology Group 
91-11 in which radiotherapy alone was compared to chemoradiotherapy and induction 
chemotherapy followed by radiotherapy in patients with advanced laryngeal cancer, 
showed that overall survival differences between the 2 treatment arms.27 However, more 
deaths unrelated to laryngeal cancer or treatment were found in patients treated with 
concomitant chemoradiotherapy, especially after a prolonged follow-up. Hypothetically, 
nephrotoxicity could have played a role in these unexpected deaths. The long-term 
results of the Radiation Therapy Oncology Group 95-01 trial, in which radiotherapy alone 
was compared to chemoradiotherapy in the postoperative setting, also did not show any 
survival differences between the 2 treatment arms despite better tumor control rates 
in the chemotherapy arm, also suggesting that (cisplatin-induced) nephrotoxicity could 
have played a role in late morbidity or mortality.28 
One of the major limitations, besides the fact that this was a retrospective study, was 
the lack of systematical assessments of  serum creatinine during follow-up. Reviewing 
patients of whom we had data on serum creatinine after treatment holds the risk of 
confounding. The available creatinine measurements  could have been performed for 
other reasons than follow-up of treatment, for example, an intercurrent illness. Despite 
this, we cannot ignore the fact that a high number of patients treated with high-dose 
cisplatin had an increase of  ≥50% in serum creatinine at follow-up in relation to baseline. 
The best way of analyzing the difference in incidence and severity of nephrotoxicity would 
be a prospectively designed nephrotoxicity substudy linked to a clinical trial containing 
both cisplatin schedules. 
We found a significantly lower baseline magnesium in the patients who developed 
nephrotoxicity in both groups, compared to those who did not. Other serum parameters 
were not correlated to development of nephrotoxicity. This in contrast to a study on 
cisplatin-induced nephrotoxicity, that found associations with higher baseline calcium 
and platelet counts and lower serum chloride, but not lower magnesium levels. Earlier, 
studies in magnesium-deficient rats showed that cisplatin-induced renal dysfunction was 
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significantly increased compared to rats fed a standard magnesium diet.29,30 Moreover, 
several retrospective and prospective studies in humans showed that magnesium 
supplementation has a protective effect on developing cisplatin-induced nephrotoxicity.31-33 
Our patients treated with intermediate-dose cisplatin received more magnesiumchloride 
during pre- and posthydration of the cisplatin infusion, which may have protected them 
from developing nephrotoxicity.  We also found that the use of ACE inhibitors was 
significantly correlated with an increase in creatinine, which is not in line with a putative 
protective effect of ACE inhibition suggested previously. 34
In conclusion, using the CTCAE version 4.03, nephrotoxicity is a common side effect in 
LAHNC and NPC patients treated with concomitant chemoradiotherapy with high-dose 
cisplatin. Renal function does not fully recover to baseline in most patients. The CTCAE 
version 3.0 criteria have important limitations when used as a measure of nephrotoxicity 
in clinical trials. Reported nephrotoxicity using CTCAE version 4.03 gave results that were 
more in line with the internationally adopted RIFLE criteria. Therefore we suggest  using 
CTCAE version 4.03 criteria in reporting nephrotoxicity in cancer clinical trials.   
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Abstract
Purpose:  To study the feasibility of induction chemotherapy added to concomitant 
cisplatin-based chemoradiotherapy (CRT) in patients with locally advanced head and neck 
cancer (LAHNC). 
Patients and methods: LAHNC patients were treated with 4 courses of docetaxel/
cisplatin/5-fluorouracil (TPF) followed by randomization to either cisplatin 100 mg/m2 
with conventional radiotherapy (cis100+RT) or cisplatin 40 mg/m2 weekly with accelerated 
radiotherapy (cis40+ART). Primary endpoint was feasibility, defined as receiving ≥ 90% of 
the scheduled total radiation dose. Based on power analysis 70 patients were needed. 
Results: 65 patients were enrolled. The data safety monitoring board advised to 
prematurely terminate the study, because only 22 % and 41% (32% in total) of the patients 
treated with cis100 (n =27) and cis40+ART (n =29) could receive the planned dose cisplatin 
during CRT, respectively, even though the primary endpoint was reached. Most common 
grade 3-4 toxicity was febrile neutropenia (18%) during TPF and dehydration (26% vs 14%), 
dysphagia (26% vs 24%) and mucositis (22% vs 57%) during cis100+RT and cis40+ART, 
respectively. For the patients treated with cis100+RT and cis40+ART, two years progression 
free survival and overall survival were 70% and 78% versus 72% and 79%, respectively.
Conclusion:  After TPF induction chemotherapy, cisplatin-containing CRT is not feasible 
in LAHNC patients, because the total planned cisplatin dose could only be administered 
in 32% of the patients due to toxicity. However, all but 2 patients received more than 90% 
of the planned radiotherapy.
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Introduction
Most locally advanced head and neck cancer (LAHNC) patients are treated with concomitant 
chemoradiotherapy, since it has been shown that 5-years survival increased with 6-8% as 
compared to radiotherapy alone.1 The most common used schedule is the RTOG schedule 
with cisplatin 100 mg/m2 on days 1, 22 and 43 combined with conventional radiotherapy. 2 
Alternatively cisplatin 40 mg/m2 combined with conventional or accelerated radiotherapy 
is applied.3-5 A direct comparison of these two schedules with respect to toxicity, feasibility, 
or efficacy has not been performed yet. 
Induction chemotherapy (IC) may improve the prognosis of LAHNC. Docetaxel, cisplatin 
and fluorouracil (TPF) has been proven superior to cisplatin and fluorouracil (PF) as 
induction chemotherapy in LAHNC with regard to efficacy and toxicity in two phase III 
studies, followed by radiotherapy alone, or by radiotherapy and concurrent carboplatin.6,7 
The main criticism on these phase III studies is their omission to use standard concomitant 
cisplatin-based chemoradiotherapy after TPF. Before the start of our study, no data 
were available on the feasibility of cisplatin containing TPF followed by cisplatin-based 
concomitant chemoradiotherapy. We conducted a randomized phase II study in which 
all LAHNC patients received TPF followed by randomization to either concomitant 
chemoradiotherapy with cisplatin 100 mg/m2 once every 3 weeks with conventional 
radiotherapy (cis100+RT) or chemoradiotherapy with weekly cisplatin 40 mg/m2 and 
accelerated radiotherapy (cis40+ART). The aim of this CONDOR study was to evaluate the 
feasibility of these schedules. 
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Patients and Methods
Patients eligibility
Patients with pathologically proven non-metastatic, previously untreated, locally 
advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or 
larynx, stage III or IV, were eligible. Patients were between 18 and 65 years of age, had 
a WHO performance status of 0-1, adequate bone marrow, hepatic and renal function. 
Exclusion criteria were active alcohol addiction, admission for chronic obstructive 
pulmonary disease during the last 12 months, weight loss of more than 10% during the 
last 3 months prior to study entry. 
The ethics committee of the participating centers approved the protocol and the study 
was conducted in accordance with the Declaration of Helsinki. All patients provided written 
informed consent. 
Treatment
The TPF regimen was the same regimen as used in the EORTC 24971/TAX 323 study. 7 
TPF was administered via a central venous catheter on an inpatient basis for the first two 
days. Thereafter the patients received the last 3 days of 5-FU using a medication cassette 
reservoir at home.  After two cycles radiological evaluation according to RECIST version 1.0 
was performed. In case of complete response (CR), partial response (PR) or SD with minor 
response, patients were randomized and received another two cycles of TPF. Otherwise 
they were randomized and started concomitant CRT.
All patients started concomitant chemoradiotherapy between 3 and 6 weeks after  the 
last cycle of TPF. Intensity-modulated radiation therapy (IMRT) technique was mandatory. 
Dose to gross tumor volume was 70 Gy/35 fractions, dose to elective nodal areas 46 
Gy/23 fractions. Patients randomized to cis100+RT received cisplatin 100 mg/m2 on days 
1, 22 and 43 combined with conventional radiotherapy 5 fractions per week with a total 
treatment time of 7 weeks. Patients randomized to cis40+ART received weekly cisplatin 
40 mg/m2 for 6 cycles and accelerated radiotherapy of 6 fractions per week, with a total 
treatment time of 6 weeks. On one day of each week two fractions were delivered with 
an interval of at least 6 h. 
Carboplatin AUC 1.5 weekly was given instead of cisplatin in case of MDRD <60 ml/min or 
ototoxicity grade 3 or 4. In case of neutrophils <1.5 x 109/l or platelets <100 x 109/l cisplatin 
was interrupted for one week or skipped in case of weekly cisplatin. Neck dissection was 
considered for patients with residual tumor.  
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Assessments
Adverse events were scored according to the NCIC-CTG Common Toxicity Criteria version 
3.0. Late radiation toxicity in the follow up was scored according to RTOG/EORTC criteria. 
Weight was assessed before the start of each cycle. In case of more than 10% weight loss 
or aspiration a feeding tube was placed.  
Tumor evaluation was performed after 2 cycles of TPF, at the end of induction chemotherapy 
and 12 weeks after the end of chemoradiotherapy. HPV status was determined with p16 
immunohistochemistry and PCR.8 Quality of life questionnaires (EORTC QLQ-C30 and 
EORTC H&N53) were assessed and audiometry was performed at different time points 
(will be published separately). Interim analysis by a data safety monitoring board (DSMB) 
was planned after treatment of 30 patients. Except for the primary endpoint, no stopping 
rules were defined. 
Statistical analysis
Primary endpoint was feasibility of the treatment schedules. All patients were classified 
according to whether or not they completed the treatment based on receiving at least 
90% of the scheduled total radiation dose. The secondary end points were toxicity, tumor 
response, progression free survival (PFS), overall survival (OS) and quality of life. 
Based on a previous study in which 80% of the patients received 100% of the total radiation 
dose, we expected that 90% of the patients in our trial would receive at least 90% of the 
radiation dose. If 32 of the 35 patients in each arm completed treatment , we could 
conclude with 95% certainty that treatment was feasible in at least 80% of the patients. 
Therefore, a total of 70 patients were needed. 
Time to progression was calculated from the date of treatment start to the date of the 
first tumor progression. Overall survival was determined by measuring the time from the 
start of treatment to the date of death. Cumulative survival data were calculated using 
the Kaplan-Meier method. Feasibility was assessed by intention-to treat as defined as 
the population of all randomized patients analyzed in the arm they were assigned by 
randomization. 
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Results
Patients and Treatment
Between December 2008 and February 2012 65 patients from three centers in the 
Netherlands were included. Of the 65 registered patients, 62 were assessable; two 
patients were excluded due to ineligibility and one patient withdrew consent (Figure 1). 
Baseline demographic and clinical characteristics are shown in Table 1. HPV status was 
positive in 13 patients, negative in 15 and unknown in 11 oropharyngeal cancer  patients. 
Figure 1. CONSORT diagram
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Table 1. Patient characteristics  
Total = 62 pts
N (%)
Cis100+RT = 27 pts
N (%)
Cis40+ART = 29 pts
N (%)
Sex
     Male 50    (80.6) 17    (63) 27   (93.1)
     Female 12    (19.4) 10    (37) 2     (6.9)
Age, years  
     Mean  53,4 54.0 53.2
     Range 27 – 65 32 - 65 27 - 64
WHO performance status
     0 49    (79) 23   (85.2) 23   (79.3)
      1 13    (21) 4     (14.8) 6     (20.7)
Tumor site  
     Oral Cavity 12    (19.4) 4     (14.8) 6     (20.7)
     Oropharynx 37    (59.7) 18   (66.7) 16   (55.2)
     Hypopharynx 8      (12.9) 3     (11.1) 5     (17.2)
     Larynx 5      (8.1) 2     (7.4) 2     (6.9)
T stage
     T1 4     (6.5) 0     (0) 3     (10.3)
     T2 7     (11.3) 5     (18.5) 2     (6.9)
     T3 22   (35.5) 8     (29.6) 12   (41.4)
     T4 29   (46.8) 14   (51.9) 12   (41.4)
N stage
     N0 14   (22.6) 5    (18.5) 8     (27.6)
     N1 3     (4.8) 2    (7.4) 1     (3.4)
     N2a 8     (12.9) 3    (11.1) 4     (13.8)
     N2b 22   (35.5) 9    (33.3) 10   (34.5)
     N2c 15   (24.2) 8    (29.6) 6     (20.6)
Disease stage
     III 5      (8.1) 2     (7.4) 3     (10.3)
     IV 57    (91.9) 25  (92.6) 26   (89.7)
HPV status OPC
     Negative 15   (40.5) 5     (27.8) 9     (56.3)
     Positive 13   (35.1) 7     (38.9) 5     (31.3)
     Unknown 9     (24.3) 6     (33.3) 2     (12.5)
Abbreviations: pts: patients; Cis100+RT: cisplatinum 100mg/m2 with conventional radiotherapy; Cis40+ART: cis-
platinum 40 mg/m2 with accelerated radiotherapy. OPC: oropharyngeal cancer
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Sixty-two patients started with induction chemotherapy, 47 patients (75.8%) received four 
cycles of TPF. Four patients (6.5%) received only 3 cycles because of toxicity. Eight patients 
(12.9%) received only two cycles of TPF, of whom five patients because they did not show 
any response and three patients were treated off protocol due to rapid PD (n=2) and poor 
clinical condition due to toxicity (n=1). Three patients only received one TPF; one patient 
died after 1 TPF, one patient had an infective arthritis and was treated off protocol and 
one patient developed renal insufficiency.  
Therefore, 56 patients were randomized to concomitant chemoradiotherapy, 27 patients 
to cis100+RT and 29 patients to cis40+RT. The mean RT dose in arm cis100+RT was 
68.3 Gy (SD 1,9) and in arm cis40+ART 69.0 Gy (SD 1.7). In arm cis100+RT, 6 (22.2%) and 
17 (63.0%) patients received three and two cycles of cisplatin 100 mg/m2, respectively. 
Two patients completed protocol with carboplatin instead of cisplatin and two patients 
received one course cisplatin and two courses carboplatin. In arm cis40+ART 12 patients 
(41.4%) received all six planned cycles of cisplatin 40 mg/m2, 8 (27.6%) patients received 5 
cycles, 5 patients (18.5%) 4 cycles and 4 (13.8%) patients received only 3 cycles, of whom 
2 patients also received one course carboplatin. The median dose cisplatin in both arms 
was 200 mg/m2.
The planned interim analysis after 30 randomized patients showed that 35% of the patients 
received the planned cisplatin dose during chemoradiotherapy in both arms. Therefore, 
the DSMB advised a second interim analysis after 50 randomized patients. This showed 
that only 32% of the patients received the planned cisplatin dose in the concomitant 
chemoradiation part of the study. Consequently, although almost all patients received at 
least 90% of the planned radiotherapy, the DSMB recommended stopping recruitment. 
At that moment 65 patients were registered instead of the planned 70 patients. 
Toxicity
Chemotherapy and acute radiotherapy toxicities are listed in Table 2. Grade 3 or 4 
neutropenic fever occurred in 18% of patients during TPF, despite prophylaxis with GCS-F. 
There was one treatment related death after 1 TPF, probably due to a cardiac event in a 
patient with a medical history of hypertension.  During TPF there were 31 hospitalizations 
in 25 patients. 
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Table 2. Chemotherapy and acute radiotherapy toxicity
 
TPF (n=62)                                
(No. of patients)
Cis100+RT (n=27)                         
(No. of patients)
Cis40+ART (n=29)                        
(No. of patients)
  all grade grade 3+4 all grade grade 3+4 all grade grade 3+4
Local toxicity
     Dysphagia 15 0 23 8 25 9
     Dyspnea 4 0 4 2 2 1
     Hair loss 45 0 14 0 13 0
     Hearing loss 11 1 15 2 8 2
     Mucositis 33 2 24 7 25 17
     Pain 13 0 16 2 18 2
     Stridor 0 0 1 1 0 0
     Taste alteration 19 0 16 0 19 0
     Tinitus 9 0 8 1 7 0
     Xerostomia 1 0 14 0 10 0
General toxicity
     Anorexia 28 4 13 2 20 9
     Constipation 30 0 11 0 16 1
     Coronary spasms 1 1 0 0 0 0
     Creatinine increase 4 2 17 5 7 1
     Deep vein thrombosis 2 2 0 0 0 0
     Dehydration 8 6 11 7 6 4
     Diarrhea 32 7 6 0 6 0
     Edema 27 0 11 0 8 0
     Fatigue 49 4 23 3 29 3
     Infection 20 3 9 5 12 4
     Nausea 44 3 21 5 23 4
     Sensory neuropathy 23 0 23 4 20 1
     Pneumonia 2 0 2 2 1 1
     Vomiting 18 2 14 3 18 3
     Weight loss 15 0 9 0 15 0
Hematological toxicity
     Febrile neutropenia 11 11 2 2 2 2
     Leukopenia 8 3 10 5 6 3
     Neutropenia 6 4 8 3 4 1
     Trombocytopenia 3 0 3 2 7 2
Abbreviations:TPF: docetaxel/cisplatin/5-fluorouracil; Cis100+RT: cisplatinum 100mg/m2 with conventional radio-
therapy; 
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Ninety-six percent of the patients in arm cis100+RT and 90% in arm cis40+ART experienced 
one or more grade 3 toxicities, whereas grade 4 toxicity occurred in 15% versus 14% of the 
patients. Mucositis grade 3/4 was seen in 26% versus 59% of the patients in arm cis100+RT 
and arm cis40+ART, respectively (p < 0.05). The onset of any grade mucositis was earlier in 
cis40+ART than in cis100+RT: during week 1 to 3 in 72% versus 40%, respectively (p=<0.05). 
In arm cis40+ART 5 patients were hospitalized due to severe mucositis needing ketamine 
or sufentanil intravenously, versus nil in the cis100 +RT arm. Renal toxicity occurred in 62% 
in patients with cisplatin 100 mg/m2 versus 14% in patients treated with weekly cisplatin 
(p <0.05). Main reasons for delay or discontinuation of cisplatin were in arm cis100+RT 
nephrotoxicity (n=7) and neutropenia (n=5) and in arm cis40+ART thrombocytopenia (n=7) 
and mucositis (n=3).
In arm cis100+RT 74% and in arm cis40+ART 90% of the patients needed a feeding tube, for 
median 10 versus 12 weeks, respectively (ns). During TPF most patients gained weight with 
a median of 2 kilograms (SD 5.42). During concomintant chemoradiotherapy patients lost 
weight,  median 5 kilograms (SD 4.14) and median 6 kilograms (SD 3.37) in arm cis100+RT 
and in arm cis40+ART, respectively (ns). None of the patients needed parental feeding.
Efficacy
After TPF four  patients reached CR (6.5%), 34 PR (54.8%), 14 SD with minor response 
(22.6%), 5 SD without any response  (8.1%) and two PD (3.2%); two patients were not 
evaluable and 1 patient died after 1 TPF. The total response rate (CR + PR) was 61.3%. 
Twelve weeks after chemoradiotherapy, response rate was 81.5% in arm cis100+RT and 
72.4%, in arm cis40+ART. Three patients in each arm were not evaluable for response.  
Elective neck dissections were performed in two of the randomized patients, 1 in each 
arm. First relapses occurred with local or regional disease site or both in 11%, 0% and 8% 
of the patients in arm cis100+RT and in 10%, 10% and 10% in arm cis40+ART, respectively. 
Distant metastases at first relapse were found in 2 patients in arm cis100+RT and in 1 
patient in arm cis40+ART.  
After a median follow-up of 38 months, two years PFS and OS for all 62 included patients 
were 65% and 72% respectively. For the randomized patients in arm cis100+RT 2 years 
PFS and OS were 70% and 78% and in arm cis40+ART 72% and 79% as shown in Figure 2 
(ns). Four patients developed a second primary tumor in the follow-up. In oropharyngeal 
cancer patients 2 years OS was 80% in HPV negative and 92% in HPV positive patients. 
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Figure 2.  Kaplan Meier survival plots for progression free survival (A), overall survival (B), loco regional 
failure (C) and distant failure (D) between the treatment arms
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Discussion
Our study shows that induction chemotherapy with TPF followed by cisplatin-based 
chemoradiotherapy is not feasible, as only 22% of the patients treated with cis100+RT and 
41% of the patients treated with cisplatin cis40+ART could receive the planned cisplatin 
dose during chemoradiotherapy. The planned radiotherapy could be given to 96% of the 
patients in each arm. TPF IC was feasible since 76% of the patients received all 4 planned 
cycles, whereas another 13% of the patients discontinued after two not because of toxicity. 
Since there is no proven survival benefit of IC compared to concomitant chemoradiotherapy, 
the latter remains standard therapy in patients with LAHNC.1,9,10 Consequently, no 
concessions should be made in the total dose of cisplatin during chemoradiotherapy as 
we know that a cumulative dose of 200 mg/m2 is needed for optimal antitumor activity.11,12 
In two phase III studies investigating concomitant chemoradiotherapy with cisplatin 100 
mg/m2 on days 1, 22, 43 70-85% of the patients received all planned cisplatin, whereas ≥ 
200 mg/m2 cisplatin could be administered in approximately 90% of the patients.2,13 In arm 
cis100+RT of our study only  85% received 200 mg/m2 cisplatin and 69% in arm cis40+ART. 
We conclude that cisplatin-based CRT after IC with 4 cycles of TPF is not feasible. 
There have been more studies in which IC with TPF has been studied. The TREMPLIN 
study investigated TPF followed by CRT with cisplatin versus bioradiotherapy for larynx 
preservation.14 In this study, 47% of patients received the planned three cycles of TPF 
with a dropout rate after TPF of 24%. Of the 58 patients starting chemoradiotherapy 
with cisplatin 100 mg/m2 only 42% completed full treatment. In both this and our 
study only approximately 30-40% of the patients received all planned cisplatin during 
chemoradiotherapy. The dropout rate after TPF in the TREMPLIN study however, was high 
(24% versus 10% in our study).  Despite their observations, the investigators still concluded 
that this treatment schedule was feasible. Another study reported on a retrospective 
analysis of TPF followed by chemoradiotherapy with cisplatin 100 mg/m2.15 In that trial, 
only two to three courses of less-intense TPF (only 4 days of 5-fluorouracil) were planned 
and only 87% of the 66 patients received 3 courses. Nine patients (14%) received no CRT 
after TPF. Of the 59 patients receiving CRT, only 5% received all planned 3 cycles of cisplatin 
and only 66% of the patients could receive ≥ 200 mg/m2 cisplatin. Grade 3 skin toxicity or 
mucositis occurred in 73% and 85% of the patients and there was a high rate of unplanned 
hospital admissions. Nevertheless, the authors stated that this schedule was feasible. 
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Likewise, high toxicity rates were found in our study. Main differences between the two 
treatment arms were a high rate of renal toxicity in patients receiving cisplatin 100 mg/m2 
with conventional radiotherapy and a high rate of mucositis in the patients who received 
weekly cisplatin 40 mg/m2 with accelerated radiotherapy. The high rate of mucositis is 
probably caused by the accelerated radiotherapy, as described earlier.5,16 
In our study we chose to treat patients with four courses of TPF, according to the TAX 323 
regimen, which seemed less toxic than the schedule used in the TAX 324.6,7 After TPF we 
decided to use the standard RTOG schedule of conventional radiotherapy with cisplatin 
100 mg/m2 versus accelerated radiotherapy with weekly cisplatin 40 mg/m2. Accelerated 
radiotherapy was selected because of the better local regional control over conventional 
radiotherapy, albeit without any benefit in overall survival.17,18
We found a 2 years OS of 70% in our total population and 76% in the intention-to-treat 
population. This compares favourably to 2 years survival rates of 37-67% in other studies 
with IC and conventional chemoradiotherapy in LAHNC. 2,6,7,10,13 In the PARADIGM and 
DeCIDE trials, developed to compare IC directly with chemoradiotherapy, overall survival at 
3 years were 70-78%.9,10 The high survival rates, even in the control arms, of these recent 
studies compared to earlier trials, may be, partly, explained by HPV status. Patients with 
HPV positive oropharyngeal cancers have better survival rates compared to HPV negative 
tumours.19 Although HPV status was not determined in the PARADIGM and DeCIDE study, 
more than half of the included patients presented with primary tumors in the oropharynx. 
We found HPV positivity in half of the patients with oropharyngeal carcinoma. 
In conclusion, based on our data we do not recommend TPF induction chemotherapy 
followed by cisplatin-based chemoradiotherapy in routine clinical daily practice, for non-
organpreservation. Still, in exceptional cases, for example in patients with N3 stages with 
collapse, or with cranial nerve involvement, or when rapid response is mandatory, and 
organpreservation, it can be considered to give one or two courses TPF induction, followed 
by concomitant chemoradiotherapy. 
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Abstract 
Purpose:  The CONDOR study showed that docetaxel/cisplatin/5-fluorouracil (TPF) followed 
by conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, 43 (cis100+RT; n=27) 
versus accelerated radiotherapy with cisplatin weekly 40 mg/m2 (cis40+ART;  n=29) in 
locally advanced head and neck cancer (LAHNC) patients was not feasible. Here, we report 
the analysis of health-related quality of life (HRQOL) of the patients entered in this study.
Methods:   HRQOL was assessed at baseline, after two TPF, before start of 
chemoradiotherapy, and 1, 4, 8, 12 and 24 months after completion of chemoradiotherapy 
using the EORTC-QLQ-C30 and QLQ-H&N35 in 62 patients.
Results: Compliance with the QOL questionnaires was 94% (59/62) at baseline, and 61% 
(30/49) at 12 months, respectively. HRQOL decreased after TPF and further decreased 
during chemoradiotherapy in both arms equally. Pain and swallowing dysfunction improved 
significantly during TPF but deteriorated below baseline levels during chemoradiotherapy, 
cis40+ART > cis100+RT (p<0.05). HRQOL and symptoms restored to baseline within 12 
months in both arms and remained at that level until 24 months. 
Conclusions: After TPF, cis40+ART had a larger negative impact on symptoms than 
cis100+RT, probably due to the ART. HRQOL and symptoms restored to baseline levels 
within 12 months after end of treatment in both arms, which is an important perspective 
for patients during the phase of most serious acute side effects of treatment. 
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Introduction
In patients with locally advanced head and neck cancer (LAHNC), both disease and 
treatment have a great impact on quality of life (QOL). Standard treatment for these 
patients is concomitant chemoradiotherapy, which induces severe acute and late toxicities. 
Common acute toxicities of chemoradiotherapy include mucositis, dermatitis, dysphagia, 
ototoxicity, and polyneuropathy. Late toxicity may consist of dysphagia sometimes with 
aspiration, odynophagia, xerostomia, fibrosis, and occasionally osteoradionecrosis 1,2. 
These toxicities negatively influence the QOL. 
Induction chemotherapy, using docetaxel/cisplatin/5-fluorouracil (TPF), has been 
proposed as a means to improve outcome of patients with locally advanced head 
and neck cancer. There are only limited data on TPF followed by chemoradiotherapy 
using cisplatin. Although it is often stated that neo-adjuvant TPF is well tolerated, 
the effect of the total regimen, including the concomitant chemoradiation part, on 
health-related quality-of-life (HRQOL) has not been reported previously 3,4. HRQOL 
comprises physical and psychosocial functioning, social interaction and disease- and 
treatment-related symptoms. HRQOL was studied in LAHNC patients receiving neo-
adjuvant TPF versus PF followed by radiotherapy alone, showing a trend towards a 
better HRQOL during treatment in favor of TPF 5. Other studies in LAHNC patients 
treated with chemotherapy and radiotherapy showed a pattern of decline of QOL 
and then return to baseline within 12 months after end of treatment 6,7. There are no 
published data of QOL in LAHNC patients treated with induction chemotherapy later 
than 12 months after end of treatment. 
We conducted a randomized phase II feasibility study, the Condor study, on induction 
chemotherapy with TPF followed by cisplatin-based concomitant chemoradiotherapy in 
two different schedules 8. Sixty-two fit LAHNC patients started treatment with TPF. Of 
these patients, 56 were randomized to treatment with concomitant chemoradiotherapy 
with conventional chemoradiotherapy and cisplatin 100 mg/m2 three weekly (cis100+RT) 
(27 patients) or concomitant CRT with accelerated radiotherapy with weekly cisplatin 40 
mg/m2 (cis40+ART) (29 patients). Ninety-six percent of the patients treated with cis100+RT 
and 90% of the patients treated with cis40+ART experienced grade 3 toxicity (on the 
Common Toxicity Criteria 3.0), whereas grade 4 toxicity occurred in 15% versus 14% of 
the patients. Most common grade 3-4 toxicity during TPF was febrile neutropenia (18%). 
During concomitant CRT grade 3-4 toxicities were mucositis in 22% vs 57%, dysphagia in 
26% vs 24%  and dehydration in 26% vs 14%,  of patients with cis100+RT and cis40+ART, 
respectively. Both treatment schedules were proven not to be feasible, since the total 
planned dosage of cisplatin during the chemoradiotherapy could only be administered 
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in 32% of all patients due to severe toxicity, leading to early termination of inclusion into 
the study. Despite high toxicity rates, efficacy was comparable with other studies using 
induction chemotherapy. Response rate after TPF was 61% and 2-years overall survival 
was 77% in patients treated with cis100+RT and 76% for those treated with cis40+ART. 
In this paper, we will focus on the HRQOL of patients treated in this phase II study with 
TPF induction chemotherapy followed by concomitant chemoradiotherapy, with emphasis 
on long-term follow-up outcome.  
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Methods 
Trial design and participants
The CONDOR study was a randomized phase II feasibility study on induction chemotherapy 
with TPF followed by cisplatin-based concomitant chemoradiotherapy in two different 
schedules. In this study, fit LAHNC patients, stage III or IV with a WHO-performance score 
of 0-1 and age ≤ 65 years, were included. Patients were between 18 and 65 years of 
age, had a WHO performance status of 0-1, adequate bone marrow, hepatic and renal 
function. Exclusion criteria were active alcohol addiction, admission for chronic obstructive 
pulmonary disease during the last 12 months, weight loss of more than 10% during the 
last 3 months prior to study entry. Details on therapy schedules, and toxicity registration 
and grading were published recently 8.  
QOL assessment 
QOL data were collected using the European Organization for Research and Treatment of 
Cancer (EORTC) QOL questionnaire (QLQ-C30) version 3.0 and the EORTC head and neck 
cancer module (HN-35) 2,5,9-11. The EORTC QLQ-C30 contains a global HRQOL score, five 
functional scales (physical, role, cognitive, emotional and social) and three symptom scales 
(fatigue, nausea/vomiting and pain), six single item scales (dyspnea, sleep disturbance, 
appetite loss, constipation, diarrhea and financial difficulties). The EORTC Head and Neck 
module, the EORTC QLQ-H&N35 has been specifically designed and validated for head 
and neck cancer patients 11. This is a 35-item questionnaire with seven symptom scales 
(pain, swallowing, senses, speech, social eating, social contact and sexuality), six single item 
scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing and feeling ill) 
and five items about the additional use of painkillers, nutritional supplements and feeding 
tube and changes in body weight. All items were transformed to scales from 0 to 100, 
according to the EORTC scoring manual recommendations 12. A high score on functional 
scale represents a better level of functioning, whereas a high score on a symptom scale 
indicates more severe symptoms. Differences of at least 10 points (on a scale of 0-100) on 
a mean value of the HRQOL parameter were classified as clinically significant 13. Changes of 
≥ 10 points are moderate, whereas changes of ≥20 points on a mean score are classified 
as large. The primary HRQOL analysis was based on preselected HRQOL scores: global 
HRQOL, pain, swallowing, speech, and coughing.
Patients completed the QOL questionnaires at baseline, after 2 cycles of TPF, before start 
of concomitant chemoradiotherapy (i.e., after 2, 3 or 4 TPF cycles) and 1, 4, 8, 12, 18, and 
24 months after the end of chemoradiotherapy. 
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Statistical analysis
HRQOL was a secondary endpoint of the CONDOR study; power analysis was calculated on 
the primary endpoint, which was feasibility. Analyses were performed using SAS version 9.2 
and SPSS version 20. Compliance rates were calculated as the number of forms received 
divided by the number of forms expected at each time point. Expected forms were from 
patients still alive at the given time point, regardless of disease state. Fishers’ exact test 
was used to determine differences in compliance between the treatment arms. One-sided 
t-test was used to compare the baseline quality of life results of the current study with 
the EORTC reference values. 
For the primary analyses, we used an Unstructured Covariance Model to conduct separate 
repeated measures analyses for each HRQOL outcome 14. We included time, treatment, 
and the interaction between time and treatment as fixed factors in the linear mixed model. 
Time was treated as a categorical variable to allow the model to fit every possible pattern 
in time. The interaction between time and treatment was only defined after the start 
of the chemoradiotherapy. In addition, we added the baseline values of the dependent 
variables as possible significant covariates to the model. Residual plots from the mixed 
models were examined to assess model assumptions. All linear mixed model analyses 
were performed on all participants, including those with incomplete datasets. Differences 
between treatments at specific time moments were estimated from the mixed model. 
Two-tailed analyses were performed with a p-value of 0.05. 
Moreover, sensitivity analysis using the proportion of patients experiencing an 
improvement/ worsening of more than 10 or 20 points in each selected scale was 
performed 13.   
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Results
Participants
Patient characteristics are shown in Table 1. 
Table 1. Patient characteristics  
Total = 62 pts
N (%)
Cis100+RT = 27 pts
N (%)
Cis40+ART = 29 pts
N (%)
Sex
     Male 50    (80.6) 17    (63) 27   (93.1)
     Female 12    (19.4) 10    (37) 2     (6.9)
Age, years  
     Mean 53,4 54.0 53.2
     Range 27 – 65 32 - 65 27 - 64
WHO performance status
     0 49    (79) 23   (85.2) 23   (79.3)
     1 13    (21) 4     (14.8) 6     (20.7)
Tumor site  
     Oral Cavity 12    (19.4) 4     (14.8) 6     (20.7)
     Oropharynx 37    (59.7) 18   (66.7) 16   (55.2)
     Hypopharynx 8      (12.9) 3     (11.1) 5     (17.2)
     Larynx 5      (8.1) 2     (7.4) 2     (6.9)
Disease stage
     III 5      (8.1) 2     (7.4) 3     (10.3)
      IV 57    (91.9) 25  (92.6) 26   (89.7)
Abbreviations: pts: patients; Cis100+RT: cisplatinum 100mg/m2 with conventional radiotherapy; Cis40+ART: cis-
platinum 40 mg/m2 with accelerated radiotherapy. 
QOL: compliance 
Data of all patients were included in this analysis. Compliance to the questionnaires was 
94% at baseline, 71% after 2 TPF, 70% before start of chemoradiotherapy, 61% after 
chemoradiotherapy, 63% after 4 months, 66% after 12 months, 68% after 18 months, 
and 62% after 24 months of follow- up. Compliance was significantly lower in patients 
treated with cis40+ART at 4 months after end of treatment, 45% versus 81%, respectively 
(p=0.006).  At all other time points compliance between the two treatment arms was 
similar. 
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Table 2. Baseline QOL scores and reference data 
CONDOR patients (n=59) Reference data (n=1722) Difference between groups
Mean SD Mean SD
QLQ-30
Global health status 75.3 19.7 63.3 22.4 p<0.001a
Physical function 92.0 15.1 81.2 20.2 p<0.001a
Role function 86.1 23.8 78.8 27.9 p=0.035
Emotional function 74.7 21.4 71.2 24.1 p=0.345
Cognitive function 91.7 15.2 86.4 19.1 p=0.017
Social function 87.5 18.1 82.2 24.7 p=0.046
Fatigue 20.8 20.9 27.6 25.0 p=0.018
Nausea/vomiting 2.5 8.6 5.2 13.3 p=0.026
Pain 25.6 29.7 24.9 26.3 p=0.809
Dyspnoea 6.7 14.7 18.0 26.6 p<0.0.1a
Insomnia 25.0 27.9 28.5 32.4 p=0.388
Appetite loss 17.2 27.8 19.4 29.3 p=0.561
Constipation 12.2 24.5 11.7 23.2 p=0.910
Diarrhoea 2.2 8.4 6.1 16.7 p=0.001
Financial problems 13.3 26.2 18.8 30.2 p=0.114
QLQ-H&N 35
Pain 27.2 22.5 29.9  25.1 p=0.356
Swallowing 24.9 25.1 27.5  26.1 p=0.454
Senses 10.5 21.0 20.0  30.0 p=0.002
Speech 18.1 21.3 27.1  27.2 p=0.003
Social eating 21.9 26.0 23.9  26.7 p=0.018
Social contact 5.6 14.9 13.2  19.1 p=0.001
Sexuality 14.2 25.2 32.3  36.1 p<0.001a
Teeth 19.1 27.2 27.8  35.0 p=0.029
Opening mouth 25.4 34.1 22.4  31.9 p=0.545
Dry mouth 15.3 24.2 31.1  34.2 p<0.001a
Sticky saliva 19.5 31.2 32.4  35.4 p=0.002a
Coughing 18.6 25.0 34.9  32.1 p<0.001a
Feeling ill 12.4 21.4 21.7  29.2 p=0.003
Pain killers 61.0 49.2 52.8  49.9 p=0.114
Nutritional support 31.0 46.7 27.0  44.4 p=0.590
Feeding tube 5.1 22.2 18.3  38.7 p<0.001a
Weight loss 43.9 50.0 41.3  49.2 p=0.620
Weight gain 17.9 38.6 25.9  43.8 p=0.125
Abbreviations: EORTC: European Organisation for Research and Treatment of Cancer; QOL: quality of life; QLQ-
C30: Quality of Life Questionnaire C30; QLQ-HN-35: Head and Neck Cancer-Specific Module.
a : Clinically significant different (10 points or more)
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QOL baseline scores
Baseline QOL scores were compared to the reference values of head and neck cancer 
patients, stage III-IV disease (Table 2), provided by the EORTC 15. All EORTC head and neck 
reference data are based on pretreatment HRQOL. A clinically and statistically significant 
difference in baseline scores of our patients compared to the EORTC reference values 
was found on global HRQOL (75.3 versus 63.3, p<0.001) and physical function (92.0 versus 
81.2, p<0.001), and on the symptom scores sexuality (14.2 versus 32.2, p< 0.001), dry 
mouth (15.3 versus 31.1, p<0.001), sticky saliva 19.5 versus 32.4, p<0.001), coughing (18.6 
versus 34.9, p<0.001), feeling ill (12.4 versus 21.7, p=0.003), and feeding tube (5.1 versus 
18.3, p<0.001), in favor of the patients in our study. This indicates that in terms of QOL a 
relatively favorable (i.e., fit) patient group was selected for this study.
QOL during TPF
Global HRQOL decreased non-significantly after 2 TPF (70.1) and even more after the end 
of TPF (64.0) (Table 3, Figure 1). Pain and swallowing problems both decreased with more 
than 10 points after 2 TPF, but both increased before start of chemoradiotherapy (Table 
3, Figure 2). Speech problems and coughing improved non-significantly after 2 TPF, but 
deteriorated at the end of TPF (Table 3, Figure 2). 
Figure 1. Mean Global Health Scores over time by treatment arm
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Table 3. Mean scores over time at baseline, after 2 TPF and after chemoradiotherapy 
Baseline 
(59/62)
After 2 TPF 
(42/59)
After CRT 
cis100+RT 
(18/27)
After CRT 
cis40+ART 
(16/29)
Difference 
between 
groups CRT
Mean SD Mean SD Mean SD Mean SD
EORTC QLQ-30
Global health status 75.3 19.7 70.1 11.5 44.9 11.9 46.1 12.0 p=0.85
Physical function 92.0 15.1 80.5a 11.2 61.0 11.5 58.4 11.6 p=0.60
Role function 86.1 23.8 59.6a 15.2 45.0 15.9 36.0 16.2 p=0.32
Emotional function 74.7 21.4 84.9a 12.3 84.9 12.3 77.6 12.8 p=0.61
Cognitive function 91.7 15.2 87.6 18.0 70.2 18.2 67.4 18.3 p=0.61
Social function 87.5 18.1 79.6 14.5 66.4 14.9 67.1 15.1 p=0.91
Fatigue 20.8 20.9 35.7a 10.6 50.6 11.2 60.8 11.5 p=0.97b
Nausea/vomiting 2.5 8.6 8.6 5.4 30.9 6.0 37.6 6.3 p=0.20
Pain 25.6 29.7 11.0a 14.6 33.8 15.0 49.2 15.3 p=0.043b
Dyspnoea 6.7 14.7 9.0 11.2 16.0 11.4 19.9 11.6 p=0.45
Insomnia 25.0 27.9 18.1 11.6 27.6 12.1 27.5 12.3 p=0.99
Appetite loss 17.2 27.8 22.8 17.5 50.2 18.1 62.2 18.3 p=0.19b
Constipation 12.2 24.5 11.4 5.6 20.6 6.5 32.0 6.9 p=0.08b
Diarrhoea 2.2 8.4 12.9a 8.8 8.1 9.1 10.5 9.3 p=0.63
Financial problems 13.3 26.2 11.4 16.9 8.3 17.2 25.0 17.3 p=0.011b
EORTC QLQ-H&N 35
Pain 27.2 22.5 14.5a 11.9 38.1 12.2 55.7 12.3 p=0.003b
Swallowing 24.9 25.1 9.7a 10.8 43.3 11.3 59.9 11.4 p=0.0101b
Senses 10.5 21.0 21.7a 15.2 45.0 15.6 47.3 15.8 p=0.74
Speech 18.1 21.3 10.9 7.9 27.1 8.5 44.8 8.7 p=0.004b
Social eating 21.9 26.0 15.3 14.3 41.4 14.6 39.9 14.8 p=0.82
Social contact 5.6 14.9 7.9 6.8 12.9 7.0 9.5 7.0 p=0.29
Sexuality 14.2 25.2 33.3a 19.4 53.9 20.0 55.0 20.1 p=0.90
Teeth 19.1 27.2 6.3a 14.1 10.4 14.5 15.2 14.9 p=0.53
Opening mouth 25.4 34.1 13.3a 16.8 27.2 17.3 31.5 17.4 p=0.58
Dry mouth 15.3 24.2 25.3a 18.2 44.4 18.7 56.8 18.9 p=0.14b
Sticky saliva 19.5 31.2 20.5 20.2 57.5 20.6 66.3 20.8 p=0.32
Coughing 18.6 25.0 14.4 12.3 31.8 12.8 45.3 13.0 p=0.076b
Feeling ill 12.4 21.4 19.8 26.6 48.1 32.8 47.9 32.1 p=0.98
Pain killers 61.0 49.2 41.2a 24.9 95.6 25.9 83.5 26.3 p=0.40b
Nutritional support 31.0 46.7 19.7a 18.5 83.0 19.6 66.0 20.0 p=0.20b
Feeding tube 5.1 22.2 4.8 15.7 52.3 16.6 85.0 17.0 p=0.003b
Weight loss 43.9 50.0 15.2a 14.6 81.3 16.1 33.3 17.1 p=0.0009b
Weight gain 17.9 38.6 50.8a 21.8 26.3 23.4 19.3 24.6 p=0.70
Abbreviations: cis100+RT: cisplatin 100 mg/m2 on day 1,22,43 in combination with conventional radiotherapy, 
cis40+ART: cisplatin 40 mg/m2 weekly in combination with accelerated radiotherapy, EORTC: European Organ-
isation for Research and Treatment of Cancer;  QLQ-C30: Quality of Life Questionnaire C30; QLQ-HN-35: Head 
and Neck Cancer-Specific Module.
a : Clinically significant different (10 points or more) after 2 TPF compared to baseline,
b: Clinically significant difference (10 points or more) between treatment arms after CRT
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Figure 2. Mean symptom scores over time by treatment arm, A =pain, B = coughed, C= speech problems, 
D = swallowing problems 
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QOL: differences between treatment arms during chemoradiotherapy and 
changes over time
Global HRQOL decreased during chemoradiotherapy, equally in both arms (Table 
3, Figure 1). Four months after end of treatment, global HRQOL increased and it was 
restored to baseline levels within 12 months after end of treatment. Beyond 12 months 
however, patients treated with cis100+RT had a higher score than the patients treated 
with cis40+ART, albeit not significant. Twenty-four months after end of treatment global 
HRQOL was equal in both arms (Table 4). Pain, swallowing problems, speech problems 
and coughing all worsened during chemoradiotherapy. A clinically and statistically 
significant difference between the treatment arms at end of treatment was found in all 
these symptom scores in favor of the patients treated with cis100+RT (Table 3, Figure 2). 
In both treatment arms, pain, swallowing problems and speech problems recovered to 
baseline level 4 months after treatment. There were no differences in mean scores of pain, 
swallowing problems, speech problems and coughing between the treatment arms at 12 
and 24 months after end of treatment (Table 4). 
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Table 4. Mean scores over time at 1 and 2 years after treatment
1 year follow 
up 
cis100+RT
1 year follow 
up
 cis40+ART
Difference 
between
groups
2 year follow 
up
 cis100+RT
2 year follow 
up 
cis40+ART
Difference 
between 
groups
Mean SD Mean SD Mean SD Mean SD
EORTC QLQ-30
Global health status 84.0 9.9 71.4 24.1 p=0.07a 80.6 16.4 76.2 23.8 p=0.64
Physical function 91.3 10.7 85.1 16.1 p=0.22 92.8 7.8 88.6 11.4 p=0.35
Role function 87.2 15.4 73.5 37.7 p=0.19a 83.3 22.5 73.8 30.2 p=0.44
Emotional function 91.0 10.5 78.6 24.9 p=0.09a 83.3 25.1 88.1 16.6 p=0.66
Cognitive function 93.6 8.4 81.3 25.7 p=0.09a 88.9 16.4 69.0 33.9 p=0.19b
Social function 91.0 12.9 81.3 29.7 p=0.28 93.1 13.2 88.1 15.9 p=0.47
Fatigue 16.2 17.9 23.5 24.5 p=0.37 22.2 21.7 28.6 31.3 p=0.61
Nausea/vomiting 0.0 0.0 3.92 11.1 p=0.16 0.0 0.0 7.1 18.9 p=0.36
Pain 5.1 10.5 16.7 30.0 p=0.16a 8.3 16.7 7.1 18.9 p=0.89
Dyspnoea 2.6 9.2 13.7 20.6 p=0.08a 2.8 9.6 9.5 16.3 p=0.35
Insomnia 2.6 9.2 17.6 20.8 p=0.02a 11.1 21.7 14.3 17.8 p=0.75
Appetite loss 7.7 20.0 17.6 26.7 p=0.25 5.6 13.0 14.3 26.2 p=0.44
Constipation 0.0 0.0 11.8 20.2 p=0.046a 5.6 13.0 0.0 0.0 p=0.17
Diarrhoea 0.0 0.0 2.1 8.3 p=0.33 0.0 0.0 4.8 12.6 p=0.36
Financial problems 10.3 16.0 14.6 29.7 p=0.62 0.0 0.0 4.8 12.6 p=0.36
EORTC QLQ-H&N 35
Pain 8.3 10.8 14.7 17.3 p=0.23 7.4 10.5 12.5 11.8 p=0.33
Swallowing 4.5 8.1 12.7 15.9 p=0.08 4.9 8.3 11.5 12.5 p=0.17
Senses 17.9 17.3 17.6 21.6 p=1.00 16.7 26.6 12.5 7.7 p=0.62
Speech 4.3 9.7 13.7 20.6 p=0.11 0.9 3.2 6.9 8.3 p=0.08
Social eating 10.9 11.0 19.1 24.6 p=0.19 6.9 12.7 17.7 22.0 p=0.18b
Social contact 0.5 1.8 7.3 14.8 p=0.23 0.6 1.9 1.7 4.7 p=0.47
Sexuality 12.5 16.1 27.8 26.5 p=0.09a 11.1 17.9 13.9 16.4 p=0.75
Teeth 2.6 9.2 14.6 27.1 p=0.11a 5.6 13.0 8.3 23.6 p=0.74
Opening mouth 12.8 16.9 15.7 20.8 p=0.69 13.9 22.3 20.8 24.8 p=0.52
Dry mouth 43.6 21.0 49.0 29.1 p=0.58 33.3 24.6 41.7 23.6 p=0.46
Sticky saliva 17.9 22.0 31.3 28.5 p=0.18a 16.7 22.5 37.5 21.4 p=0.05b
Coughing 10.3 16.0 15.7 23.9 p=0.49 8.3 15.1 8.3 15.4 p=1.00
Feeling ill 2.6 9.2 17.6 31.4 p=0.08a 8.3 20.7 4.2 11.8 p=0.61
Pain killers 7.7 27.7 23.5 43.7 p=0.24a 16.7 38.9 25.0 46.3 p=0.67
Nutritional support 15.4 37.6 23.5 43.7 p=0.60 0.0 0.0 12.5 35.4 p=0.35b
Feeding tube 0.0 0.0 5.9 24.3 p=0.39 0.0 0.0 12.5 35.4 p=0.35b
Weight loss 0.0 0.0 25.0 44.7 p=0.04a 8.3 28.9 12.5 35.4 p=0.78
Weight gain 46.2 51.9 31.3 47.9 p=0.43a 41.7 51.5 25.0 46.3 p=0.47b
Abbreviations: cis100+RT: cisplatin 100 mg/m2 on day 1,22,43 in combination with conventional radiotherapy, 
cis40+ART: cisplatin 40 mg/m2 weekly in combination with accelerated radiotherapy, EORTC: European Organ-
isation for Research and Treatment of Cancer;  QLQ-C30: Quality of Life Questionnaire C30; QLQ-HN-35: Head 
and Neck Cancer-Specific Module.
a : Clinically significant different (10 points or more) 1 year after treatment between treatment arms, b: Clinically 
significant difference (10 points or more) between treatment arms after 2 years. 
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Other HRQOL scales
All other HRQOL items were analyzed on an exploratory basis.  Patients treated with 
cis40+ART scored clinically and statistically significantly worse on feeding tube dependence 
after CRT, but significantly better on nutritional support and use of painkillers. Patients 
treated with cis100+RT scored clinically and statistically significant worse on weight loss. 
Moreover, a clinically significant difference (> 10 points) was found for fatigue, appetite 
loss, constipation and dry mouth in favor of cis100+RT.
Furthermore, after two years follow-up patients treated with cis100+RT had clinically 
significant (> 10 points) better cognitive function and less sticky saliva compared to patients 
treated with cis40+ART. Patients treated with cis40+ART scored clinically significant worse 
on nutritional support and feeding tube than patients in arm cis100+RT (Table 4).
Sensitivity analyses 
The proportion of patients experiencing an improvement or worsening of 10 or 20 points 
on the selected scales between baseline and end of chemoradiotherapy were compared 
between the treatment arms. These analyses showed the same trend of more pain in 
patients treated with cis40+ART compared to cis100+RT (Table 5). Moreover, a higher 
percentage of patients experienced a worsening in speech and swallowing problems in 
the group treated with cis40+ART, whereas more patients experienced improvement in 
the group treated with cis100+RT (Table 5).
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Table 5. Sensitivity analysis: proportion of patients experiencing improvement/ worsening of selected 
scales after chemoradiotherapy compared to baseline
Cis100 +RT (N=27) N (%) Cis40+ART (N=29) N (%) p-value for difference
Global qualiy of lifea
   ≥16.6 points worsening 15 (83.3) 10 (71.4) 0.669
   ≥ 25 points worsening 13 (72.2) 8 (57.1) 0.465
   ≥16.6 points improvement 0 (0) 1 (7.1) 0.437
   ≥ 25 points improvement 0 (0) 0 1.00
Coughingb
   ≥33.3 points worsening 10 (58.8) 8 (57.1) 1.00
   ≥ 33.3 points improvement 3 (17.6) 3 (21.4) 1.00
Painc
   ≥11.1 points worsening 8 (47.1) 12 (85.7) 0.057
   ≥ 22.2 points worsening 7 (41.2) 11 (78.6) 0.067
   ≥11.1 points improvement 4 (23.5) 2 (14.3) 0.664
   ≥ 22.2 points improvement 2 (11.8) 1 (7.1) 1.00
Speech problemsd
   ≥11.1 points worsening 8 (47.1) 10 (71.4) 0.275
   ≥ 22.2 points worsening 6 (35.3) 8 (57.1) 0.289
   ≥11.1 points improvement 5 (29.4) 2 (14.3) 0.412
   ≥ 22.2 points improvement 4 (23.5) 2 (14.3) 0.664
Swallowinge
   ≥11.1 points worsening 12 (70.6) 11 (78.6) 0.698
   ≥ 22.2 points worsening 11 (64.7) 10 (71.4) 1.00
   ≥11.1 points improvement 4 (23.5) 2 (14.3) 0.664
   ≥ 22.2 points improvement 3 (17.6) 1 (7.1) 0.607
Abbreviations: cis100+RT: cisplatin 100 mg/m2 on day 1,22,43 in combination with conventional radiotherapy, 
cis40+ART: cisplatin 40 mg/m2 weekly in combination with accelerated radiotherapy, aGlobal QoL score may take 
all values from 0 to 100 distant by 8.3 points (0, 8.3, 16.6, and so on). A shift of more than 10 points means a shift 
of 16.6 points or more. A shift of more than 20 points means a shift of 25 points or more. bCoughing score may 
take all values from 0 to 100 distant by 33.3 points (0, 33.3, 66.6, and so on). cPain score may take all values from 
0 to 100 distant by 2.8 points. dSpeech score may take all values from 0 to 100 distant by 5.5 points. eSwallowing 
score may take all values from 0 to 100 distant by 2.8 points.
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Discussion
HRQOL was assessed as secondary endpoint of the randomized phase II CONDOR 
study in patients with locally advanced head and neck cancer treated with TPF induction 
chemotherapy followed by cisplatin 100 mg/m2 with conventional radiotherapy versus 
cisplatin 40 mg/m2 with accelerated radiotherapy. Our study patients had a clinically and 
statistically significant better global HRQOL and physical function compared to the EORTC 
reference values for head and neck cancer patients with stage III-IV disease, which data 
were obtained during standard treatment15. Global HRQOL in our patients was also better 
than the patients included in the EORTC 24971/TAX 323 study 5. This is a reflection of 
our selection criteria to include only very fit LAHNC patients, i.e., no admissions for COPD 
in the past year, WHO 0-1, no weight loss more than 10% in the past three months, no 
active alcohol addiction and adequate bone marrow, liver and kidney function. Despite the 
excellent clinical condition of our patients at baseline reflected by the good global HRQOL, 
both treatment schedules were shown not feasible 8. 
Global HRQOL declined during TPF and more during chemoradiotherapy, without any 
difference between the two treatment arms. The declining global HRQOL is in contrast 
with the results of the EORTC 24971/TAX 323 study, where global HRQOL improved 
during TPF5. In that study however, baseline global HRQOL was significantly lower than 
in our study (61.2 versus 75.3, respectively, p<0.001). After 2 cycles of TPF though, global 
HRQOL scores in the CONDOR and TAX 323 cohorts were comparable, 70.1 and 69.3, 
respectively. However, before start with CRT the global HRQOL scores of the CONDOR 
cohort decreased further (64.0) while the TAX 323 cohort remained stable (70.7; p<0.05). 
This is in agreement with Tribius et al who reported a significant greater deterioration in 
global HRQOL in patients with the highest baseline scores 16.  
Global HRQOL restored to baseline levels within 12 months after end of treatment 
and remained at that level after 24 months. This is in line with other QOL in head and 
neck cancer studies6,9,17 and is not very satisfying, because an improvement in QOL is 
desirable in cured patients. This pattern of no improvement in quality of life could be 
hypothetically caused by substitution of tumor-associated complaints at presentation by 
therapy sequelae-associated complaints leading to high symptom scores after the end of 
treatment 18. Other studies concerning induction chemotherapy in head and neck cancer 
did not include QOL analysis 19-21. 
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In contrast to the declining global HRQOL scores, we found improvement of symptom 
scores, especially for pain and swallowing problems during TPF. This is in line with the 
results of the EORTC 24971/TAX 323 study 5 and presumably reflects tumor response, 
which is consistent with our efficacy results; 62% of the patients had partial or complete 
responses after TPF. The improvement in pain and swallowing problems did not lead 
to better global health. Probably the increase of other symptom scores such as fatigue, 
constipation and feeling ill plays a role in declining global health score. 
Patients in the CONDOR study showed differences in physician rated toxicity scores of 
mucositis and dysphagia between the two treatment arms, showing more grade 3 and 
4 mucositis in the patients treated with cis40+ART (59% versus 26%). The differences 
in symptom scores on speech problems, swallowing problems and pain in favor of the 
patients treated with cis100+RT are in line with this. As described earlier, the difference 
in mucositis can be explained by the toxicity caused by accelerated radiotherapy and the 
weekly radio-sensitizing effect of cisplatin 8,22. High toxicity rates were observed with this 
treatment schedule, causing increasing symptom scores and decreasing global HRQOL 
during treatment. Despite this, all symptom scores in both treatment arms returned to 
baseline level at 12 months after end of treatment. 
The main limitations of this study are the relatively small patient population and 
the difference in compliance between the two treatment arms at 4 months after 
chemoradiotherapy namely 45% versus 81% in cis40+ART and cis100+RT respectively. 
This difference in compliance rate at 4 months could have led to selection bias, since 
patients treated with cis40+ART experienced more toxicity during chemoradiotherapy and 
had worse symptom scores. Assuming that the patients treated with cis40+ART who had 
more symptoms were less likely to return the questionnaires, possibly the QoL scores at 
4 months for this group are overestimated.   
Our study has several strengths. It has a randomized design and it is the first study 
reporting on QOL in patients treated with induction chemotherapy followed by 
concomitant cisplatin-based chemoradiotherapy. Because we used standard and validated 
questionnaires, comparison of our results with other studies in locally advanced head and 
neck cancer is possible. Overall compliance in our study was high, with more than 60% 
returned questionnaires during treatment as well as after one and two years after end 
of treatment. This is much higher than the compliance rate of 45% after 9 months in the 
EORTC 24971/TAX 323 study 5.
5QUALITY OF LIFE OF TPF INDUCTION FOLLOWED BY CISPLATIN-CONTAINING CHEMORADIOTHERAPY
89
In summary, in our patients with locally advanced head and neck cancer we found high 
baseline HRQOL scores. However, despite this initial high global health score, reflecting 
the good condition of the patients participating in the Condor study, both chemoradiation 
treatment schedules after prior TPF chemotherapy were shown not feasible. Especially 
patients treated with cis40+ART experienced high rates of grade 3 and 4 mucositis 
and consequently high symptom scores (pain, swallowing problems and feeding tube 
dependence) during treatment. 
Importantly, global health and all the symptom scores, restored to baseline levels within 
12 months after end of treatment in both arms and remained at that level at two years 
of follow up after end of treatment. This is remarkable given the impressive toxicity the 
patients have gone through, and important with regard to the quality of the survivorship 
of these patients who presented with such advanced localized head and neck carcinomas. 
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Abstract
Background: This study evaluated ototoxicity in locally advanced head and neck cancer 
patients treated in the CONDOR study with docetaxel/cisplatin/5-fluorouracil (TPF) 
followed by conventional radiotherapy with concomitant cisplatin 100 mg/m2 on days 1, 
22, 43 (cis100+RT) versus accelerated radiotherapy with concomitant cisplatin weekly 40 
mg/m2 (cis40+ART). 
Methods:  Sixty-two patients were treated in this study. Audiometry was performed at 
baseline, during TPF, before start of chemoradiotherapy, and 1, 4, 8 and 12 months after 
treatment. 
Results: A complete dataset of audiometric data was available of 12 patients treated with 
high dose cisplatin and of 11 patients treated with intermediate dose cisplatin. Patients 
in the high dose group showed significant more hearing loss than in the intermediate 
group at 4 kHz ((z=1.98; p=0.04) and 8 kHz (z=2.07; p<0.03)). Interindividual variation was 
high in both groups. 
Conclusions: After induction TPF, more ototoxicity was observed  in chemoradiotherapy 
with cis100+RT than after chemoradiotherapy with cis40+ART.
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Introduction
Cisplatin-based concomitant chemoradiotherapy is the cornerstone of the treatment of 
patients with locally advanced head and neck cancer (LAHNC). 1 Several chemoradiation 
schedules are used, including the most common used RTOG schedule with cisplatin 
100mg/m2 on days 1, 22 and 43 and a weekly schedule with cisplatin 40 mg/m2.2-6 Cisplatin 
containing induction chemotherapy is being promoted as an attempt to further improve 
survival of these patients.1,7,8 However, studies exploring a combination of induction 
chemotherapy and concomitant chemoradiotherapy, did not use the standard cisplatin-
based chemoradiotherapy, i.e. cisplatin 100 mg/m2 on day 1, 22 and 43. Therefore, a 
randomized phase II feasibility study was performed of induction chemotherapy 
with docetaxel/cisplatin/5-fluorouracil (TPF) followed by concomitant cisplatin-based 
chemoradiotherapy, with the two most commonly used cisplatin schedules, the CONDOR 
study.9 After induction treatment with TPF, patients were randomized to either high dose 
cisplatin, i.e. 100mg/m2 on days 1, 22 and 43 in combination with conventional RT or 
intermediate dose cisplatin, i.e. 40 mg/m2 weekly during 6 weeks in combination with 
accelerated radiotherapy. The aim of this study was to evaluate the feasibility and toxicity of 
these schedules. The main conclusion of the study was that induction chemotherapy with 4 
cycles of TPF followed by cisplatin-based concomitant chemoradiotherapy was not feasible, 
since the total planned dose of cisplatin during the concomitant chemoradiotherapy could 
only be administered in 32% of the patients due to severe toxicity, i.e. febrile neutropenia, 
dehydration, dysphagia and mucositis, which led to premature closure of the study. 
Induction chemotherapy followed by chemoradiotherapy with cisplatin is not standard 
of care. 
The most common, well-known, and potentially permanent side effects encountered in 
patients  treated with high dose cisplatin are ototoxicity, nephrotoxicity and neurotoxicity. 
Ototoxicity caused by cisplatin is related to both dose and schedule and mainly affects 
the high-frequency area.10,11 Most studies on cisplatin-induced ototoxicity in LAHNC have 
been performed in patients treated with high dose cisplatin, i.e. 100 mg/m2 on days 1, 22 
and 43.12 The incidence of sensorineural hearing loss after chemoradiotherapy in LAHNC 
patients is 17-88%.13 This wide range is due to heterogeneity of the population, different 
definitions of ototoxicity and different treatment schedules. Daily low dose cisplatin 
chemoradiotherapy leads to less acute hearing loss as compared to high dose cisplatin 
in a pooled analysis.14 However, no prospective studies were performed to compare 
ototoxicity using different schedules of cisplatin-based chemoradiation. Moreover, no 
data are available on TPF-induced hearing loss.
CHAPTER 6
96
Besides cisplatin-induced ototoxicity, radiotherapy can also lead to hearing loss. This 
sensorineural hearing loss is correlated with the radiation dose to the cochlea and affects 
mainly the high-frequency area. Another type of radiotherapy associated hearing loss may 
be conductive hearing loss. This can be caused by middle ear effusion secondary to loss 
of Eustachian tube competence if the tube included in the radiation treatment volume.
In the CONDOR study the effect on ototoxicity of two concomitant, high dose and 
intermediate dose,  cisplatin schedules was prospectively evaluated. It was hypothesized 
that patients treated with intermediate dose cisplatin would develop less hearing 
deterioration than those treated with high dose cisplatin.
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Methods 
Treatment schedules
From 2008 until 2012, 62 LAHNC patients were included in this randomized phase II 
study in three centers in the Netherlands. The main study results were published before.9 
Induction chemotherapy consisted of docetaxel 75 mg/m2 on day 1, followed by cisplatin of 
75 mg/m2, day 1 and fluorouracil 750 mg/m2 per day, by continuous infusion on days 1-5. 
This treatment was administered every three weeks for 4 cycles in case of a good response, 
or 2 cycles in case of no response. Thereafter, patients were randomly assigned to either 
concomitant chemoradiotherapy with high dose cisplatin, 100mg/m2 on days 1, 22 and 43, 
combined with conventional radiotherapy or concomitant chemoradiotherapy with weekly 
intermediate dose cisplatin, 40 mg/m2 for 6 cycles, with accelerated radiotherapy. Thus, in 
total patients could receive up to 600 mg/m2 cisplatin in the high dose cisplatin group and 
540 mg/m2 in the intermediate group. Conventional radiotherapy consisted of 5 fractions 
per week with a total treatment time of 7 weeks. Accelerated radiotherapy was given in 6 
fractions per week, with a total treatment time of 6 weeks. During one of the week days 
two fractions were delivered with an interval of at least 6 hours. In both arms intensity-
modulated radiation therapy (IMRT) was mandatory. Dose to gross tumor volume was 
70Gy in 35 fractions, dose to elective nodal areas was 46 Gy in 23 fractions in both arms.
Audiometry
Audiometry was performed according to standard procedures using standard equipment. 
Air-conduction thresholds were determined in 1, 2, 4 and 8 kHz. Bone-conduction 
thresholds were measured, from 1 kHz to 4 kHz. The equipment was calibrated according 
to ISO 389-1 (ISO, 1998). All measurements were carried out in special sound treated 
double-walled booths.
According to the study protocol, audiometry was carried out at baseline, during and after 
TPF before start of chemoradiotherapy, and 1, 4, 8 and 12 months after the ending of 
treatment. To increase the accuracy, hearing thresholds of the two ears were averaged. 
In case of asymmetry in thresholds at the base-line measurement exceeding 15 dB HL 
(hearing loss), only the data of the best hearing ear were considered. 
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Statistics
To compare hearing deterioration in the two groups statistically, non-parametric testing 
was applied. The hypothesis was that high dose group patients would show more hearing 
deterioration than those in the intermediate group. Audiometric data at a frequency of 1, 
2, 4 and 8 kHz of 4 months’  post-chemoradiotherapy  and 1-year post-chemoradiotherapy 
were compared to baseline, in those patients were data were available.
Furthermore, we analyzed the patients based on their baseline thresholds. We divided 
our patients in two categories based on their baseline thresholds. Category 1 contained 
all the data of patients with baseline threshold at or below 50 dB HL, whereas category 2 
contained the data of patients with baseline threshold above 50 dB HL(at 2, 4 and 8 kHz). 
We compared our results with those of Zuur et al.. She treated LAHNC patients with intra 
arterial cisplatin and used sodium thiosulphate rescue.15 
6OTOTOXICITY OF TPF INDUCTION FOLLOWED BY CISPLATIN-CONTAINING CHEMORADIOTHERAPY
99
Results
Patients and treatment characteristics
Sixty-two patients participated in the study. Of these 62 patients 32% received the planned 
dose of cisplatin during concomitant chemoradiotherapy. We did not have complete 
audiometric datasets of all patients at the different time points, which was mostly caused by 
no shows due to physical conditions. The 4 months’ post-chemoradiotherapy audiometric 
data were available of 13 patients treated with high dose and of 12 patients treated with 
intermediate dose cisplatin. One patient in each group was excluded because of lack of 
baseline audiometric data or drop out before randomization, which led to 12 patients in 
the high dose group and 11 in the intermediate dose group and these two groups were 
used to test the research hypothesis. Moreover, of 8 and 7 patients of these groups, 
respectively, also the 1 year’s post chemoradiotherapy audiometric results were available.
Table 1 shows the baseline and treatment characteristics of the patients included in this 
analysis. Patients had a median age of 57 years. The majority of patients was male and 
had oropharyngeal cancer. Eighty-seven percent of the patients included in this analysis 
received all 4 planned cycles of TPF induction chemotherapy. Ten patients in the high 
dose group received all 3 cycles and 2 pts received 2 of the planned cycles cisplatin, with 
a mean cisplatin dose during treatment of 497.7 mg/m2. In the intermediate dose group, 
3 patients received all planned 6 cycles, 4 patients received 5 cycles, the others received 
less cycles with a median total cisplatin dose during all treatment of 482.2 mg/m2. The 
median cisplatin dose during all treatment was not significantly different between the 
treatment arms. 
Audiometry
With regard to the high and intermediate cisplatin dose groups, per frequency, the 4-months 
and 1-year post chemoradiotherapy threshold were compared to the baseline threshold. 
Figures 1 and 2 present the individual data. At 8 kHz and 4 kHz, the patients treated with 
high dose cisplatin showed more severe deteriorations in hearing than the group treated 
with intermediate dose cisplatin (z=2.07; p<0.03 and z=1.98; p=0.04, respectively) (Figure 
1 and 2). At 2 kHz level a similar trend was observed, albeit less prominent and non-
significant. In each group there was a large variation between individuals. 
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Table 1. Characteristics of patients participating in the audiometric analyses and their treatments
Variables
High dose group  
N(%)
Intermediate dose group
N (%)
Sex
      Male 7   (58.3) 10   (90.9)
      Female 5   (41.7) 1     (9.1)
Age, years
      Mean 52.7 53.4
      Range 37 – 64 27 - 64
WHO performance status
      PS 0 12  (100) 10   (90.9)
      PS 1 0       (0) 1     (9.1)
Tumor site
      Oral Cavity 2     (16.7) 1     (9.1)
      Oropharynx 7     (58.3) 6     (54.5)
      Hypopharynx 2     (16.7) 3     (27.3)
      Larynx 1     (8.3) 1     (9.1)
T classification
      T 1 0     (0) 1     (9.1)
      T 2 2     (16.7) 0     (0)
      T 3 3     (25.0) 8     (72.7)
      T 4 7     (58.3) 2     (18.2)
N classification
      N 0 3     (25.0) 3     (27.3)
      N 1 2     (16.7) 0     (0)
      N 2a 2     (16.7) 2     (18.2)
      N 2b 2     (16.7) 4     (36.4)
      N 2c 3     (25.0) 2     (18.2)
TPF cycles
      1 0     (0) 0     (0)
      2 1     (8.3) 0     (0)
      3 1     (8.3) 1     (9.1)
      4 10   (83.3) 10   (90.9)
Cisplatin dose during CRT
     300 mg/m2 2     (16.7) 3 cycli 0     (0)
    240 mg/m2 0     (0) 3     (27.3) 6 cycli
    200 mg/m2 10   (83.3) 2 cycli 4     (36.4) 5 cycli
    160 mg/m2 0     (0) 2     (18.2) 4 cycli
    120 mg/m2 0     (0) 2     (18.2) 3 cycli
    Median 217 mg/m2 189 mg/m2
Mean RT dose 67.3 Gy 69.3 Gy
Cumulative cisplatin dose (total treatment) 497.9 mg/m2 482.2 mg/m2
6OTOTOXICITY OF TPF INDUCTION FOLLOWED BY CISPLATIN-CONTAINING CHEMORADIOTHERAPY
101
Figure 1: Hearing capability (in dB HL) at different frequencies in high dose cisplatin group over time 
(n=12)




 


 

 


 


 

 






 
 
 
 
 
 
 
 
 
 
 
 

 





 


 

 


 


 

 






 
 
 
 
 
 
 
 
 
 
 
 

 






 


 


 

 


 


 

 






 
 
 
 
 
 
 
 
 
 
 
 

  

 

A = 2 kHz, B= 4 kHz and C = 8 kHz
Long-term data, 1-year post chemoradiotherapy, were available for 15 patients, 8 in the 
high dose and 7 in the intermediate dose group.  Overall in all these 15 patients, limited 
improvements in hearing thresholds were found of (mean with standard deviations) 2.9 
+/- 6.3 dB, 4.7 +/- 4.9 dB and 1.7 +/- 5.9 dB at 8kHz, 4kHz and 2 kHz, respectively. On an 
individual level, a large spread was seen (Figures 1 and 2). It should be kept in mind that 
the standard deviation of test-retest hearing thresholds is 6.2 dB 16. As the thresholds of 
the left and right ear were averaged, theoretically, the standard deviation decreases to 4.4 
dB. Therefore, the 95% confidence interval for threshold measurements as carried out 
in this study equals 8.8 dB (twice the standard deviation). With this in mind, one patient 
from the high dose group showed a significant improvement in hearing of 13, 17, 20 dB 
HL for the 3 frequencies. One further patient from the high dose group had a significant 
improvement at 4 kHz (of 14 dB) and one patient from the intermediate group had a 
significant deterioration of 10 dB at 8kHz only. For all the others no significant changes 
were found. 
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Bone-conduction testing revealed no air-bone gap in any of these patients, suggesting 
that the observed changes over time in hearing thresholds were due to cochlear 
functioning only. 
The effect of radiation on hearing deterioration was also studied. An asymmetry in radiation 
dose on the middle ear was found in eight patients. In 5 of these 8 patients there was no 
difference in hearing deterioration between both ears. In two patients however, hearing 
loss was more prominent in the ear that received the highest radiation dose, 15 and 23 dB, 
respectively. Remarkably, in 1 patient in the intermediate dose group, we found a decline 
of 15 dB in the ear that received the lowest radiation dose. 
Figure 2: Hearing capability (in dB HL) at different frequencies in intermediate dose cisplatin group over 
time (n=11)
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The data presented in the figures were analyzed in more detail, taking into account that the amount of deterio-
ration in hearing threshold depends on the baseline value. Table 2 shows the mean deterioration of our patients 
with baseline thresholds in the category 1 (baseline hearing thresholds at or below 50 dB HL ). Mean deterioration 
data of Zuur et al. (averaged data quartiles 1 and 2) is added for comparison15. Again, hearing deterioration is 
mostly modest in the intermediate dose group while that of the high dose group is more prominent. 
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Table 2. Mean deterioration in hearing thresholds (in dB) for the subgroups of patients in quartiles 1 and 
2 from the high (100 mg/m2) and intermediate dose (40 mg/m2) cisplatin groups compared to Zuur et al. 
15 (intra-arterial cisplatin, high dose, 150 mg/m2 with sodium thiosulphate rescue)
Frequency High dose cisplatin Intermediate dose cisplatin Zuur et al. intra-arterial cisplatin
8 kHz 41 dB 20 dB 38 dB
4 kHz 30 dB 12 dB 22 dB
2 Khz 8 dB 3 dB 6 dB
The data of Zuur et al., were calculated from their Figure 5. Per subgroup, the mean deterioration over time was 
calculated and the mean data of the quartiles 1 and 2 subgroups were subsequently average as well as those 
of the quartiles 3 and 4 subgroups. 
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Discussion
We show that after induction chemotherapy with TPF, chemoradiotherapy with high dose 
cisplatin seems to be more ototoxic than chemoradiotherapy with intermediate dose 
cisplatin in a limited number of LAHNC patients. The cumulative dose of cisplatin was 
similar. We showed a significant difference with more hearing loss at hearing threshold 
at 4 and 8 kHz in chemoradiotherapy with high dose versus intermediate dose cisplatin. 
Furthermore, no structural improvement in hearing thresholds was found during 1-year’s 
follow-up after the end of treatment. The variation in hearing loss between individuals was 
large. Hearing deterioration caused by the treatment mainly affects the high frequencies, 
as has been described before.11,15 
Differences between cisplatin schedules on ototoxicity have been described earlier. 
Vermorken et al. studied ototoxicity in 48 patients treated with different doses of cisplatin.17 
They found higher incidences of ototoxicity in patients treated with higher cumulative 
doses, but also in patients treated with higher dosages per infusion and also with rapid 
infusion. Rademakers-Lakhai et al. studied ototoxicity in a cohort of non-small cell lung 
cancer patients treated with a dose-escalating schedule of cisplatin in combination with 
gemcitabine. 18 Cisplatin doses ranged from weekly 25 mg/m2 to 105 mg/m2 every two 
weeks. They concluded that hearing loss after cisplatin was dose, schedule and frequency 
dependent, with the highest losses at a dose of cisplatin ≥ 60 mg/m2 per cycle. Niemensivu 
et al. also compared ototoxicity in LANHC patients treated with chemoradiotherapy with 
high and intermediated dose cisplatin.19 They collected a prospective cohort of 22 patients 
treated with intermediate dose cisplatin and compared that with a retrospective cohort 
of 9 patients treated with high dose cisplatin. This comparison showed more hearing 
problems in patients in the high dose group, especially at the higher frequencies.
Analysis based on baseline thresholds also showed more ototoxicity in the high dose 
group. Zuur et al. who treated patients with cisplatin intra-arterially 150 mg/m2 on days 
1, 8, 15 and 22, divided their patients in 4 quartiles based on baseline thresholds. They 
reported an obvious deterioration in the 8 kHz threshold after treatment for patients 
in quartiles 1 and 2 (patients with favorable pretreatment hearing) of 41 dB and 35 dB, 
respectively.15 For quartiles 3 and 4, thus baseline threshold above 50 dB HL, the mean 
deterioration was significantly less, approx. 10 dB for either quartile. Our patients treated 
with high dose cisplatin showed somewhat more hearing deterioration than the patients of 
Zuur et al. treated with intra-arterial cisplatin 150mg/m2 with sodium thiosulfate cisplatin 
rescue.  
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Not only higher dosages of cisplatin can cause differences in ototoxicity, co-medication 
can also be of influence. As described earlier, furosemide is known to induce ototoxicity 
especially when combined with cisplatin.17,20 Unfortunately, the use of furosemide was 
not registered in our population. Patients treated with high dose cisplatin receive more 
fluid for pre- and posthydration than patients with intermediate dose cisplatin, which 
conceivably could have led to more furosemide use.
Theoretically, the different radiation schedules in our study could also have played a role 
in the differences in ototoxicity between the treatment arms. We did not find data in 
literature on LAHNC patients, but in a cohort of patients with glioblastoma multiforme, 
ototoxicity of two different treatment schedules with cisplatin 30 mg/m2 weekly combined 
with standard radiotherapy versus accelerated radiotherapy was studied.21 They found 
no statistically or clinically differences in ototoxicity between both arms, suggesting that 
acceleration of radiation did not change susceptibility to hearing loss.
Compared with the data of Zuur et al, who treated patients with four courses of intra-
arterial cisplatin 150 mg/m2 with sodium thiosulfate cisplatin neutralization or three 
courses of high dose chemoradiotherapy 100 mg/m2, our results in patients with high 
dose cisplatin are in the same range as their patients, which is remarkable, because our 
patients also had received prior TPF induction therapy with cisplatin with a maximum of 
300 mg/m2 in total, 75 mg/m2 per cycle. 
Theunissen et al. showed discrete progressive hearing loss in long-term follow up (median 
4.5 years) in patients treated with high dose chemoradiotherapy.22 Also, Ho et al. found 
progressive hearing loss in long-term follow up of patients with nasopharyngeal cancer 
treated with radiotherapy and chemoradiotherapy with cisplatin. However, in the latter 
study, radiotherapy may have played a large role in the hearing loss because of the higher 
dose of radiation on the Eustachian tube and middle ear in patients with nasopharyngeal 
cancer.23 
Ototoxicity caused by chemoradiotherapy is a serious problem, sometimes even dose-
limiting. Although there are some known risk factors, such as age, baseline hearing 
thresholds and cumulative dose of cisplatin, it is still impossible to predict which patient 
will suffer from hearing loss. 
Genetic variations of drug-processing genes, pharmacogenetics, may play a role in the 
difference of experienced toxicity. Genetic variants of single nucleotide polymorphisms, 
SNPs, are studied in this regard. For example, an association of genetic variants in 
Thiopurine S-methyltransferase (TPMT) and Catechol-O-methyltransferase (COMPT) with 
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cisplatin-induced hearing loss in children was described by Ros et al.24 Moreover, Vos 
et al, showed a significant correlation between ACYP2 variant rs1872328 and cisplatin-
induced ototoxicity in children with osteocarcoma.25 The ACYP2  is a gene that encodes 
an acylphosphatase expressed in muscle and the cochlea and may be involved in hair 
cell development. 
Other studies found an association with other polymorphisms, for example in the genes 
megalin, glutathione-S-transferases.26,27 A potentially protective effect for ototoxicity was 
described for genetic variants of the Otos gene.28 
The main strength of our study is the randomized design, with prospective audiometrics 
at predefined moments during treatment. As far as we know, this is the first study which 
compares audiological data in a prospective randomized trial in patients receiving 
high and intermediate dose cisplatin combined with radiotherapy, after TPF induction 
chemotherapy. 
Unfortunately, because of a poor performance status during treatment, not all subjects 
participated in all audiological measurements. Consequently, the analysis had to be carried 
out in a relatively limited number of patients. 
In summary, we have observed more frequent and more severe ototoxicity in patients 
treated with high dose cisplatin, although the number of patients was limited. From a toxicity 
perspective, our current data on ototoxicity and our previous data on nephrotoxicity do 
not support high dose cisplatin schedules over intermediate doses in LAHNC patients.29
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Abstract
Objectives
Ototoxicity and nephrotoxicity are well-known, potentially irreversible side effects of 
cisplatin-containing chemoradiotherapy in locally advanced head and neck cancer (LAHNC) 
patients. Several predictive genetic variants have been described, but unknown in a well-
defined group of LAHNC patients. The aim of this study is to investigate these genetic 
variants as predictors for ototoxicity and nephrotoxicity in LAHNC patients treated with 
cisplatin-containing chemoradiotherapy. 
Methods
A prospective cohort of 102 LAHNC patients treated with cisplatin-containing 
chemoradiotherapy was genotyped for 10 genetic variants in the genes ACYP2, COMT, 
TPMT, WFS1, OCT2, MATE1 and XPD and evaluated for their association with cisplatin-
induced ototoxicity (ACYP2, COMT, TPMT and WFS1) and nephrotoxicity (OCT2, MATE and 
XPD). Ototoxicity was determined by patient-reported complaints according to CTCAE v 
4.03 as well as tone audiometrical assessments. Nephrotoxicity was defined as a decrease 
of ≥25% in creatinine clearance by the MDRD during treatment compared to baseline.
Results
A significant association was observed between carriership of the A allele for rs1872328 
in the ACYP2 gene (0.019) and cisplatin-induced clinically determined ototoxicity, but not 
with ototoxicity measured by tone audiometrical assessments (p=0.449). Carriership of 
a T allele for rs316019 in the OCT2 gene was significantly associated with a decrease of 
more than 25% in creatinine clearance at any time during chemoradiotherapy (p=0.022), 
but not with nephrotoxicity at the end of the chemoradiotherapy. No associations were 
found with the other genes. 
Conclusion
We showed prospectively that in LAHNC patients genetic variants in ACYP2 and OCT2 
are significantly associated with ototoxicity and nephrotoxicity, respectively. Validation 
studies are necessary to prove the added value for individualized treatments plans in 
these patients. 
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Introduction
Head and neck cancer is a common type of cancer worldwide, with an estimation of 
61,670 new patients diagnosed in the United States and 139,531 new cases in Europe in 
2016 1,2. The most frequently used treatment for patients with locally advanced head and 
neck cancer (LAHNC) is concomitant chemoradiotherapy with cisplatin, which improves 
loco-regional control as well as overall survival compared to radiotherapy alone. 3 4 
Chemoradiotherapy can also be applied as adjuvant treatment in case of a high recurrence 
risk after surgery. Concomitant chemoradiotherapy with cisplatin however, induces a high 
rate of acute toxicities such as mucositis, dysphagia and dermatitis, most of which will 
recover with time, but can also induce irreversible ototoxicity and nephrotoxicity. 3,5-7
Ototoxicity, characterized by sensorineural hearing loss, can be an adverse effect of either 
systemically administered cisplatin or radiotherapy to the inner ear. Both chemotherapy 
and radiotherapy cause lesions in the cochlea, which may lead to ototoxicity. 8 Ototoxicity 
caused by cisplatin begins with high frequency loss and is often bilateral, permanent and 
can be progressive also after the end of administration of cisplatin. 8,9 Chemotherapy 
with cisplatin is applied either at a dose of 100mg/m2 every 3 weeks for 3 cycles (high 
dose) or at a dose of 40mg/m2 every week for 6 or 7 cycles (intermediate dose). 5,6 The 
incidence of ototoxicity is dependent on the cisplatin dose per course and cumulative 
dose (79% with high dose and 31% with 6mg/m2 daily). 10,11 Besides ototoxicity, another 
common side effect of cisplatin is nephrotoxicity that also can be irreversible. However, 
unlike ototoxicity, part of the nephrotoxicity can be reduced by prophylactic measures 
such as hyperhydration with high Natrium Chloride dose regimens. The occurrence and 
the severity of nephrotoxicity is also related to the cisplatin dose; 100% of the patients 
treated with high dose cisplatin experienced nephrotoxicity of any grade compared with 
75% of the patients with intermediate dose cisplatin. 7
With the aim to prevent ototoxicity and nephrotoxicity, several studies have been 
performed to identify risk factors and predictive markers. Known clinical risk factors for 
ototoxicity after chemoradiation in LAHNC patients are the cumulative dose of cisplatin 
and cumulative radiation dose to the cochlea, younger age, good pretreatment hearing, 
administration of furosemide and low levels of serum albumin and hemoglobin. 12 13 
However, cisplatin-induced toxicity cannot totally be predicted by these factors. Recently, 
various studies found genetic variants, i.e., single nucleotide polymorphisms (SNPs), that are 
associated with cisplatin-induced side-effects. Genetic variants in ACYP2 (Acylphosphatase 
2) and WFS1 (Wolframin ER transmembrane glycoprotein) were identified as predictive 
markers for hearing loss. 14-18 The ACYP2 gene is expressed in the cochlea.15 Mutations 
in WFS1 can cause progressive deafness after administration of cisplatin. 19 Cisplatin-
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induced ototoxicity could be related to increased levels of S-adenosylmethionine through 
reduced thiopurine S-methyltransferase (TPMT) or catechol O-methyltransferase (COMT) 
activity, however, their predictive value for ototoxicity is controversial. 20,21 With respect to 
nephrotoxicity, genetic variants in OCT2 (organic cation transporter 2), MATE1 (multidrug 
and toxin extrusion 1) and XPD (xeroderma pigmentosum group D), are believed to be of 
predictive value.22-25 OCT2 and MATE1 are expressed in the human kidney at the basolateral 
membrane of renal proximal tubules, and are involved in the secretion of various cationic 
substances from the circulation into tubular cells. In that way OCT2 and MATE1 are involved 
in the cellular uptake of cisplatin.22,24 XPD is part of the nucleotide excision repair pathway 
and is involved in removal of cisplatin and radiotherapy induced DNA damage. 25,26
However, most of the above-mentioned studies showed correlations in a limited number 
of patients and thus confirmation of the association between the SNPs and cisplatin 
related side effect is needed. Furthermore, the studies were performed in patients 
with other cancers than head and neck cancer. Therefore, the aim of this study is to 
investigate the relationship between the different SNPs and cisplatin-induced ototoxicity 
and nephrotoxicity in LAHNC patients. 
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Materials and methods
Patients and treatment
A cohort of Dutch patients with pathologically proven LAHNC and treated with cisplatin-
based concomitant chemoradiotherapy was prospectively recruited at the Radboud 
university medical center, Nijmegen, and the Erasmus University Medical Center, 
Rotterdam, in the Netherlands. Eligibility criteria included a minimum age of 18 years and 
a WHO performance score of 0 or 1. Patients with distant metastasis and renal dysfunction 
were not considered eligible. Before inclusion, written informed consent was obtained 
from all patients. The local ethical committee waived the study from ethical approval.
Patients were treated with cisplatin-based concomitant chemoradiotherapy for either primary 
treatment or adjuvant treatment. Concomitant chemoradiotherapy was administered in three 
different treatment schedules; 1. Conventional radiotherapy in combination with cisplatin 100 
mg/m2 on days 1, 22 and 43; 2. Accelerated radiotherapy combined with cisplatin 40 mg/m2 on 
a weekly basis for 6 weeks; 3. Conventional radiotherapy combined with cisplatin 40 mg/m2 on 
a weekly basis for 7 weeks. Intensity-modulated radiation therapy (IMRT) was mandatory. Dose 
to gross tumor volume was 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions. 
Cisplatin was given by infusion in combination with standard prehydration, posthydration 
and anti-emetics. If during the weeks of treatment the creatinine clearance was below 60 
mL/min because of dehydration, cisplatin was only administered if the creatinine clearance 
recovered to 60 mL/min after rehydration. Dose modifications and discontinuation of 
cisplatin were performed according to standard local practice.  
Measurements
Tone audiometry was performed according to standard procedures under standardized 
conditions. Air-conduction and thresholds were determined in 1, 2, 4, 8, 10, 12.5 and 16 
kHz. Bone-conduction thresholds were measured, from 1 kHz to 8 kHz. According to the 
study protocol, audiometry was carried out at baseline, during chemoradiotherapy after 
100 mg/m2 or 120 mg/m2 cisplatin as total dosage at that moment and within 2 months 
after completion of treatment. 
Ototoxicity was scored utilizing two different approaches. In the first approach, clinically 
determined ototoxicity, physicians asked their patients to the hearing loss according 
to the CTCAE 4.03 (grade 1: no hearing loss, grade 2: hearing loss but hearing aid or 
intervention not indicated, grade 3: hearing loss with hearing aid or intervention indicated). 
In the second approach, hearing loss was classified using the tone audiometric data from 
baseline and end of treatment based on the ear with the worst hearing loss. Hearing 
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loss was defined by threshold shifts at 2,4 or 8 kHz of ≤ 25 dB (grade 1; no hearing loss), 
threshold shift of 26-40 dB (grade 2; mild hearing loss) or threshold shift of ≥ 40 dB (grade 
3; moderate-profound hearing loss). 16
Additionally, weekly laboratory tests were performed including creatinine and the creatinine 
clearance by use of calculation of the Modification of Diet in Renal Disease (MDRD). 
Nephrotoxicity was defined as a decrease of 25% or more in creatinine clearance by the MDRD 
at any point during treatment compared to baseline. We used a decrease of 25% or more in 
creatinine clearance as definition for nephrotoxicity based on the international accepted Risk, 
Injury, Failure, Loss and End Stage Renal Disease (RIFLE) criteria.7 Blood or saliva (Oragene 
saliva collection kit (DNA Genotek, Kanata, Ontario, Canada)) were used for DNA extraction. 
Genotyping
Genotyping of genetic variant in TPMT (rs12201199, rs1800460, rs1142345) and COMT 
(rs9332377) were performed using Taqman SNP genotyping according to the instructions 
of the manufacturer (ThermoFisher, Nieuwerkerk aan den IJssel, The Netherlands). The 
other genetic variants (COMT rs4646316, ACYP2 rs1872328, OCT2/SLC22A2 rs316019, 
WFS1 rs62283056, XPD/ERCC2 rs13181 and MATE1 rs2289669) were genotyped using 
Kompetitive Allele Specific PCR (KASPTM) (KASPar-On_Demand assays (Laboratory of the 
Government Chemist (LGC) Genomics, Hoddesdon, UK)) according to the instructions 
of the manufacturer 14,27. Analysis of the Taqman and KASP assay was carried out on a 
7500FAST Real-Time PCR System (ThermoFisher). Genotypes were scored using 7500 
software (v2.0.6, ThermoFisher). Negative controls as well duplicates (8%) were included 
as quality controls for genotyping.
Statistics
A sample size calculation showed that the inclusion of 100 patients in our study would 
give us 80% power to identify a statistically significant association between a SNP and our 
outcome of ototoxicity, assuming a 40% ototoxicity rate, an alpha of 0.05, an allelic OR of 
3 and a minor allele frequency of 10%. 20,21 
The association between the SNPs and clinically relevant hearing loss (“yes” versus “no”) 
and between the SNPs and nephrotoxicity (“yes” versus “no” decrease in MDRD ≥ 25%) 
were analyzed with a Pearson’s chi-square or Fisher-exact tests. P-values were tested 
two-sided and were considered as statistically significant when <0.05. SPSS version 22 
was used for performing the analyses. 
Meta-analysis of the data of ototoxicity and ACYP2 was performed using a fixed-effects 
model in review Manager version 5.3 (The Cochrane Collaboration, Oxford, UK). 
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Results
Between August 2013 and February 2017, 103 patients were included in this study. One 
patient withdrew consent. In 10 cases no blood or saliva samples were available for DNA 
analysis. Thus, in total 92 patients were included in the final analysis. Thirty-eight patients 
and eighteen patients were treated with low dose cisplatin 40mg/m² weekly for 6 and 7 
weeks, respectively, and thirty-five patients were treated with high dose cisplatin 100mg/
m² on days 1, 22 and 43. Baseline characteristics are shown in Table 1. 
Table 1. Patient characteristics of the 92 patients analyzed
Number of patients (%)
Age mean (range) 57.8 (28-69)
Gender
     Male 67 (72.8)
     Female 25 (27.2)
WHO score
    0 63 (68.5)
    1 28 (30.4)
    2 1 (1.1)
Treatment indication   
     Primary treatment 62 (67.4)
     Postoperative treatment 29 (31.5)
     Primary treatment tumor, postoperative 
      treatment for lymph nodes
1 (1.1)
Primary site
     Oral cavity 21 (22.8)
     Oropharynx 42 (45.7)
     Hypopharynx 10 (10.9)
     Larynx 13 (14.1)
     Unknown primary 4 (4.3)
     Nasal vestibule 2 (2.2)
Cisplatin dose 
     40 mg/m2 57 (61.3)
     100 mg/m2 35 (37.6)
Cumulative cisplatin dose (median, range)                  240mg (80-300)
Ototoxicity
In all 92 patients, data on clinically-determined ototoxicity were available, whereas hearing 
loss after treatment based on tone audiometric measurements was available for 79 
patients. Of all the 92 patients, six patients reported new hearing loss without a hearing 
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aid or intervention indicated (grade 2) and one patient reported hearing loss for which 
a hearing aid or intervention was indicated (grade 3) at end of treatment. Of these 7 
patients, 4 were treated with cisplatin 40 mg/m2 and 3 were treated with cisplatin 100 mg/
m2. Based on audiometric measurements, of the 85 patients included in the analysis, 52 
patients (55.9%) were graded no hearing loss (grade 1), whereas 16 patients (17%) and 11 
patients (12%) were graded mild (grade 2) and moderate-profound (grade 3) hearing loss, 
respectively. Nine of the 11 patients with moderate-profound hearing loss were treated 
with cisplatin 100 mg/m2. There was no statistically difference in cumulative cisplatin 
dose in patients with or without hearing loss when measured clinically or audiometrically 
(p=0.231 and p=0.142). 
Unfortunately, bone conduction was only available in 55 patients. Of these 41 patients 
(74%) showed no hearing loss, 11 patients (20%) showed mild hearing loss, 3 patients (6%) 
suffered moderate-profound hearing loss. (Table 2)
Table 2. Ototoxicity and nephrotoxicity 
Number of patients (%)
Ototoxicity clinically at the end of treatment (N=92)
     None (grade 0 or grade 1) 85 (92.4)
     Hearing loss without hearing aid indicated (grade 2) 6  (6.5)
     Hearing loss with hearing aid indicated (grade 3) 1 (1.1)
Ototoxicity by tone audiometry (N=79)
     None (≤25 dB loss) 52 (65.8)
     Mild (26-40 dB loss) 16 (20.3)
     Moderate (≥40 dB loss) 11 (13.9)
Ototoxicity by audiometry, only bone conduction (N=55) 
     None (≤25 dB loss) 41 (74.5)
     Mild (26-40 dB loss) 11 (20)
     Moderate (≥40 dB loss) 3 (5.5)
Nephrotoxicity any time during study (N=92)
     MDRD < 25% decrease 39 (42.4)
     MDRD ≥25 % decrease 53 (57.6)
Nephrotoxicity at the end of study (N=86)
     MDRD < 25% decrease 78 (84.8)
     MDRD ≥25 % decrease 8 (8.7)
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Nephrotoxicity
Of the 92 patients included, 53 patients (58%) had a decrease of 25% or more in creatinine 
clearance at any time during treatment. Cumulative cisplatin dose was not different 
between those patients groups intentionally treated with high dose or intermediate dose 
cisplatin  (p=0.107). In 86 patients end of treatment creatinine clearance was available. 
Of these patients, 8 (9%) had a decrease of 25% or more in creatinine clearance relative 
to baseline. All these 8 patients (100%) were treated with cisplatin 100 mg/m2.  (Table 2)
SNP and ototoxicity
Nine patients were heterozygous GA for the ACYP2 variant rs1872328; all other patients 
(n=83) were homozygous GG. Forty-three percent of the patients reporting clinically 
hearing loss grade 2 or 3 (3 out of 7 patients) were carrying an A allele, whereas 7% of the 
patients without clinically hearing loss (grade 0 or 1) were carrier of the A allele. Association 
analysis showed a statistically significant difference between the groups (p=0.019, OR 
9.9 95%CI [1.8-54.7]). We found no differences between carriership of the A allele and 
ototoxicity based on tone audiometrical measurements. (Table 3)  A meta-analysis of the 
cohorts of the previous published studies performed in humans also indicated a significant 
association of the ACYP2 variant with ototoxicity. For this analysis we used the data of the 
audiometrical assessments in our patients to compare with the other performed studies. 
(Figure 1)
Figure 1. Forest plot of meta-analysis of ACYP2 rs1872328. Meta-analysis of published cohorts in humans 
and present study using a fixed-effects model. 95% CI, 95% confidence interval of odds ratio; M-H, Man-
tel-Haenszel method
For the tested genetic variants in TPMT, COMT and WFS1 no statistically differences were 
found in either clinically or tone audiometrically assessed hearing loss. (Table 3) Also, the 
association analysis in patients with hearing loss using bone conduction as outcome, 
showed no statically significant difference. 
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Table 3. Significance levels for genetic variants related to ototoxicity. *=significantly different
Genotype
Clinical no ototoxicity
N (%)
Clinical ototoxicity
N (%) p-value
Audiometrical no ototoxicity
N (%)
Audiometrical mild ototoxicity
N (%)
Audiometrical moderate 
ototoxicity N (%) p-value
TPMT:rs12201199
   AA
   AT/TT
77 (91.6)
8 (100)
7 (8.3)
0 (0)
p=1.0 47 (66)
5 (63)
14 (20)
2 (25)
10 (14)
1 (12)
p=0.939
TPMT:rs1142345
   TT
   TC/CC
77 (91.6)
8 (100)
7 (8.3)
0 (0)
p=1.0 47 (66)
5 (63)
14 (20)
2 (25)
10 (14)
1 (12)
p=0.863
TPMT:rs1800460 
  CC
  CT/TT
77 (91.6)
8 (100)
7 (8.3)
0 (0)
p=1.0 47 (66)
5 (63)
14 (20)
2 (25)
10 (14)
1 (12)
p=0.863
COMT:rs4646316
  CC
  CT/TT
49 (94)
36 (90)
3 (6)
4 (10)
p=0.463 31 (67)
21 (64)
10 (22)
6 (18)
5 (11)
6 (18)
p=0.863
COMT:rs9332377
   CC
   CT/TT
66 (93)
19 (90)
5 (7)
2 (10)
p=0.657 40 (66)
12 (67)
11 (18)
5 (28)
10 (16)
1 (5)
p=0.666
ACYP2:rs1872328
   GG
   GA
79 (95)
6 (67)
4 (5)
3 (33)
p=0.019* 48 (67)
4 (57)
15 (21)
1 (14)
9 (12)
2 (29)
p=0.499
WFS1:rs62283056
    GG
    GC/CC
53 (88)
30 (100)
7 (12)
0 (0)
p=0.090 34 (65)
16 (64)
12 (23)
4 (16)
6 (12)
5 (20)
p=0.522
Table 4. Significance levels for genetic variants related to nephrotoxicity. *=significantly different (p<0.05)
Genotype
No nephrotoxicity during 
treatment
N (%)
Nephrotoxicity
during treatment
N (%) p-value
No nephrotoxicity
at end of treatment
N (%)
Nephrotoxicity 
at end of treatment
N (%) p-value
OCT2/SLC22A2:rs316019
   GG
   GT/TT
35 (48.6)
4 (20.0)
37 (51.4)
16 (80)
p=0.022* 61 (91.0)
18 (89.5)
6 (9.0)
2 (10.5)
p=1.00
MATE1:rs2289669
   GG
   GA/AA
15 (42.9)
23 (41.1)
20 (57)
33 (58)
p=0.867 29 (90.6)
49 (90.6)
3 (9.4)
5 (9.4)
p=1.00
XPD/ERCC2:rs13181
   TT
   TG/GG
18 (53)
20 (36)
17 (47)
36 (64)
p=0.139 31 (96.9)
45 (86.8)
1 (3.1)
7 (13.2)
p=0.249
Table 5. Overview of performed studies to ototoxicity and cisplatin
Discovery Xu15 Replication Xu15 Vos14 Thiesen17 Drogemoller16 Our study
Patients Children with brain 
tumours
Children with brain 
tumours
Children (3-43 yrs) with 
osteosarcoma
Children with 
different tumours
Testicular 
cancer
Head and 
neck cancer
Number of patients 238 68 156 149 229 92
Cummulative dose 
cisplatin (median, range)
287 mg/m2
(unknown)
Unknown* 480 mg/m2
(140-720)
378 mg/m2
(60-800)
400 mg/m2
(200-920)
240mg/m2
(80-300)
Concomitant drugs Vincristine, amisfostine, 
cyclofosfamide
Vinblastin, 
carboplatin
Vincristine, carboplatin 
in some pts
Vincristine, 
carboplatin
Etoposide, 
bleomycine
-
Radiation Craniospinal Focal in some pts 0 Some pts 0 IMRT
* But same cisplatin dose as discovery cohort
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Table 3. Significance levels for genetic variants related to ototoxicity. *=significantly different
Genotype
Clinical no ototoxicity
N (%)
Clinical ototoxicity
N (%) p-value
Audiometrical no ototoxicity
N (%)
Audiometrical mild ototoxicity
N (%)
Audiometrical moderate 
ototoxicity N (%) p-value
TPMT:rs12201199
   AA
   AT/TT
77 (91.6)
8 (100)
7 (8.3)
0 (0)
p=1.0 47 (66)
5 (63)
14 (20)
2 (25)
10 (14)
1 (12)
p=0.939
TPMT:rs1142345
   TT
   TC/CC
77 (91.6)
8 (100)
7 (8.3)
0 (0)
p=1.0 47 (66)
5 (63)
14 (20)
2 (25)
10 (14)
1 (12)
p=0.863
TPMT:rs1800460 
  CC
  CT/TT
77 (91.6)
8 (100)
7 (8.3)
0 (0)
p=1.0 47 (66)
5 (63)
14 (20)
2 (25)
10 (14)
1 (12)
p=0.863
COMT:rs4646316
  CC
  CT/TT
49 (94)
36 (90)
3 (6)
4 (10)
p=0.463 31 (67)
21 (64)
10 (22)
6 (18)
5 (11)
6 (18)
p=0.863
COMT:rs9332377
   CC
   CT/TT
66 (93)
19 (90)
5 (7)
2 (10)
p=0.657 40 (66)
12 (67)
11 (18)
5 (28)
10 (16)
1 (5)
p=0.666
ACYP2:rs1872328
   GG
   GA
79 (95)
6 (67)
4 (5)
3 (33)
p=0.019* 48 (67)
4 (57)
15 (21)
1 (14)
9 (12)
2 (29)
p=0.499
WFS1:rs62283056
    GG
    GC/CC
53 (88)
30 (100)
7 (12)
0 (0)
p=0.090 34 (65)
16 (64)
12 (23)
4 (16)
6 (12)
5 (20)
p=0.522
Table 4. Significance levels for genetic variants related to nephrotoxicity. *=significantly different (p<0.05)
Genotype
No nephrotoxicity during 
treatment
N (%)
Nephrotoxicity
during treatment
N (%) p-value
No nephrotoxicity
at end of treatment
N (%)
Nephrotoxicity 
at end of treatment
N (%) p-value
OCT2/SLC22A2:rs316019
   GG
   GT/TT
35 (48.6)
4 (20.0)
37 (51.4)
16 (80)
p=0.022* 61 (91.0)
18 (89.5)
6 (9.0)
2 (10.5)
p=1.00
MATE1:rs2289669
   GG
   GA/AA
15 (42.9)
23 (41.1)
20 (57)
33 (58)
p=0.867 29 (90.6)
49 (90.6)
3 (9.4)
5 (9.4)
p=1.00
XPD/ERCC2:rs13181
   TT
   TG/GG
18 (53)
20 (36)
17 (47)
36 (64)
p=0.139 31 (96.9)
45 (86.8)
1 (3.1)
7 (13.2)
p=0.249
Table 5. Overview of performed studies to ototoxicity and cisplatin
Discovery Xu15 Replication Xu15 Vos14 Thiesen17 Drogemoller16 Our study
Patients Children with brain 
tumours
Children with brain 
tumours
Children (3-43 yrs) with 
osteosarcoma
Children with 
different tumours
Testicular 
cancer
Head and 
neck cancer
Number of patients 238 68 156 149 229 92
Cummulative dose 
cisplatin (median, range)
287 mg/m2
(unknown)
Unknown* 480 mg/m2
(140-720)
378 mg/m2
(60-800)
400 mg/m2
(200-920)
240mg/m2
(80-300)
Concomitant drugs Vincristine, amisfostine, 
cyclofosfamide
Vinblastin, 
carboplatin
Vincristine, carboplatin 
in some pts
Vincristine, 
carboplatin
Etoposide, 
bleomycine
-
Radiation Craniospinal Focal in some pts 0 Some pts 0 IMRT
* But same cisplatin dose as discovery cohort
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SNP and nephrotoxicity
Data on the OCT2 gene were available in 92 patients. Eighteen patients were heterozygous 
GT for the OCT2 variant rs316019; 2 patients were homozygous TT and all other 72 
patients were homozygous GG. Thirty percent of the patients with a decrease of 25% or 
more in creatinine clearance during treatment were carrying a T allele, whereas 10% of 
the patients without nephrotoxicity, which was significantly different (p=0.049, OR 3.78 
95%CI [1.1-12.4]). No association was found between carriers of the T allele and a decrease 
in creatinine clearance of more than 25% at end of treatment compared to baseline 
(p=0.845). Creatinine clearance was not significantly associated with the analyzed genetic 
variants in MATE1 and XDP. (Table 4)
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Discussion
Since a high percentage of LAHNC patients treated with cisplatin-based chemoradiotherapy 
develop irreversible ototoxicity and nephrotoxicity, to avoid these it would be worthwhile 
to add predictive biomarkers for toxicity to treatment decision-making. In this study 
we investigated whether germline genetic variants were associated to ototoxicity and 
nephrotoxicity, we focused on 10 SNPs in 7 genes which were previously reported to 
be related to these adverse effects16,17,20,22. We could confirm the association between a 
genetic variant in ACYP2 and clinical reported hearing loss, but not with tone audiometrical 
measurements. Moreover, we found an association with OCT2 and nephrotoxicity during 
treatment with cisplatin, but not with nephrotoxicity at end of treatment, which makes it 
not very useful in clinical practice. Furthermore, in these chemoradiation treated patients 
we were unable to replicate the association between genetic variants in TPMT, COMT, WSF1 
and ototoxicity and variation in the MATE1 and XDP genes and nephrotoxicity.
With our findings we are the fifth to report on the association between genetic variation 
in the ACYP2 gene and cisplatin-induced ototoxicity 14-17. The initial studies of Xu and Vos 
reported that the A allele of the genetic variants rs1872328 in the ACYP2 gene was only 
present in patients with ototoxicity, i.e.,  13.8% and 6.5%, respectively, carried the A allele.
 More recent studies, also identified the A allele in patients without hearing loss, but only 
in a low percentage (1%).16  In contrast to these studies we found that 57% of the patients 
without audiometrical measured ototoxicity carried the A allele and 43% of the patients 
with mild to moderate audiometrical measured ototoxicity. Compared to all the other 
studies, we found relatively high frequencies of carriership of the A allele, namely in 10% 
of our patients. 
We could not find an association between the other variants investigated and ototoxicity. 
This is in line with previous studies which already showed variable results16,20,21.  (Table 
5) A possible confounder in ototoxicity rate in our patient population is radiation in the 
head and neck region, because radiation can induce conductive hearing loss as a result 
of inflammation and edema as well as sensorineural hearing loss caused by radiation on 
the inner ear. 12 Although some patients in the studies by Xu et al. and Ross et al. received 
cranial radiation as well.15,28
There is a great variance in the used scoring systems for ototoxicity between the studies, 
as the initial studies were done in children, most systems are only validated in children. 
29 We decided to perform two analyses, one based on clinical hearing loss and the other 
on objective audiometrical assessments. For the audiometrical assessments we used 
the same scoring system as Drogemoller, because this system can be applied to adults, 
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in contrast to the Chang scoring system which is only used for children14,16. We are the 
first to use clinically-determined ototoxicity scored by the CTCAE as well, as this is a 
clinically relevant outcome measure reflecting the patients’ perspective. Interestingly we 
could detect an association between the genetic variant in ACYP2 when using the clinical 
measure but not for audiometrically determined ototoxicity. In the meta-analysis which 
we performed, our study had the same direction of effect (OR>1)  as the other studies, 
however we did not find a significant association between carriership of the A allele in 
ACYP2 and audiometrically determined ototoxicity. Nevertheless our study supports the 
association based on the direction of the effect. 
Cisplatin-induced sensorineural hearing loss can best be evaluated with bone conduction 
measurements. Theunissen et al. argued that air conduction measurements also include 
information on bone conduction as these reflect the functionality of the whole auditory 
system. 30 To optimize our study, we decided to perform an association analysis using both 
outcomes, but we did not find any association between the studies genetic variants and 
the two ototoxicity outcomes. 
With respect to SNPs as predictive markers for nephrotoxicity, the genetic variant in 
OCT2 was found to be associated with a significant decrease of 25% or more in MDRD 
at any point during chemoradiotherapy, but not with nephrotoxicity at end of treatment. 
OCT2 has been suggested as a marker for nephrotoxicity in other studies. 22 24. To our 
knowledge, only two studies have been performed to assess the relationship between 
OCT2 and cisplatin-induced nephrotoxicity in humans. 22,31. Filipski et al. investigated the 
effect of the rs316019 variant in OCT2 in 78 cancer patients receiving cisplatin. Renal 
function was determined 1 day before and 1-8 days after the first dose cisplatin. Iwata et 
al. investigated the rs316019 variant of OCT2 in 53 patients receiving cisplatin during more 
cycles. Remarkably, both Iwata et al. and Filipski et al. showed that the presence of T of 
the genetic variant rs316019 in OCT2 was ameliorating cisplatin-induced nephrotoxicity, 
whereas our study found the opposite. The variation in the results might be related to 
the different endpoints for nephrotoxicity that have been used. Based on the previous 
studies and ours we believe that at the moment  the use of this SNP does not seem to be 
relevant for clinical practice. 
In our study, patients treated with high dose cisplatin and intermediate dose cisplatin 
were taken together, because of the small number of patients treated with the high dose 
schedule. Therefore we cannot draw conclusion regarding association between SNPs and 
toxicity for specific cisplatin dosages, while we know from previous studies that high dose 
cisplatin induces higher rates of ototoxicity as well as nephrotoxicity. 
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A limitation of our study is that we were not able to reach the planned sample size of 
100 patients, due to lack of DNA of 10 patients, resulting in a somewhat smaller patient 
cohort. Besides this, in our power calculation we estimated an ototoxicity rate of 40%, 
but only 34% of our patient experienced ototoxicity based on audiometrical assessment. 
Furthermore, because of the relative small patient population, we did not correct for 
multiple testing and could not perform subgroup analyses. Therefore this study should 
be viewed as the first steps in the link between the studied genes and toxicities in LAHNC 
patients.
In conclusion, we are the first to report an association of ACYP2 and cisplatin-induced 
ototoxicity in LAHNC patients and the fifth to describe the possible predictive value of 
ACYP2 regarding cisplatin-induced ototoxicity. These findings should be validated in a large 
cohort, to finally determine the predictive value of ACYP2 in ototoxicity. As personalized 
medicine is getting more important, these findings could eventually lead to individualized 
treatment for LAHNC patients.
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Summary
The majority of locally advanced head and neck cancer (LAHNC) patients are treated 
with concomitant chemoradiotherapy with cisplatin 100mg/m2 on days 1, 22 and 43. This 
intensive treatment can induce high rates of acute and late toxicities leading to a negative 
impact on quality of life. Despite this intensive treatment, LAHNC is associated with a poor 
prognosis with 5-years overall survival rates ranging from 30-50%. The main objective of 
this thesis is to evaluate options to improve efficacy and decrease toxicity of concomitant 
chemoradiotherapy in LAHNC patients. 
Since toxicity of chemoradiotherapy is partly dependent on cisplatin, a possible way to 
reduce this toxicity is decreasing the cisplatin dose and by acceleration of radiotherapy, 
efficacy may be increased. Chapter 2 describes a retrospective study in 106 LAHNC patients 
treated with accelerated radiotherapy up to a dose of 68 Gy in 5.5 weeks combined with 
cisplatin 40 mg/m2 weekly for 6 weeks. Radiotherapy either consisted of intensity-modulated 
radiation therapy (IMRT) or of 3D-conformal radiotherapy. Treatment compliance was high, 
99% of the patients received all planned radiotherapy and 90% received five or more 
cycles of cisplatin. Local toxicity rates were high, with confluent mucositis in 77% and moist 
dermatitis in 27% of the patients treated with IMRT, whereas toxicity rates were even higher 
in patients treated with 3D-conformal radiotherapy. Cisplatin-based toxicity was relatively 
mild, with low rates of grade 3 and 4 toxicity. Three-year loco-regional control, disease-free 
(DFS) and overall survival (OS) were 72%, 54% and 61%, respectively. Despite a high rate of 
confluent mucositis, treatment feasibility was excellent, without compromising on survival 
when compared to the high dose cisplatin regimen. Ideally, a multicenter phase III study of 
this treatment regime versus radiotherapy with cisplatin 100 mg/m2 should be performed.
A common side effect of cisplatin is nephrotoxicity. Chapter 3 shows the results of a 
retrospective study in which nephrotoxicity of both cisplatin-based chemoradiotherapy 
schedules as described above, are compared. Furthermore, different grading systems 
for nephrotoxicity were evaluated. Forty patients were treated with radiotherapy in 
combination with 3 cycles of cisplatin 100 mg/m2 (high dose) and 104 were treated with 
accelerated radiotherapy combined with cisplatin 40 mg/m2 during 6 weeks (intermediate 
dose). Nephrotoxicity, defined as an increase in serum creatinine of ≥50% relative to 
baseline was found in 60% of the patients in the high-dose versus 7% in the intermediate 
dose group (p=<.001). Using the Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.03 grade 2 and 3 nephrotoxicity was present in 53% and 8% of the 
high dose versus 7% and 0% in the intermediate dose group, respectively. When grading 
nephrotoxicity according to CTCAE version 3.0 underreporting of renal toxicity is found, 
with grade 2 and 3 nephrotoxicity in 8% and 3% in the high dose group versus 0% and 0% 
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in the intermediate dose group, respectively. The Risk, Injury, Failure, Loss and End stage 
(RIFLE) kidney disease criteria are an international widely accepted classification in grading 
acute kidney injury. Using these criteria, 43% of the patients treated with high dose and 
7% in the intermediate dose group were classified as Risk, whereas 10% and 8% scored 
Injury and Failure in the high dose group compared to none in the intermediate dose 
group. These numbers are in line with those using the CTCAE 4.03 criteria.  In conclusion, 
intermediate dose cisplatin causes significantly less nephrotoxicity, which is best graded 
using the CTCAE version 4.03. 
As described before, adding induction chemotherapy to radiotherapy or chemoradiotherapy 
is another attempt to improve survival of LAHNC patients. Docetaxel, 5-fluorouracil and 
cisplatin (TPF) is the most effective and used induction chemotherapy schedule in LAHNC, 
but this has never been studied followed by cisplatin-based chemoradiotherapy. That is why 
we performed the CONDOR study, a randomized phase II study in which LAHNC patients 
received TPF followed by randomization to either concomitant chemoradiotherapy with 
cisplatin 100mg/m2 once every three weeks with conventional radiotherapy (cis100+RT) 
or chemoradiotherapy with weekly cisplatin 40 mg/2 and accelerated radiotherapy 
(cis40+ART), as described in Chapter 4. Sixty-two patients were included, 27 patients were 
randomized to cis100+RT and 29 to cis40+ART. This treatment schedule was not feasible, 
since only 32% of the patients could receive the total planned cisplatin dose during the 
concomitant chemoradiotherapy due to toxicity. During TPF grade 3 or 4 neutropenic 
fever occurred in 18% of the patients, during chemoradiotherapy most common toxicities 
were dehydration, dysphagia and mucositis. There was one treatment related death. 
Despite high toxicity rates, two years progression free and overall survival were 70% 
and 78% versus 72% and 79% for cis100+RT and cis40+ART, respectively. Chapter 5 
describes the health-related quality of life data of the patients treated in the CONDOR 
study, a secondary endpoint of the study. Health-related quality of life was assessed at 
baseline, after 2 TPF, before start of chemoradiotherapy and 1, 4, 8, 12 and 24 months after 
completion of therapy using the EORTC-QLQC30 and QLQ-H&N35. Baseline scores were 
relatively high, reflecting the good clinical condition of the patients. Health-related quality of 
life decreased after TPF and even more during chemoradiotherapy, in both arms equally. 
Pain and swallowing dysfunction deteriorated significantly more below baseline levels during 
chemoradiotherapy with cis40+ART compared to cis100+RT. Health-related quality of life and 
symptom scores restored to baseline levels within 12 months after end of treatment in both 
arms. In Chapter 6 the audiological data of the patients treated in the CONDOR study are 
described. A complete dataset of audiometric data was available of 12 patients treated with 
cis100+RT and of 11 patients treated with cis40+ART. Patients treated with cis100+RT showed 
significant more hearing loss than those treated with cis40+ART at 4 kHz ((z=1.98; p=0.04) and 
8 kHz (z=2.07; p<0.03)). There was a large inter-individual variation in both groups. 
8SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES
133
Chapter 7 describes the use of genetic variants to predict cisplatin-induced ototoxicity and 
nephrotoxicity in LAHNC patients. One-hundred and two patients entered the study and 
genetic data were available of 92 of them. Single nucleotide polymorphisms, (SNPs) in OCT2 
and ACYP2 were significantly related to nephrotoxicity and ototoxicity (patient reported) as 
determined by CTC v4.03. We did not find an association with hearing loss measured with 
tone audiometry. Further research is needed before determination of SNPs can be used to 
individualized treatments plans and to take this potential predictive factor for ototoxicity 
into account in the process of shared decision-making with the patients.
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General discussion
Chemoradiotherapy in locally advanced head and neck cancer; the optimal schedule
Cisplatin-based chemoradiotherapy is one of the cornerstones of the primary treatment 
of LAHNC. The most widely used treatment schedule is the Radiation Therapy Oncology 
Group (RTOG) schedule with conventional radiotherapy with concomitant cisplatin 
100 mg/m2 on days 1, 22 and 43, offered with curative intention, but associated 
with high toxicity rates, especially mucositis and dysphagia leading to feeding tube 
dependence, and furthermore hematological toxicity, nephrotoxicity and ototoxicity.1-3 
This has a huge impact on the health-related quality of life of LAHNC patients due 
to a high rate of acute and late toxicities. Because of the high acute toxicity rate, 
as illustrated by the fact that only 70% of patients complete all 3 planned cycles of 
chemotherapy, other chemoradiotherapy schedules have been investigated. One of 
those is a chemoradiotherapy schedule consisting of cisplatin 40 mg/m2 weekly, often 
combined with hyperfractionated or accelerated radiotherapy.4-7 In our retrospective 
analysis of 104 patients treated with accelerated radiotherapy combined with 6 cycles 
of weekly cisplatin 40 mg/m2 we found high treatment compliance.8 Treatment was 
well tolerated, with low rates of hematological toxicity. Furthermore, we showed that 
concomitant chemoradiotherapy with weekly cisplatin 40mg/m2 induces significantly 
less nephrotoxicity compared to concomitant chemoradiotherapy with cisplatin 
100mg/m2 every three weeks.9 However, in 80% of the patients confluent mucositis was 
observed, which most likely was due to the accelerated radiotherapy, which notoriously 
leads to a higher rate and severity of mucositis.10 
Recently, in 2017, two phase III trials were presented comparing weekly intermediate 
dose cisplatin to high dose cisplatin every 3 weeks in combination with radiotherapy. In 
the first study two cycles of cisplatin 100 mg/m2 were compared to weekly cisplatin 40 
mg/m2 in combination with IMRT in locally advanced nasopharyngeal cancer patients.11 
This trial included 529 patients, 267 were randomized to the weekly schedule and 259 
to cisplatin every three weeks. The primary endpoint, failure free survival, showed no 
significant difference at median follow up time of 17.5 months (92% versus 88%; hazard 
ratio 1.056). Remarkably, significantly more leucopenia and thrombocytopenia were 
found in patients treated with weekly cisplatin, but other grade 3 and 4 toxicities did 
not differ between the treatment arms. The second phase III study was a non-inferiority 
phase III trial in LAHNC patients and compared chemoradiotherapy with cisplatin 100 
mg/m2 every three weeks for 3 cycles to cisplatin 30 mg/m2 weekly for 7 cycles.12,13 
Three-hundred patients were included, 150 in each arm; 93% received treatment in the 
adjuvant setting, and 87% were oral cavity tumors.  Median cisplatin dose was 300 mg/
m2 in the high dose versus 210 mg/m2 in the intermediate dose group. In the high dose 
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group, 60% of the patients received all 3 cycles of chemotherapy and in the intermediate 
dose group 65% of the patients received all 6 cycles. The primary endpoint, locoregional 
relapse rate, showed a significant difference in favor of the high dose three-weekly 
schedule, 42.2% versus 29.6%, hazard ratio 1.58 with a median follow up of 20 months. 
Acute toxicity of grade 3 and higher and number of hospitalizations were significantly 
higher in the high dose cisplatin schedule. The intermediate dose cisplatin of 30 mg/m2 
was not a logical choice, since more data are available on cisplatin 40 mg/m2 that is far 
more widely used. Moreover, in this study when patients could only receive six cycles of 
cisplatin they did not receive a cumulative dose of at least 200 mg/m2 cisplatin, which 
is assumed to be the required total dose for optimal synergistic antitumor effect in 
combination with radiotherapy.14For both phase III studies no data on late toxicity and 
health-related quality of life are available yet. 
In conclusion, treatment with high dose cisplatin induces more ototoxicity, nephrotoxicity 
and leads to more hospitalizations in comparison with weekly intermediate dose cisplatin. 
In nasopharyngeal cancer efficacy of both schedules is shown to be comparable. Since high 
dose cisplatin leads to more ototoxicity and nephrotoxicity, intermediate dose cisplatin 
with radiotherapy is recommended in nasopharyngeal cancer. 
However, In LAHNC data on primary definite chemoradiotherapy comparing high dose 
cisplatin with intermediate dose 40 mg/m2 are needed in a randomized multicenter phase 
III trial for definitive conclusions on efficacy, toxicity and quality of life.
The role of induction chemotherapy in treatment of locally advanced head and 
neck cancer
In a meta-analysis, published in 2009, induction chemotherapy in LAHNC showed no 
significant improvement of survival.15 In this analysis however, a lot of different, and 
nowadays regarded as suboptimal, chemotherapy schedules were included. Also, there 
was a large heterogeneity in patient and tumor characteristics.  None of the studies 
included in this meta-analysis used cisplatin-based concomitant chemoradiotherapy, the 
most effective cytotoxic drug for head and neck cancer. We showed in our CONDOR study, 
described in Chapter 4, that induction chemotherapy with TPF followed by cisplatin-based 
chemoradiotherapy was not feasible. 
In the Tremplin study, published in 2013, 3 cycles of TPF followed by randomization 
to chemoradiotherapy with cisplatin 100 mg/m2 or bioradiotherapy with cetuximab 
was studied in 153 patients.16 The primary endpoint of this study was the feasibility of 
preservation of the larynx.  In this study only 40% of the patients completed all planned 
cisplatin in the chemoradiotherapy arm. Although the authors concluded that this was 
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a feasible treatment option, the 40% is within the range of our result of 32%, which we 
ranked in our LAHNC study as unfeasible. The primary endpoint, laryngeal preservation 3 
months post induction and bio-or chemoradiotherapy, did not show significant difference 
between treatment with cisplatin or cetuximab.  
More recently, two phase III trials published in 2013 and 2014 evaluated the efficacy 
of induction therapy followed by chemoradiotherapy compared to chemoradiotherapy 
alone.17,18 The DeCIDE study randomized LAHNC patients to either chemoradiotherapy 
with docetaxel, fluorouracil and hydroxyurea (DFHX), or two cycles of TPF followed by 
chemoradiotherapy with DFHX. Only 285 patients were included, instead of the planned 
400 patients. Toxicity during TPF included myelosuppression, mucositis and dehydration 
and there were 4 toxic deaths during TPF (2.9%). No significant differences between 
both arms were found in overall survival, recurrence free survival or distant failure free 
survival. Overall survival was higher than expected in both arms, with 2-years overall 
survival of approximately 80%. In the PARADIGM trial three cycles of TPF followed by 
chemoradiotherapy with either docetaxel or carboplatin as experimental treatment 
were compared to standard treatment consisting of concomitant chemoradiotherapy 
with cisplatin 100 mg/m2 on days 1 and 22. Instead of the planned 300 patients, only 
145 patients were included. Patients randomized to TPF followed by chemoradiotherapy 
suffered from significant more grade 3-4 febrile neutropenia and mucositis than those 
randomized to chemoradiotherapy alone. In this study also no significant difference 
was found in overall and progression free survival. Three-year overall survival rates 
were 73% and 78% for TPF followed by chemoradiotherapy versus chemoradiotherapy, 
respectively.  Both studies did not meet their planned accrual (due to slow recruitment) 
and survival rates were higher than expected, which makes interpretation of the results 
challenging. Nevertheless, both studies showed that induction chemotherapy followed by 
chemoradiotherapy is a toxic treatment without any benefit in survival. 
In conclusion, the randomized phase II CONDOR study, described in Chapter 4, and other 
published phase III studies, do not support the combination of induction chemotherapy 
followed by concomitant chemoradiotherapy in LAHNC patients. Selected patients, 
however, may have benefit from (short lasting) induction chemotherapy before offering 
concomitant chemoradiotherapy. TPF induction can cause rapid disease response, which 
can be used in highly symptomatic patients with LAHNC or nasopharyngeal cancer patients. 
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Future perspectives
In LAHNC there are three important challenges: 1. to improve overall survival in patients 
with a poor prognosis by intensifying therapy or by use of new treatment approaches and 
2. to decrease toxicity in patients with a good prognosis by de-intensifying therapy, and 
3. improving management of toxicity in general. With this in mind I will discuss (i) the use 
of immunotherapy, (ii) radiosensitizing drugs,  (iii) de-intensifying therapy; (iv) improving 
management of toxicity, (v) use of pharmacogenetics to predict toxicity, and (vi) patient 
reported outcomes measures 
(i) Immunotherapy  
The growing understanding of the immune system in tumor suppression has led to 
the development of immunotherapy in cancer treatment. Our immune system has 
checkpoints that induce tolerance of lymphocytes to antigens that otherwise activate 
apoptosis and cytotoxic tumor suppression. These checkpoints are used by malignant 
cells to suppress the immune response against tumors leading to an escape of immune 
surveillance. One of the most important checkpoints is PD-L1, programmed death-ligand 
1, which is a transmembrane protein. Binding of PDL1 on the tumor cell to PD1 on 
the lymphocyte leads to immune suppression. Pembrolizumab is a monoclonal PD-1 
antibody and blocks the PD1 to PDL1 binding, which can lead to an immune response 
to cancer cells. In the KEYNOTE-012 study, a phase I-b trial, pembrolizumab was given 
to recurrent or metastatic head and neck squamous cell carcinoma patients with PD-L1 
expression.19. In 60 patients treated with pembrolizumab, the overall response was 
18%. In 82% of these responders the response lasted more than 6 months. In a single 
arm phase II study that did not take into account PDL-1 expression of the tumors, 
pembrolizumab was studied in 171 recurrent or metastatic head and neck cancer 
patients, who were progressive after treatment with platinum and cetuximab.20 The 
overall response rate was 16% with a median duration of response of 8 months. Grade 
≥ 3 toxicity was found in 15% of the patients. 
Nivolumab, a monoclonal PD-1 antibody, was investigated in a phase III trial in patients 
with recurrent or metastatic head and neck cancer whose disease was progressive within 
6 months after platinum treatment.21 Three hunderd sixty-one patients were randomized 
2:1 to nivolumab or standard systemic therapy (methotrexate, docetaxel or cetuximab). 
Overall survival, the primary endpoint, was significantly longer in the nivolumab group 
7.5 months versus 5.1 months (hazard ratio for death 0.70) in the standard treatment 
arm. The 1-year survival rate was 36% in the nivolumab group and 17% in the standard 
of care group. Treatment-related adverse events grade 3 or 4 occurred in 13% of the 
nivolumab group, versus 35% in the standard of care group. Moreover, in an exploratory 
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analysis of quality of life data, nivolumab stabilized symptoms and functioning up to week 
15 whereas standard therapy led to clinically meaningful deterioration.    
Both the US Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) approved nivolumab and the FDA also approved pembrolizumab for treatment of 
patients with recurrent or metastatic head and neck cancer. Based on the results of the 
phase III trial with nivolumab the committee  ‘Beoordeling van Oncologische Middelen’ 
(BOM) in The Netherlands, which evaluates the value of new and EMA approved oncological 
medications, did not approve nivolumab for treatment of head and neck cancer patients, 
because it did not meet the so-called PASKWIL criteria, criteria set by the Dutch Society 
of Medical Oncology to evaluate new drugs.22 
The first data on the use of pembrolizumab in combination with chemoradiotherapy in 
LAHNC patients show that it is a safe combination not impairing chemotherapy or radiation 
dose.23 In a phase II trial patients with resectable, HPV-negative LAHNC were treated with 
one gift of pembrolizumab neo-adjuvant and only patients with extracapsular extension or 
positive margins received post-operative chemoradiation followed by pembrolizumab.24 In 
the first 21 patients enrolled in this study, in only 38% extracapsular extension or positive 
margins were found, compared to 80% expected. Moreover, 43% of the patients showed 
pathological treatment response to the neoadjuvant pembrolizumab. These preliminary 
results make the use of anti-PD1 in LAHNC patients promising. 
Since only a subset of patients responds to anti-PD1 therapy, there is a need for predictive 
biomarkers for response. Biomarkers that are of interest in head and neck cancer patients 
treated with anti-PD1 are PDL-1 and PDL-2 expression, HPV status, microsatellite instability 
and mutational load.19,25
Currently, phase III trials of anti-PD1 in (neo-) adjuvant setting, in combination with 
radiotherapy and combination with chemoradiotherapy in LAHNC patients are recruiting. 
Tumor irradiation stimulates the immune system by release of apoptotic cell bodies which 
act as tumor associated antigens and danger signals, which can prime and activate new 
antitumor T cells. This suggests the synergistic function of radiotherapy and immune 
checkpoint inhibitors.    
Hopefully this will lead to better survival for LAHNC patients. If immunotherapy will 
substitute cisplatin in next future this will probably lead to a better quality of life. 
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(ii) Radiosensitizing drugs
In addition to being cytotoxic by itself, cisplatin also has a radiosensitizing effect, albeit 
small when given three-weekly. Another treatment strategy is the combination with, 
hopefully more potential, radiosensitizing drugs. Radiotherapy induces cell death by single- 
and double-strand DNA breaks (ratio 25:1).26 The ability of the tumor cells to repair this 
DNA damage limits the effect of radiotherapy. Poly ADP-ribose polymerase (PARP) is an 
essential enzyme in base excision repair and single-strand break DNA. Double-strand 
breaks are the most cytotoxic lesions, while the effect on single-strand breaks repair has 
minimal impact on survival of non-replicating cells. PARP inhibition increases the level of 
double-strand breaks of replicating cells, by delayed repair of radiation induced single-
strand breaks which convert into double-strand breaks. This makes that PARP-inhibitors 
increase radiosensitivity in replicating cells, i.e. tumour cells. This was tested in head 
and neck cancer cell lines with positive results.27-29 PARP-inhibitors in combination with 
radiotherapy are currently tested in phase I studies in head and neck cancer patients 
(NCT02229656, NCT02308072). 
(iii) De-intensifying therapy 
It is known that patients with HPV-associated oropharyngeal cancer with a minimal smoking 
history have a good 3-years overall survival of 94% when treated with chemoradiotherapy. 
30 Probably, these patients can be treated with less intensive treatment without 
compromising survival.
Cisplatin-based chemoradiotherapy is known to induce significant toxicity, including 
ototoxicity, neuropathy, nephrotoxicity and myelosuppression. An alternative treatment 
could be cetuximab in combination with radiotherapy, which is probably better tolerated, 
as shown in a phase III trial in 2006.31 In addition to radiotherapy, cetuximab toxicity 
comprises acneiform rash and radiation dermatitis. A retrospective analysis of the 
oropharyngeal patients included in this trial with respect to HPV, based on p16 status, was 
performed.32 This analysis showed a longer overall survival of p16-positive oropharyngeal 
cancer patients compared to p16-negative oropharyngeal cancer patients, as expected. 
Furthermore, the addition of cetuximab to radiotherapy, increased 3-years overall survival 
in both p16-positive and –negative patients. Therefore, currently several ongoing phase III 
trials are investigating outcomes in locally advanced oropharyngeal HPV-positive patients 
comparing standard cisplatin-based chemoradiotherapy to cetuximab in combination 
with radiotherapy, as for example the De-ESCALaTE (NCT01874171), the RTOG1016 
(NCT01302834) and the TROG HPVOropharynx (NCT01855451). 
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Another way of de-intensifying treatment in HPV-positive oropharyngeal cancer is 
de-escalating the radiation dose to the primary tumor or elective nodes. Standard 
radiation is 70Gy in 35 fractions. 
A phase II study was performed in 43 HPV/p16 positive oropharyngeal patients (T0 to T3, N0 
to N2c, M0) with a minimal smoking history to evaluate efficacy of 60 Gy radiotherapy with 
IMRT concurrent with weekly cisplatin 30 mg/m2.33 Although the locoregional control rate, 
disease free and overall survival are not known, yet, the complete response rate of 86% is 
promising. Moreover, acute toxicity seems to be mild, with 11% grade 3-4 hematological 
toxicity and only 39% temporally feeding tube dependency, which makes this treatment 
promising.  At this time, phase II studies are ongoing to evaluate if decreasing radiation 
dose can achieve a similar excellent survival in this patient group (NCT03215719 and 
NCT02254278). 
(iv) Improving management of toxicity
Swallowing dysfunction and aspiration are seen in a high proportion (30%-100%) of LANHC 
patients treated with chemoradiotherapy, which has an immense impact on quality of 
life.34,35 Cisplatin-based chemoradiotherapy induces dysphagia and aspiration pneumonia. 
Around half of the patients will develop an aspiration pneumonia during or shortly after the 
treatment. Aspiration pneumonia leads to hospitalization and reduced quality of life. The 
use of prophylactic antibiotics to prevent aspiration pneumonia in LAHNC patients treated 
with chemoradiotherapy has been assessed in a multicentre trial, which was initiated in 
our hospital.36 Patients were randomized to standard management or to prophylactic 
amoxicillin/clavulanic acid from day 29 until 14 days after end of chemoradiotherapy. The 
rate of pneumonia did not differ between the two treatment groups in the 94 randomized 
patients (p=0.56). However, significant less fever of any grade was seen in patients treated 
with prophylactic antibiotics. In addition, patients treated with prophylactic antibiotics 
needed less hospitalizations compared to those in the standard treatment group (20% 
versus 35%, p=0.08). There was a trend in decreased use of painkillers and improvement 
of general health related quality of life in patients using the prophylactic antibiotics. The 
reduction in hospitalizations led to a significant reduction in costs.37 There was no difference 
in quality of life between the treatment groups and no adverse events associated with 
antibiotic use were reported. Based on this study, a recommendation can be made to use 
prophylactic antibiotics in LAHNC patients during and after chemoradiotherapy according 
to the schedule used in the study.
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(v) Use of pharmacogenetics to predict toxicity
It has been suggested that genetic variants in genes involved in cisplatin metabolism 
can predict the development of cisplatin-induced toxicity, especially ototoxicity and 
nephrotoxicity. 
As described in Chapter 7, we found a significant correlation between carriers of the A 
allele in the ACYP2 gene and cisplatin induced ototoxicity clinically determined based on the 
CTCAE 4.03. We could not confirm this for ototoxicity based on tone audiometrical data.38-
41 The predictive value of ACYP2 in cisplatin-induced ototoxicity needs to be determined 
by a large cohort validation study, before it can be used in clinical practice. Other single 
nucleotide polymorphisms (SNPs) that have been reported in relation to cisplatin-induced 
ototoxicity, such as TPMT, COMT and WFS1, could not be replicated and this makes them 
not useful in clinical practice.  
For cisplatin-induced nephrotoxicity we found an association between carriership of the T 
allele in the OCT2 gene. However, 2 other studies investigating genetic variants in the OCT2 
gene, showed that carriership of the T allele was protective in developing renal damage 
by cisplatin.42,43 The role of these SNPs in predicting nephrotoxicity is therefore unclear. 
Further research is needed before determination of SNPs can be used for individualized 
treatments plans.
(vi) Patient reported outcomes
Cancer patients undergoing treatment suffer from symptoms, which are often not 
documented by their clinicians.44 Therefore, there is a growing interest in patient reported 
outcomes (PROs); patients are asked to report their symptoms on a routine base and when 
there is a severe or worsening of symptoms, a trigger is given to the treating physician. 
Moreover, a report of symptom burden is used during the clinic visits. Recently, the 
integration of PROs in the care of metastastic cancer patients was proven to induce overall 
survival benefit compared to usual standard practice.45 Probably, the early response to 
patients symptoms, prevented adverse downstream interventions. 
Data of the use of patient reported outcome measures (PROMs) in head and neck 
cancer patients are scarce. The agreement between patient-reported and practitioner-
reported toxic effect during chemoradiotherapy in patients with oropharyngeal cancer 
has been studied.46 Forty-four patients with oropharyngeal cancer were treated with 
concomitant chemoradiotherapy. Toxic effects were scored using the Common 
Terminology Criteria for Adverse Events (CTCAE) and the Patient-reported Outcome 
version of the CTCAE (PRO-CTCAE). At baseline when most symptoms were absent, 
there was a high agreement between patient- and practitioner reported symptom 
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severity. However, during treatment, practitioners reported lower severity of toxic 
effects, especially for domains that are not easily evaluated by physical examination, 
such as anxiety and fatigue.  
The use of PROMs in patients treated with cetuximab and panitumumab was investigated.47 
Sixty patients (69%) in this study had head and neck cancer, and 52 of these patients 
had LAHNC treated with cetuximab in combination with radiotherapy. These patients 
showed a decrease in well-being during the first five weeks of treatment. Moreover, dose-
modifications were comparable as described by Bonner et al.31 The use of PRO could 
not prevent dose discontinuation. More studies on evaluation of PRO to improve toxicity 
management and quality of life of LAHNC patients treated with chemoradiotherapy are 
needed. The use of PROMs should be more implemented in new clinical studies. 
In our multidisciplinary head and neck chain care of the Radboud university medical center 
we will start with using PROMs in head and neck cancer patients in 2018 to investigate if 
we can further improve care for these patients. 
Conclusion
The survival of LAHNC patients varies widely, with for example 3-year overall survival 
rates that range between 10 and 95%, which mostly depends on stage, HPV-status and 
smoking habits. HPV-associated oropharyngeal carcinoma has the best prognosis. Most 
LAHNC patients are treated with cisplatin-based concomitant chemoradiotherapy, which 
is complicated by a high rate of serious toxicities and negative impact on health-related 
quality of life. In the future, treatment needs to be more individualized, based on known 
prognostic indicators such as stage, HPV-status and smoking. In addition, other novel 
potential predictive factors for tumor response or toxicity, such as tumor immunogenicity, 
pharmacogenetics and tumor microenvironmental characteristics, need to be explored. 
If possible, treatments need to be adapted to reduce toxicity, on the other hand they 
need to be intensified where necessary. Well-informed patients take better decisions, 
and shared decision making should be part of routine medical care before starting any 
treatment. Finally, implementation of PROMs and related adequate actions could further 
improve the outcome of LAHNC patients. 
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Hoofd-hals kanker
Hoofd-hals kanker bestaat uit een groep van verschillende maligniteiten, gelokaliseerd 
op de lip, in de mondholte, neusholte, paranasale sinussen, farynx (orofarynx, 
hypofarynx en nasofarynx), larynx en de speekselklieren. Met uitzondering van 
tumoren in de speekselklieren en de nasofarynx, zijn deze tumoren in het algemeen 
plaveiselcelcarcinomen.  Dit proefschrift beschrijft resultaten van onderzoek bij patiënten 
met plaveiselcelcarcinomen van de mondholte, orofarynx, hypofarynx en larynx, die ik 
verder zal aanduiden als patiënten met ‘hoofd-hals kanker’.
In Nederland werden er in 2016 3192 nieuwe patiënten met hoofd- hals kanker 
gediagnosticeerd. Risicofactoren voor het ontwikkelen van hoofd-hals kanker zijn roken, 
alcohol gebruik/misbruik, en met name bij het orofarynxcarcinoom een infectie met het 
humaan papillomavirus (HPV). 
De overleving van patiënten met hoofd-hals kanker is vooral afhankelijk van het 
ziektestadium bij presentatie. Ongeveer de helft van de patiënten presenteert zich 
met lokaal uitgebreide ziekte (stadium III of IV). Zij moeten een intensieve behandeling 
ondergaan die vaak uit meerdere modaliteiten bestaat, zoals (i) chirurgie al dan niet 
gevolgd door radiotherapie of chemoradiotherapie, (ii) primaire chemoradiotherapie 
of (iii) radiotherapie in combinatie met cetuximab (bioradiotherapie). Ondanks deze 
intensieve behandeling is de prognose van deze patiëntengroep slecht, met een 5-jaars 
overleving van 30-50%. Een uitzondering hierop zijn patiënten met een lokaal uitgebreid 
HPV-positief orofarynxcarcinoom zonder een voorgeschiedenis van roken, waarbij een 
3-jaarsoverleving na chemoradiotherapie behaald wordt van 94%.
De behandeling
Primaire chemoradiotherapie is de behandeling van keuze bij patiënten met een lokaal 
uitgebreid orofarynx-, hypofarynx- of larynxcarcinoom. De keuze voor deze behandeling 
wordt gemaakt om orgaansparend te zijn, dus om tong, spraak- of slikfunctie te behouden, 
of omdat de ziekte chirurgisch niet in zijn geheel te verwijderen is. 
Het meest gebruikte schema ter wereld voor chemoradiotherapie is het zogenaamde 
“Radiation Therapy Oncology Group” (RTOG) schema, waarbij conventionele radiotherapie 
(70Gy in 35 fracties gedurende 7 weken) gecombineerd wordt met cisplatin 100 mg/
m2 op dag 1, 22 en 43. Dit is een behandeling die gepaard gaat met veel bijwerkingen, 
zowel acuut als ook op latere termijn. De acute bijwerkingen die kunnen ontstaan zijn 
vooral lokale problemen zoals slikproblemen, mucositis (kapotte slijmvliezen), pijn, en 
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een droge mond waardoor er een verminderde inname van voedsel en vocht is, alsmede 
dermatitis (ontsteking van de huid). Daarnaast kan er gehoorschade optreden door de 
radiotherapie en door de chemotherapie en kan de chemotherapie, naast misselijkheid en 
braken, ook nierschade en perifere neuropathie (schade aan de zenuwen) veroorzaken. 
Late bijwerkingen van de behandeling ontstaan maanden tot jaren na het einde van de 
behandeling en kunnen blijvend zijn. Xerostomie, een droge mond, is de meest bekende 
en meest voorkomende late bijwerking, welke ontstaat door beschadiging  van de 
speekselklieren. Andere late bijwerkingen zijn osteoradionecrose, schildklierproblemen, 
atherosclerose van de halsvaten, gehoorschade, polyneuropathie, nierschade en fibrose. 
Verder hebben deze patiënten een verhoogd risico op het ontstaan van andere vormen 
van kanker, met name een tweede primaire hoofd-hals tumor of longkanker. Dit risico is 
vooral verhoogd door roken en alcohol gebruik, maar is, is zeer veel mindere mate, ook 
gerelateerd aan bestraling.
De huidige chemoradiotherapie voor hoofd-hals kanker is beperkt effectief en gaat 
gepaard met aanzienlijke bijwerkingen. Daarom is het doel van mijn onderzoek, zoals 
beschreven in dit proefschrift, om te bestuderen of er mogelijkheden zijn om enerzijds de 
behandeling effectiever te maken en anderzijds de toxiciteit te verminderen. 
Eén van de mogelijkheden om de behandeling effectiever te maken is de radiotherapie 
te intensiveren, bijvoorbeeld door het geven van geaccelereerde radiotherapie. Bij 
geaccelereerde therapie, wordt een even grote dosis bestraling gegeven, maar in een 
kortere tijdsduur. Hierdoor is de kans op lokale controle groter en is de 3-jaarsoverleving 
iets beter. Doordat de geïntensiveerde radiotherapie periode is ingekort tot 35 dagen, 
is dit schema niet te combineren met de chemotherapie van het RTOG schema, waarbij 
cisplatin 100 mg/m2 op dag 1, 22 en 43 wordt gegeven omdat op dag 43 de radiotherapie 
is beëindigd. Daarom is, in combinatie met geaccelereerde radiotherapie, een alternatief 
cisplatin schema bestudeerd, waarin patiënten wekelijks cisplatin 40 mg/m2 krijgen 
gedurende 6 weken. 
In hoofdstuk 2 van dit proefschrift beschrijf ik een retrospectieve studie waarin 106 
patiënten met lokaal uitgebreide kanker zijn behandeld met geaccelereerde radiotherapie 
met wekelijks cisplatin 40 mg/m2. Bijna alle patiënten konden de gehele radiotherapie 
afronden (99% van de patiënten) en 90% van de patiënten kregen minimaal 5 kuren 
cisplatin. Er werd veel lokale toxiciteit gezien, meer dan drie kwart van de patiënten kreeg 
een ernstige confluerende mucositis en ruim een kwart een vochtige dermatitis. De 
bijwerkingen van de cisplatin waren relatief mild. De lokale controle en de overleving na 
3 jaar waren respectievelijk 72% en 61%. De conclusie van deze studie was dat, ondanks 
het veel vóórkomen van lokale acute  toxiciteit, de behandeling, mits vergezeld van 
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adqueate supportive care, goed werd verdragen en afgerond, zonder afbreuk te doen 
aan de overleving, voor zover het mogelijk is die te vergelijken met studies waarin het 
RTOG schema werd gebruikt. De twee behandelschema’s, conventionele radiotherapie 
met cisplatin 100 mg/m2 op dag 1, 22 en 43 versus geaccelereerde radiotherapie met 
wekelijks cisplatin 40 mg/m2, zijn namelijk niet in een fase III studie met elkaar vergeleken. 
Zoals eerder beschreven is nefrotoxiciteit, ofwel nierschade, een bekende en beperkende 
bijwerking van cisplatin. Deze bijwerking is afhankelijk van de dosis en de frequentie van 
de cisplatin kuren. Het verschil in nefrotoxiciteit tussen de twee cisplatin-gebaseerde 
chemoradiotherapie schema’s heb ik beschreven in hoofdstuk 3. Hierbij heb ik ook 
gekeken naar verschillende manieren om de nefrotoxiciteit te graderen. Veertig patiënten 
werden behandeld met de hoge dosis cisplatin (cisplatin 100 mg/m2 op dag 1,22 en 43) 
en 104 patiënten werden behandeld met de intermediaire dosis cisplatin (wekelijks 
cisplatin 40 mg/m2). Nefrotoxiciteit, gedefinieerd als een stijging van het serum kreatinine 
van meer dan 50% ten opzichte van de uitgangswaarde, werd gevonden in 60% van 
de patiënten die werden behandeld met de hoge dosis cisplatin versus in 7% van de 
patiënten die behandeld werden met de intermediaire dosis cisplatin. Ook met de andere 
graderingssystemen, de Common Terminology Criteria for Adverse Events (CTCAE) versie 
3.0 en versie 4.03 en de Risk, Injury, Failure, Loss and End stage (RIFLE) criteria werden 
grote verschillen gezien tussen beide groepen, ten nadele van de hoge dosis cisplatin. De 
intermediaire dosis cisplatin is dus duidelijk minder nefrotoxisch en geconcludeerd werd 
dat de CTCAE 4.03 criteria de beste criteria zijn om nefrotoxiciteit van cisplatin in deze 
patiëntengroep te scoren.
Een andere manier om de overleving van patiënten met lokaal uitgebreide hoofd-hals 
kanker te verbeteren is om voorafgaand aan de chemoradiotherapie, chemotherapie 
toe te voegen. Het doel van deze inductie ofwel neo-adjuvante chemotherapie is om het 
volume van de tumor te verkleinen en de eventueel aanwezige micrometastasen te laten 
verdwijnen. 
Er zijn in het verleden meerdere studies geweest om te onderzoeken welk schema het 
best gebruikt kan worden als inductie chemotherapie bij hoofd-hals kanker. Het meest 
effectieve schema is een combinatie van docetaxel, cisplatin en 5-fluorouracil (TPF) 
gebleken, zoals beschreven in de TAX 323 en TAX 324 studies. In deze twee studies werd 
TPF gevolgd door radiotherapie alleen of chemoradiotherapie met carboplatin. Een studie 
waarin inductie chemotherapie, bestaande uit TPF, gecombineerd werd met cisplatin-
bevattende chemoradiotherapie was toentertijd nog niet verricht.
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In de CONDOR studie, een gerandomiseerde fase II studie, onderzochten wij of het 
haalbaar is om TPF inductie chemotherapie te combineren met cisplatin-bevattende 
chemoradiotherapie. In hoofdstuk 4 worden de resultaten van deze studie beschreven. 
Patiënten met lokaal uitgebreide hoofd-hals kanker kregen 2 tot 4 TPF kuren en werden 
daarna gerandomiseerd tussen conventionele radiotherapie met cisplatin 100 mg/m2 op 
dag 1, 22 en 43 of geaccelereerde radiotherapie met wekelijks cisplatin 40 mg/m2. 
In deze studie werden 62 patiënten geïncludeerd, 27 patiënten werden behandeld 
met de hoge dosis cisplatin en 29 met de intermediaire dosis cisplatin. Ten gevolge 
van toxiciteit kon slechts 22% en 41% (32% in totaal) van de patiënten met de hoge 
versus intermediaire dosis alle geplande doseringen van cisplatin krijgen tijdens het 
chemoradiotherapie gedeelte, daarom werd er besloten om de studie voortijdig te staken. 
Er werd geconcludeerd dat TPF gevolgd door cisplatin-bevattende chemoradiotherapie 
niet haalbaar is. De radiotherapie kon in beide studiearmen wel bij vrijwel alle patiënten 
volledig gegeven worden. 
Kwaliteit van leven was een van de secundaire eindpunten van de CONDOR studie en de 
resultaten van onderzoek hiernaar worden beschreven in hoofdstuk 5. De kwaliteit van 
leven werd door middel van twee verschillende gevalideerde vragenlijsten gemeten vóór 
de start van de behandeling, na 2 kuren TPF, voor de start van de chemoradiotherapie 
en 1, 4, 8, 12 en 24 maanden na afronden van de behandeling. De uitgangsscores waren 
hoog, wat betekent dat het patiënten betreft die voorafgaand aan de behandeling in 
een relatief goede conditie waren. De globale kwaliteit van leven daalde tijdens de 
TPF inductie chemotherapie en nog verder tijdens de chemoradiotherapie. Patiënten 
die werden behandeld met de geaccelereerde radiotherapie met intermediaire dosis 
cisplatin ervoeren significant meer slikklachten en pijn tijdens de chemoradiotherapie 
ten opzichte van de patiënten die werden behandeld met de conventionele radiotherapie 
met hoge dosis cisplatin. Dit verschil wordt het meest waarschijnlijk veroorzaakt door 
de geaccelereerde radiotherapie. Een jaar na het beëindigen van de behandeling was 
de kwaliteit van leven weer op hetzelfde niveau als voor de start van de behandeling in 
beide armen. 
Zoals eerder beschreven is ototoxiciteit een bekende en soms ook dosis beperkende 
bijwerking van cisplatin. De ernst van cisplatin geïnduceerde ototoxiteit is afhankelijk van 
de dosering en het schema. 
In hoofdstuk 6 beschrijf ik de audiologische data van de patiënten behandeld in de 
CONDOR studie. Tijdens de studie werden op meerdere momenten audiogrammen 
verricht. Een complete data set van audiogrammen was beschikbaar van 12 patiënten 
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die behandeld werden met hoge dosis cisplatin en van 11 patiënten die werden behandeld 
met intermediaire dosis cisplatin. Patiënten die werden behandeld met hoge dosis 
cisplatin hadden significant meer gehoorverlies dan de patiënten die werden behandeld 
met intermediaire dosis cisplatin op toonhoogte 4 kHz en 8 kHz; dit zijn de hoge tonen.  
Vooralsnog is het niet mogelijk om te voorspellen welke patiënten die behandeld gaan 
worden met cisplatin bijwerkingen, zoals nefrotoxiciteit en ototoxiciteit, gaan ervaren. 
Verschillen in het DNA zijn mogelijk van invloed op de bijwerkingen die door cisplatin 
worden veroorzaakt en heten ‘single nucleotide polymorfisms’ (SNPs). In hoofdstuk 7 wordt 
de studie beschreven die de relatie tussen verschillende van deze genetische varianten en 
cisplatin geïnduceerde nefrotoxiciteit en ototoxicieit beschrijft. Er werden 102 patiënten 
geïncludeerd in de studie, de genetische data waren beschikbaar van 92 patiënten. De SNP 
in ACYP2  was significant gecorreleerd aan het door de patiënt aangegeven gehoorverlies, 
maar niet aan het gehoorvlies gemeten met een audiogram. Verder onderzoek is nodig 
om te bekijken of het gebruik van SNPs ingezet kan worden als een predictieve factor en 
uiteindelijk kan worden ingezet bij het maken van een geïndividualiseerde keuze voor 
behandeling, wat inhoudt dat bij een genetisch bepaald hoog risico op gehoorschade 
ten gevolge van cisplatin  een alternatieve behandeling zou kunnen worden overwogen.
De toekomst
De overleving van lokaal uitgebreide hoofd-hals kanker patiënten varieert sterk, met 
3-jaars overlevingspercentages van 10 tot 95%, die meestal afhankelijk zijn van het stadium 
van de ziekte, HPV-status en rookgewoonten. Het HPV-geassocieerde orofarynxcarcinoom 
bij patiënten die nooit gerookt hebben, heeft de beste prognose. De meeste patiënten 
met lokaal uitgebreide hoofd-hals kanker worden behandeld met cisplatin-bevattende 
chemoradiotherapie, wat gepaard gaat met een hoog percentage ernstige toxiciteit en een, 
tijdelijk, negatieve impact op de kwaliteit van leven. In de toekomst moet de behandeling 
meer geïndividualiseerd worden, gebaseerd op bekende prognostische indicatoren zoals 
stadium, HPV-status en roken. Daarnaast moeten andere nieuwe potentiële voorspellende 
factoren voor tumorrespons of toxiciteit, zoals tumorimmunogeniciteit, farmacogenetica 
en micro-omgevingseigenschappen van tumoren, worden onderzocht. Indien mogelijk 
moeten behandelingen worden aangepast om de toxiciteit te verminderen bij patiënten 
met een goede prognose, aan de andere kant moeten ze waar nodig worden geïntensiveerd 
bij patiënten met een slechte prognose. Goed geïnformeerde patiënten nemen betere 
beslissingen en gedeelde besluitvorming moet deel uitmaken van de standaard medische 
zorg voordat een behandeling wordt gestart. 
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